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MEMBRANE-BOUND MATRIX METALLOPROTEINASES INFLUENCE REACTIVE 
SYNAPTOGENESIS FOLLOWING TRAUMATIC BRAIN INJURY 
 
By: Kelly Michelle Warren, MPT 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2010 
 
Major Director: Linda L. Phillips, Ph.D., Professor,  
Anatomy and Neurobiology Department  
 
 
 
Traumatic brain injury (TBI) produces axonal damage and deafferentation, triggering 
injury-induced synaptogenesis, a process influenced by matrix metalloproteinases 
(MMP) and their substrates.  Here we report results of studies examining the expression 
and potential role of two membrane-bound MMPs, membrane-type 5-MMP (MT5-MMP) 
and a disintegrin and metalloproteinase-10 (ADAM-10), along with their common 
synaptic substrate N-cadherin, during the period of reactive synaptogenesis.  Protein 
and mRNA expression of MT5-MMP, ADAM-10 and N-cadherin were compared in two 
TBI models, one exhibiting adaptive plasticity (unilateral entorhinal cortex lesion; UEC) 
and the other maladaptive plasticity (fluid percussion injury + bilateral EC lesions; 
TBI+BEC), targeting 2, 7, and 15d postinjury intervals.  In adaptive UEC plasticity, 
membrane-bound MMP expression was elevated during synaptic degeneration (2d) and 
xv 
 
regeneration (7d), and normalized at 15d.  By contrast, N-cadherin expression was 
significantly decreased at 2 and 7d after UEC, but increased during 15d synaptic 
stabilization.  In maladaptive plasticity, 2d membrane-bound MMP expression was 
dampened compared to UEC, with persistent ADAM-10 elevation and reduced N-
cadherin protein level at 15d.  These results were supported by 7d microarray and qRT-
PCR analyses, which showed transcript shifts in both hippocampus and dentate 
molecular layer (ML) for each model.  Parallel immunohistochemistry revealed 
significant MT5-MMP, ADAM-10 and N-cadherin localization within ML reactive 
astrocytes, suggesting a glial synthetic or phagocytotic role for their processing during 
recovery.  We also investigated the effect of MMP inhibition on molecular, 
electrophysiological, behavioral and structural outcome at 15d following TBI+BEC.  
MMP inhibitor GM6001 was administered at 6 and 7d postinjury, during elevated MT5-
MMP/ADAM-10 expression and synapse regeneration.  MMP inhibition showed: 1) 
reduced ADAM-10 and elevated N-cadherin protein expression, generating profiles 
similar to 15d post-UEC, 2) attenuation of deficits in the initiation phase of long-term 
potentiation, and 3) improved hippocampal dendritic and synaptic ultrastructure.  
Collectively, our results provide evidence that membrane-bound MMPs and N-cadherin 
influence both adaptive and maladaptive plasticity in a time and injury-dependent 
manner.  Inhibition of membrane-bound MMPs during maladaptive plasticity produces 
more adaptive conditions, improving synaptic efficacy and structure.  Thus, targeting 
MMP function and expression have potential to translate maladaptive plasticity into an 
adaptive process, facilitating improved recovery.
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Introduction 
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TRAUMATIC BRAIN INJURY 
Incidence, Demographics, and Classification 
Traumatic brain injury (TBI) is defined as any external force applied to the head 
that disrupts the normal function of the brain.  Each year, approximately 1.7 million 
Americans sustain different severities of TBI, often leading to long-term and life-altering 
physical, cognitive and/or psychosocial impairments.  Of these 1.7 million cases, 
approximately 1.365 million are admitted, treated and released from an emergency 
department, 275,000 are hospitalized, and it is estimated that 52,000 cases result in 
fatalities (Faul et al., 2010).  In addition to these staggering statistics, another cohort of 
TBI sufferers are never seen or treated by a medical professional, therefore indicating 
an even larger number of annual TBI incidents.  In the United States (US), children 
aged 0-4 years, adolescents 15-19 years and adults over the age of 65 years are 
among the groups most likely to sustain a TBI.  In each of these age groups, males 
have a higher TBI rate than females, which is often attributed to inherent risky behaviors 
(Faul et al., 2010).  The leading causes of TBI include falls, motor vehicle accidents, 
violence/assault, and sports-related head injuries (NIH, 1999).  TBI incidents each year 
in the US outnumber cases of multiple sclerosis, breast cancer, and spinal cord injury 
combined, making it one of most pervasive medical epidemics facing our society today 
(Weber and Maas, 2007).  Due to the complicated and patient-specific nature of TBI, 
evidence-based diagnostic methods and consistency of standards of care have been 
difficult to define and implement across medical institutions.  Consequently, TBI remains 
a “silent epidemic” that requires continual laboratory and clinical investigation with the 
common goal to limit the severity and incidence of persistent deficits that affect the 
millions of Americans who are living with the consequences of TBI today.  
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TBI is classified as either mild, moderate, or severe, however the diagnosis and 
treatment of patients who fall within this spectrum is not always clear.  Within these 
broad groups, patients can be further classified based on the type of TBI sustained, 
including open vs. closed head injury, contusions, hematomas, ischemic damage, 
diffuse axonal injury, and blast injury to name a few.  Based on these categories, 
patients are often classified as either having a focal or diffuse injury, however these two 
types of injury are not exclusive and often found to coexist and contribute to morbidity 
(Graham et al, 2000).  All aforementioned sub-classifications are determined upon 
admission, after patients are put through a battery of tests designed to further delineate 
mechanism of injury, determine prognosis, and guide treatment.  Postinjury details, 
such as duration of loss of consciousness (LOC) and post-traumatic amnesia (PTA), are 
collected and used as initial prognostic indicators.  A longstanding component of the 
initial and ongoing post-traumatic assessment is the Glasgow Coma Scale (GCS), 
which was designed in the 1970‟s to quantify injury severity and outcome by scoring eye 
opening, motor and verbal responses (Teasdale and Jennett, 1974).  Today, the GCS is 
still an integral part of initial and follow-up patient assessment however it cannot stand 
alone in the postinjury care process, and additional specific tests are necessary to 
properly classify TBI severity and outcome.  With technological advances, greater 
emphasis has been placed on the use of different imaging techniques such as computer 
tomography (CT), magnetic resonance imaging (MRI), functional MRI (fMRI), positron 
emission tomography (PET), and diffusion tensor imaging (DTI) to improve classification 
through identifying different postinjury pathologies and structural changes.  Hospitalized 
TBI patients also may undergo intracranial pressure (ICP) and Brain Tissue Oxygen 
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monitoring as a more sensitive method of determining injury classification, extent and 
prognosis.  Additionally, the measurement of brain biomarkers in serum and cerebral 
spinal fluid (CSF) samples continues to show great promise in improving diagnostic 
accuracy following TBI (Povlishock and Katz, 2005).  Despite the number of tests and 
measurement that have been developed, consistency between medical institutions 
remains poor, and a universally accepted protocol for TBI classification, diagnosis, and 
treatment has yet to be created. 
However, current broad categories of mild, moderate, and severe TBI carry their 
own set of postinjury impairments.  Depending on the level of severity, patients may 
experience acute and chronic neurological, cognitive, behavioral and social 
consequences.  Neurological consequences of TBI may include acute impairments in 
sensory, motor, and autonomic functions, followed by long-term problems such as 
movement disorders, seizures, visual impairments and sleep disorders (NIH, 1999).  
Cognitively, patients may experience postinjury memory impairment and difficulty with 
attending to different tasks for periods of time.  If the frontal lobe is involved in the injury, 
higher executive skills such as judgment, insight, abstract thinking and information 
processing may be affected.  Often times, TBI patients exhibit behavioral and social 
deficits including increased aggression, agitation, hyper-sexuality, and lack of social 
inhibition.  Collectively, these consequences leave patients and their families/caregivers 
feeling lost, hopeless, and overwhelmed well after the actual TBI incident.  Proper 
coordination of medical care and involvement in physical, occupational and speech 
therapies, family/caregiver training, and social reintegration programs greatly improve 
outcomes and quality of life following TBI.  
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TBI Pathophysiology 
In order to appreciate the complexity of TBI pathophysiology it is important to 
review the elements which contribute to injury mechanism.  As indicated above, TBI is 
caused by an external force applied to the cranium that causes damage to the brain.  
The amplitude, timing, and direction of the force directly relates to the amount and type 
of mechanical stress placed on the brain tissue and subsequent injury.  It is well 
accepted that the primary traumatic insult involves exposure to mechanical force that 
exceeds normal tolerable limits of the affected tissue, therefore leading to structural 
damage.  Mechanical damage caused by the primary injury event triggers a series of 
secondary injury responses that invoke additional downstream cellular responses and 
tissue damage.  The timing and severity of the secondary injury response depends on 
the primary injury, as well as the state of the tissue prior to the initial insult.  Age and 
repetitive traumatic brain injuries have been shown to influence the extent of secondary 
injury response and recovery. 
Multiple in vivo and in vitro studies have identified a number of intracellular 
events that follow the initial traumatic insult.  Within the CNS, this response involves not 
only neurons, but also astroglia and other supportive cells, microvasculature, and 
extracellular matrix molecules, all capable of responding during either primary or 
secondary phases of injury.  Subsequent to the frank membrane breakdown, principal 
pathology develops in metabolic pathways, particularly those related to adenosine 
triphosphate (ATP) production.  Mitochondria are highly vulnerable and part of the 
secondary injury cascade affecting both aerobic and anaerobic mechanisms (Verweij et 
al., 2007; Liftshitz et al., 2003; Gilmer et al., 2009).  In addition, TBI elicits a significant 
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immune response throughout the brain, directly releasing upstream modulators of cell 
signaling such as chemokines and cytokines (reviewed by Lenzlinger et al., 2001; 
Israelsson et al., 2008; Lloyd et al., 2008).  These molecules are also intimately involved 
in stabilization of the neuronal/vascular interface within the injured brain, ultimately 
affecting cerebral blood flow, intracranial pressure (ICP) and O2/CO2 exchange.  
Historically, the primary mechanical disruption of neuronal membrane has been linked 
to massive pre-synaptic depolarization and the excessive release of excitatory amino 
acids (EAA), especially glutamate and aspartate (Hayes et al., 1992; Yoshino et al., 
1992; Palmer et al., 1993).  EAA release activates excitatory neurotransmitter receptors, 
such as the N-methyl-D-aspartate (NMDA) type, allowing for dramatic post-synaptic 
intracellular shifts in Na 2+, K+ and Ca2+ ions (Faden et al., 1989; Katayama et al., 1990; 
Hayes et al., 1992; McIntosh et al., 1994; Wolf et al., 2001).  Such excessive 
neuroexcitation has been recognized as a major contributor to injury-induced structural 
and functional impairments.  Other studies have also probed the role of dopamine as a 
modulator of the neuroexcitatory cascade following TBI (Zhu et al., 2000; Massucci et 
al., 2004; Wanger et al., 2005; as reviewed by Bales et al., 2009).  In an attempt to 
attenuate the impaired excitatory/inhibitory imbalance generated by TBI, animal studies 
first applied N-methyl-D-aspartic acid (NMDA) antagonists as postinjury therapy, 
showing protective effects against injury-induced deficits and the facilitation of recovery 
following TBI (Faden et al., 1989; Hayes et al., 1992; Hamm et al, 1993; Phillips et al., 
1998).  Although NMDA antagonism showed therapeutic efficacy in animal models of 
TBI, translation to the clinic has proven difficult, further indicating the complexities and 
variation among human TBI cases (Muir, 2006).  More recently, dopamine agonists, 
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which significantly attenuate the negative effects of excessive neuroexcitation following 
rodent TBI (Dixon et al, 1999; Kline et al., 2004; Wanger et al., 2005 and 2007), are 
being applied in clinical trials (as reviewed by Warden et al., 2006).  Pharmacologically 
targeting these different neuropathological mechanisms has potential to improve 
outcome following human TBI.      
Mechanical neuronal insult induced by TBI also leads to secondary 
deafferentation and, in severe cases, neuronal death.  Following injury, a subpopulation 
of vulnerable neurons also sustains mechanoporation of their axolemmae.  This process 
is mediated by ionic imbalance, Ca 2+ influx, mitochondrial failure, breakdown in axonal 
transport and cytoskeletal compaction, ultimately resulting in the disconnection of 
affected axons.  These secondary events are observed in both animals and humans, 
and are signaled by a number of molecular pathways activated by the primary insult 
(Erb and Povlishock, 1991; Povlishock et al., 1992).  In certain cases, postinjury 
membrane damage can generate both necrotic and apoptotic neuronal death, ultimately 
resulting in the loss of susceptible neurons (Farkas and Povlishock, 2007).  
Ultrastructural analysis of these dying neurons revealed profiles with pyknotic nuclei, 
swollen mitochondria, vacuolated cytoplasm, and membrane disruption (Dietrich et al., 
1994).  With diffuse TBI (dTBI), neuronal loss can be demonstrated in the neocortex, 
hippocampal fields, dentate gyrus, thalamus, and at scattered sites throughout the 
caudate/putamen (Farkas and Povlishock, 2007).    While the mechanically-induced 
membrane disruption associated with TBI is generally believed to trigger neuron death 
cascades, it is important to note that intact cells with damaged axons are capable of 
delayed membrane resealing, therefore eschewing death and exhibiting the potential for 
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regeneration (Farkas et al., 2006).  The process of regeneration actually begins with 
axonal disconnection at the site of injury, resulting from impaired axonal transport, 
neurofilament degradation and cytoskeletal compaction (Pettus et al., 1994; Maxwell et 
al., 1997; Stone et al, 2004).  Several hours to days following injury the proximal 
damaged axon segment swells and the distal segment is disconnected, undergoing 
Wallerian degeneration (Povlishock, 1992; Povlishock and Pettus, 1996; Kelley et al., 
2005; Buki and Povlishock, 2006).  The ultimate effect of such degeneration is the loss 
of pre-synaptic terminals at neurons targeted by these damaged axons (Erb and 
Povlishock, 1991).  This produces deafferentation of post-synaptic sites, inducing the 
process of reactive synaptic plasticity at those sites.  Because TBI produces diffuse 
axonal injury in the context of a complex pathology, it is difficult to study a focal group of 
affected axons and their deafferented targets.  Our focus has been to better understand 
the potential for recovery following such diffuse axonal injury by using a model which 
generates this complex pathology in the presence of focal deafferentation.  The effects 
of TBI-induced axonal injury on synaptic recovery can then be examined in the context 
of adaptive neuroplasticity.  
Neuroplasticity and TBI 
Historically, it was believed that the brain was a hardwired structure, lacking the 
capacity to undergo neurogenesis or structural alterations beyond the period of its 
development.  However, over the course of the last century this theory shifted as 
evidence emerged that demonstrated the concept of “plasticity” within the nervous 
system, or neuroplasticity.  Neuroplasticity refers to the ability of the nervous system to 
be altered though processes including neurogenesis and synaptogenesis, often in 
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response to some type of activity, experience, or even injury (Keyvani and Schallert, 
2002).  Injury-induced deafferentation is well documented to induce a regenerative 
neuroplasticity within the central nervous system (CNS), producing both new terminal 
sprouts from damaged axons and reforming new synaptic connections (Lynch et al., 
1976; Scheff et al., 1977; as reviewed by Steward, 1989; Deller et al., 1996).  
Depending upon the injury location and severity, this response may result in favorable 
recovery (adaptive neuroplasticity) or unfavorable recovery (maladaptive 
neuroplasticity).  The process of synaptic neuroplasticity induced by CNS injury is 
termed reactive synaptogenesis.  In rodent models, reactive synaptogenesis occurs 
over a two week period following injury, stepping through a series of phases which 
include early degeneration, subsequent regrowth and final stabilization of affected 
synapses.  Injury-induced synaptogenesis within the hippocampus will be discussed in 
detail below.  Relative to TBI, animal models which reproduce mild and moderate injury, 
along with diffuse axotomy, tend to achieve adaptive recovery over time after injury 
(Phillips and Reeves, 2001; Clausen et al., 2005; Gurkoff et al., 2006).  It is assumed 
that this occurs because sufficient spared axons sprout into deafferented areas and 
form new synapses to restore function.  Conversely, more severe combined TBI 
pathology clearly results in maladaptive recovery, where fewer synaptic connections are 
replaced and those generated appear dysfunctional (Phillips and Reeves, 2001; Phillips 
et al., 1994).  These animal studies suggest that the extent of adaptive and maladaptive 
present following human TBI may be correlated with injury severity and the extent of 
recovery possible.  Although certainly not exclusive, we have shown that modulation of 
the extracellular synaptic environment by matrix metalloproteinases (MMPs) occurs 
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during both adaptive and maladaptive plasticity, and may be a critical to the 
enhancement of recovery following TBI.        
Surrounding supportive cells, particularly local astrocytes, are also affected by 
the primary TBI insult, which is evident by the morphological and functional changes 
that they undergo.  Normally, astrocytes support CNS homeostasis through maintaining 
ionic balance, interfacing with vessels to stabilize the blood-brain barrier (BBB), 
providing nutrition for neurons, and recycling neurotransmitters (Wilhelmsson et al, 
2006).  Following brain injury, astrocytes undergo a transformation to become 
“reactive”, which is characterized by cellular hypertrophy and hyperplasia, thickening 
and elongation of main cellular processes, and increased glial fibrillary acidic protein 
(GFAP) expression (Baldwin and Scheff, 1996; Amaducci et al, 1981; Wilhelmsson et 
al, 2006).  These morphologically distinct astrocytes often infiltrate the pericontusional 
region and may act to either inhibit or promote recovery.  Although infiltrating reactive 
astrocytes form a “glial scar” which inhibits regeneration in the nervous system (Liuzzi 
and Lasek, 1987; Silver and Miller, 2004; Goldshmit and Bourne, 2010), they have also 
been shown to protect adjacent uninjured tissue from further secondary damage and 
decrease the inflammatory response (White and Jakeman, 2008; Sofroniew, 2005, Su 
et al., 2009; Rasouli et al., 2009), therefore revealing dual roles.  As a result of injury, 
reactive astrocytes can alter their expression of ion transporters, neurotransmitter 
receptors, as well as matrix proteins and proteases which can be membrane bound or 
secreted into the extracellular space (Wells et al., 1996; Muir et al., 2002; Falo et al., 
2006; Belanger and Magistretti, 2009).  Depending on the injury severity, the expression 
of these proteins can determine the role of local reactive astrocytes in the regulation of 
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brain pH and neuroexcitability and their influence during injury-induced plasticity (Laird 
et al., 2008).  For example, secreted and membrane-bound MMPs are upregulated in 
reactive astrocytes postinjury, and can influence plasticity through interaction with their 
extracellular matrix (ECM) substrates or synaptic junction modulation (Falo et al., 2006; 
Kim et al., 2005).  Secreted ECM molecules, such as proteoglycans, are critical to the 
formation of the glial scar and often are vulnerable to MMP processing after CNS injury 
(Pizzi and Crowe, 2007).  Reactive astrocytes also play a direct role in the neuroplastic 
response by phagocytic removal and degradation of damaged tissue (Sofroniew, 2005).  
In some injury models, reactive astrocytes fail to express inwardly reflecting K+ 
channels, therefore compromising their ability to buffer extracellular K+, maintain ion 
homeostasis and dampen neuronal excitation (Bordey and Sontheimer, 1998; 
D‟Ambrosio et al., 1999; Bordey et al., 2001).  Clearly, the astrocytic response following 
TBI appears to be injury specific and shows the capacity to either facilitate or impede 
neuroplastic recovery.  Despite their often opposing functional roles, reactive astrocytes 
are important players in the pathophysiology of TBI.  The magnitude and direction of 
astrocytic response may correlate with injury severity and outcome, therefore making 
them potential therapeutic targets to facilitate adaptive synaptic plasticity.  
Based on this brief review, it is evident that postinjury neuropathology is a 
complex and dynamic series of events that can result in a wide range of cellular 
damage and dysfunction.  While each element of the postinjury process is important, 
here we choose to focus on the recovery component of injury-induced synaptogenesis, 
particularly within the hippocampus of the injured brain.     
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PLASTICITY WITHIN THE INJURED HIPPOCAMPAL FORMATION 
Multiple studies have shown that CNS injury induces a synaptogeneic response, 
particularly in regions of high plasticity, such as the subventricular zone, dentate gyrus 
and hippocampus (as reviewed by Taupin, 2006).   While there is extensive literature 
describing activity, experience and injury-induced plasticity in these different regions, 
the focus of this review will be the injury-induced synaptogenesis within the 
hippocampus.  
Hippocampal Structure  
The hippocampus is comprised of two interlocked U-shaped sectors that lie deep 
within the temporal lobe and are surrounded by entorhinal (EC), parahippocampal and 
perirhinal cortices.  The fascia dentata (or dentate gyrus) and the hippocampal 
formation (CA1-CA3 laminae) interlock to form a structure that contains a limited 
number of neuron types that are tightly packed into distinct layers (Fig. 1.1).  Intrinsic 
and extrinsic afferent inputs synapse in dendritic fields of the dentate and hippocampus 
proper, linking the hippocampus to other limbic structures including the amygdala, 
cingulate gyrus, mammilary bodies thalamus, EC, and septal nuclei.  The organized 
limbic circuitry (discussed below) and functions of the hippocampus are due, in part, to 
the structural organization of the dentate gyrus and hippocampal formation (reviewed by 
Amaral et al., 2007).   
The tri-laminar dentate gyrus is made up of granule, molecular and polymorph 
(hilar) layers, and resembles an arrowhead with suprapyramidal and infrapyramidal 
blades.  The granule cell layer contains small, densely packed excitatory granule cells 
along with scattered inhibitory dentate pyramidal basket cells at the interface of the  
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Figure 1.1 Hippocampal Structure and Circuitry. Schematic representation of 
hippocampal structure and circuitry, including dentate gyrus (DG) and hippocampal 
fields CA3- CA1.  Primary afferent inputs include lateral and medial perforant path (LPP; 
MPP) projections from the entorhinal cortex (EC) and secondary inputs from 
contralateral associational-commissural (CA) projections.  The tri-synaptic loop circuit 
includes PP projections to DG granule cell dendrites, which send mossy fiber (MF) 
projections to the CA3 field.  CA3 pyramidal neurons send contralateral AC projections 
and primary Schaffer collateral (SC) projections to CA1 pyramidal cell dendrites, which 
send efferents to the subiculum (Sb) and on to the lateral and medial EC (LED; MEC).      
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granule and polymorph layers.  The spiny apical dendrites of granule cells extend into 
the molecular layer, their outermost processes reaching the hippocampal fissure.  
These dendrites receive primarily excitatory input from the EC through the perforant 
(ipsilateral EC) and crossed temporodentate (CTD; contralateral EC) pathways, as well 
as Commissural-Associational (C/A) and septal projections.  The granule cells give rise 
to axonal projections called mossy fibers that travel through the hilar polymorph layer 
and terminate in the CA3 field of the hippocampus.  Along the mossy fiber course, these 
axons extend collateral afferents to synapse on the proximal dendrites of the hilar 
mossy cells, basal dendrites of the pyramidal basket cells and GABAergic interneurons.  
The mossy fibers serve as the initial segment of the hippocampal „trisynaptic loop”, 
linking granule neurons with CA3 and CA1 pyramidal neurons.  
The hippocampal formation is comprised of two main sectors of pyramidal 
neurons, regio superior and regio inferior.  The regio superior, or CA1 field, contains 
multiple rows of medium-sized to large pyramidal neurons, whose apical dendrites 
receive their principal input from the Schaffer collateral axons.  The Schaffer collateral 
projections arise from large pyramidal neurons located within the regio inferior, or CA3 
field.  The apical dendrites of CA3 neurons receive afferent mossy fiber projections from 
the dentate granule cell layer.  CA1 and CA3 fields are arranged in organized layers 
similar to those observed in the dentate gyrus, however, additional layers are identified 
based on the specific features of pyramidal cell input.  These layers include (dorsal to 
ventral) the alveus, stratum oriens, stratum pyramidale, stratum radiatum, and stratum 
lacunosum/moleculare.  The alveus contains pyramidal cell axons that are either 
directed towards the fimbria or subiculum.  The stratum oriens contains pyramidal and 
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basket cell basal dendrites and septal afferents.  The stratum pyramidale is made up of 
pyramidal cell somas, whose proximal and distal apical dendrites are localized in the 
stratum radiatum and lacunosum/moleculare, respectively.  There is an additional layer, 
stratum lucidum, within the CA3 field which is situated between the stratum pyramidale 
and stratum radiatum that contains the mossy fiber projections (as reviewed by O‟Keefe 
and Nadel, 1978).  
While there are intrinsic connections within the dentate gyrus and hippocampus 
proper and between contralateral hippocampal structures, there are also a number of 
extrinsic inputs and outputs that link the hippocampus to other brain regions.  
Hippocampal afferent inputs and efferent outputs are primarily associated with the 
circuit of Papez, and include a number of cortical and subcortical connections.  
Subcortically, the hippocampus makes connections with the anterior nucleus of the 
thalamus, hypothalamic mammillary bodies and septal nucleus of the basal forebrain 
through the fornix, as well as direct connection with the amygdala (Bird and Burgess, 
2008).  The presubiculum is another subcortical structure that projects to the 
hippocampus through the EC.  Additionally, many cortical afferent inputs are connected 
to the hippocampus through the EC including the perirhinal and parahippocampal 
cortices, the superior and middle frontal gyri, superior temporal and cingulate gyri, 
precuneus, lateral occipital cortex, occipitotemporal gyri and subcallosal cortical regions 
(Bird and Burgess, 2008; Haines, 2004).  Collectively, these subcortical and cortical 
connections link the hippocampus to a number of functional CNS networks, including 
the neuroendocrine, olfactory and visual systems. 
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Hippocampal Function and Response to Injury 
Based on its structural organization and extensive CNS connections, the 
hippocampus has received significant attention in the research community over the past 
decades.  The hippocampus is among a number of limbic brain structures involved in 
emotional, motivational and learning/memory processes.  Within the limbic system, it is 
believed that the hippocampus plays a major role in long-term memory, however, this is 
limited to specific types of memories.  While much debate continues to focus on 
hippocampal function, most researchers agree that declarative memories are controlled 
by the hippocampus (Anderson et al., 2007; LaFerla et al., 2007).  Declarative 
memories are those based on facts (semantic) or events/episodes (episodic).  Within 
the category of declarative memory, many theorists agree that the hippocampus is 
critical for coding and storage of episodic, rather than semantic memory (Good, 2002; 
Bird and Burgess, 2008).  Additionally, animal and human studies both show that the 
hippocampus plays a role in spatial memory and navigation, as well as temporal lobe 
amnesia (Morris et al., 1982; Good, 2002).   
Beyond basic neuroscience, many studies have focused on the role of the 
hippocampus in neuropathologies such as Alzheimer‟s disease (AD) (Ball et al., 1985), 
epilepsy (Kuruba et al., 2009), and TBI (McCarthy, 2003).  A common element in all 
three conditions is the resultant loss of cognitive function.  Following TBI, the 
hippocampus is highly vulnerable to cellular damage, a feature considered to be directly 
linked with the long-term cognitive deficits observed clinically.  Despite theoretical 
differences as to the role of the hippocampus in such memory loss, its structural 
organization has fostered a more recent, detailed study of synaptic neurophysiology, 
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including parameters such as unidirectional excitatory transmission and synaptic 
efficacy (Anderson et al., 2007).  Initial studies of hippocampal electrophysiology lead to 
the discovery of synaptic long-term potentiation (LTP), which evolved into the prominent 
cellular model for the processing of functional learning and memory (Bliss and 
Collingridge, 1993).  Subsequent LTP studies showed that the capacity to evoke such 
potentiation was directly associated with the structural and functional efficacy of the 
underlying hippocampal synaptic junctions (Steward, 1982 and 1989; Reeves and 
Steward, 1986).  Further investigation found LTP to be a common synaptic link between 
memory processing and injury-induced neuroplasticity (Reeves et al., 1997; Phillips and 
Reeves, 2001; Tang and Zhang, 2002; Reeves et al., 2003; Su et al., 2009), serving to 
generate a prototype for associating synaptic recovery after TBI with positive cognitive 
outcome.  In the present studies, we have utilized hippocampal LTP as an outcome 
measure to complement molecular, structural and behavioral endpoints, looking for 
direct links between ECM/MMP driven mechanisms and functional synaptic recovery 
after TBI. 
While TBI studies of the hippocampus have principally focused on the loss of 
neurons and attenuating cell death, we now know that the affected circuitry is efficient in 
its plasticity and, given the right conditions, has the capacity to reorganize and promote 
significant cognitive recovery (Dietrich et al., 1994; Hicks et al., 1996; Sifringer et al., 
2007).  Although more investigation into the complexity of TBI pathology is certainly 
warranted, we feel that the hippocampus is a critical site for understanding 
neuroplasticity after brain injury based on its well organized and understood circuitry.  
Given that the hippocampus exhibits significant synaptic plasticity in response to stimuli 
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such as activity, experience or injury, we have focused on understanding more about its 
capacity for synaptic reorganization after TBI.  While the literature is vast documenting 
activity- and experience-associated plasticity within the hippocampus, here we will 
review the area of our focus, reactive or injury-induced synaptogenesis. 
Injury-Induced Synaptogenesis    
Injury-induced or “reactive” synaptogenesis is a process whereby the nervous 
system replaces lost synaptic inputs through growth of local spared afferents into a 
dennervated zone (Steward, 1989).  As previously described, a traumatic insult to the 
brain induces a series of secondary-injury events that often terminate in axonal 
disconnect and diffuse deafferentation.  Such deafferentation triggers a local 
synaptogenic response, where sprouting of spared axon terminals provide new pre-
synaptic input into the denervated region.  Reorganized post-synaptic sites emerge in 
concert with these axonal sprouts to complete new synapses.  While replacement by 
proximal spared fibers would most direct, rodent unilateral EC lesion studies show that 
homotypic fiber sources are preferred (i.e., CTD fibers from intact contralateral EC), and 
that other sprouting axons (i.e., C/A projections) may travel up to 20-40 μm into the 
damaged dentate gyrus to replace degenerated axonal terminals (Steward, 1989).   
The unilateral entorhinal cortex (UEC) lesion model has been used in multiple 
studies to characterize the spatial and temporal profile of reactive synaptogenesis.  
UEC eliminates 80-90% of the EC afferent fibers projecting to the dentate molecular 
layer, and, over time, synaptogenesis leads to significant structural and functional 
recovery.  The time course of this process is often described in three distinct postinjury 
phases.  During the first phase of degeneration (1-5d), damaged axon terminals are 
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removed and degraded by reactive glia, while post-synaptic structures are morphed in 
shape, often collapsing at their base into the underlying dendritic shaft.  This is followed 
by the regenerative phase (6-15d), which involves collateral sprouting of spared axons 
into the deafferented zone, concomitant with the reformation of post-synaptic spines 
and junctions.  Finally, a stabilization/maturation phase (15-30+d) follows, where 
nascent synapses are either stabilized or pruned away, re-establishing a close match to 
the original synaptic profile (Steward and Vinsant, 1983).  At the end of these three 
phases, synaptic junctions return to a pattern mimicking the uninjured side and synaptic 
function is restored.  It is important to note that while the above timeline is relevant for 
the UEC model in adult rat hippocampus/dentate gyrus, variations will exist between 
species, injury type, ages, and brain regions.  Therefore, it is important to investigate 
the time course of injury-induced synaptic reorganization in each experimental design.   
UEC studies also provide evidence of selective pre- and postsynaptic target 
specificity and competition between spared sprouting fibers.  Within the hippocampus 
the C/A afferent projections synapse in the inner third of the dentate molecular layer, 
while the outer two thirds of the molecular layer contains EC perforant path afferents.  
Additionally, the CTD sends projections to the dentate outer molecular layer from the 
contralateral EC (Fawcett et al, 2003).  When the ipsilateral EC is 80-90% ablated, 
these projections are replaced by CTD, C/A and septal afferents in a hierarchical 
fashion.  Elimination of the C/A projections entirely, leads to septal afferent growth, but 
no EC afferent re-growth, further indicating reinnervation specificity and competition 
(Cotman, 1979; Nadler et al, 1980).  Additionally, there is dramatic dendritic plasticity 
within each molecular layer zone that aids in the restoration of pre-injury synaptic 
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density (Deller and Frotscher, 1997; Fawcett et al, 2003).  Although these results 
illustrate changes in a single model, the spatial and temporal reorganization displayed in 
the adaptive UEC are fundamental to our understanding the differences between 
adaptive and maladaptive plasticity post-TBI.  
Adaptive vs. Maladaptive Plasticity 
Based on the above review, the UEC induction of reactive synaptogenesis can 
be considered a model of adaptive (successful) plasticity, producing functional recovery.  
This recovery involves restoration of synaptic cytoarchitecture, dendritic laminar 
organization, and re-emergence of functional efficacy, demonstrated by both 
electrophysiological and behavioral measures (Reeves and Smith, 1987; Losche and 
Steward, 1977).  Therefore, contrasting the UEC conditions with other TBI models 
which fail to show synaptic recovery can be quite beneficial.  Maladaptive plasticity can 
occur when the process is dysregulated, generating disordered neuropil and aberrant 
synaptic structure, a situation which is consistent with the severe cognitive impairments 
seen in human TBI patients (Phillips et al, 1994, 1997).  Our lab has developed an 
animal TBI model of maladaptive plasticity that combines the excessive neuroexcitation 
of the cFPI with targeted deafferentation of bilateral EC lesions (TBI+BEC).  This model 
was developed to mimic the complex synaptogenic aspects seen in human TBI, and is 
studied in concert with the UEC model of adaptive plasticity.  Comparing cellular and 
molecular response within these two models provides a better understanding the 
underlying mechanisms that contribute to poor synaptic reorganization.  Our overall goal 
is to characterize recovery-dependent differences in molecular expression during injury-
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induced synaptogenesis and develop therapeutic interventions that will improve 
functional recovery following TBI in humans.     
Both adaptive and maladaptive plasticity are influenced by the type and timing of 
injury, ensuing neuropathology, and the expression, activity, and interaction of different 
cellular and matrix proteins that contribute to synaptic reorganization.  Of particular 
interest is the upregulation of matrix metalloproteinase (MMP) family members and their 
paired substrates in different nervous system diseases, including TBI (Yong, 2005; 
Rosenberg, 2009).  In CNS neuropathologies, MMPs modulate of the extracellular 
environment through proteolysis of not only free ECM molecules, but also proteins 
which are integral to synaptic adhesion and functional activity (Rosenberg, 2002, 2009; 
Kim et al., 2005; Falo et al., 2006; Komori et al., 2004; Wang et al., 2000).  Prior studies 
have shown that the gelatinases MMP-2 and -9 contribute to BBB breakdown and 
exacerbate posttraumatic edema through degradation of the vessel basal lamina 
(Truettner et al., 2005; Vilalta et al., 2008; Vajtr et al., 2009).  MMP-9 also plays a role in 
glial scar formation and cytoskeletal reorganization during axonal regeneration following 
spinal cord injury, as well as contributing to TBI neuronal damage and increased infarct 
size after stroke (Hsu et al., 2008; Wang et al., 2000; Romanic et al., 1998).  In the 
context of this dissertation study, our lab has shown that altered MMP-3 expression is 
correlated with disorganized ultrastructural synaptic profiles and spatial learning deficits 
after TBI+BEC insult (Kim et al., 2005; Falo et al., 2006).  MMP-3 appears to influence 
the development of synaptic pathology and behavioral impairment through its target 
ECM protein agrin, which contributes to receptor organization within the synapse (Falo 
et al., 2008).  Earlier studies showed hippocampal upregulation of MMP-2, -3, and -9 
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expression/activity within the TBI+BEC, paralleled by increased levels of the MMP ECM 
substrates collagen IV, chondroitin sulfate proteoglycan (CSPG) and tenascin  (Phillips 
and Reeves, 2001; Kim et al., 2005).  More recently, members of the membrane-type 
MMP family and the A Disintegrin and Metalloproteinase (ADAM)/ A Disintegrin and 
Metalloproteinase with a Thrombospondin type 1 motif (ADAMTS) subgroup have been 
shown to interact with ECM and synaptic molecules during injury-induced 
synaptogenesis (Komori et al., 2004; Mayer et al., 2005; Yang et al., 2006).  While 
these studies linking MMPs to TBI and synaptogenesis are small in number, it is 
apparent that MMPs and their paired ECM substrates play an important role in 
neuroplastic recovery.  However, it is also recognized that their interaction must be 
tightly regulated to promote successful synaptic repair.  It is our overall hypothesis that 
unregulated MMP/substrate interaction contributes to maladaptive post-injury 
reorganization and persistent functional impairments following TBI.  Therefore, it is 
important to continue to investigate MMP/substrate interaction as it relates to the 
processes of adaptive and maladaptive injury-induced synaptogenesis. 
The following section reviews the general structural and functional features of the 
MMP family of enzymes, and takes a closer look at how two membrane-bound MMPs, 
membrane-type 5 MMP (MT5-MMP) and ADAM-10 can potentially influence the 
postinjury plasticity process through proteolytic interaction with synaptic adhesion 
molecule, Neural Cadherin (N-cadherin). 
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MATRIX METALLOPROTEINASES 
General Classification, Structure, and Function 
MMPs constitute a large family of highly regulated zinc and calcium dependent 
proteolytic enzymes that play important roles in both development and disease states.  
In either secreted or membrane-bound forms, MMPs are collectively capable of 
degrading virtually all components of the ECM, as well as cleaving other proteinases, 
proteinase inhibitors, growth factors, chemotactic molecules, growth factor binding 
proteins, cell surface receptors and cell adhesion molecules (Cawston and Wilson, 
2006; Ahmad et. al, 2006; Nagase and Woessner, 1999; Maskos and Bode, 2003; 
Cunningham et. al, 2005; Conant and Gottshall, 2005).  MMPs first gained recognition 
in 1962, when Gross and Lapiere detected collagenolytic activity in involuting tadpole 
tales, and revealed collagenase-1 (MMP-1) as the first member of the MMP family. 
Subsequent studies revealed new members of the MMP family, often with overlapping 
substrate preferences. Until recently, MMPs had been placed into groups such as 
collagenases, gelatinases, and stromelysins, based on these similar substrate 
preferences. With technological advances, distinct structural variations within these 
groups and overlap in substrate specificity led scientists to rethink MMP classification.  
A total of 25 vertebrate MMPs have been identified and grouped into the 
following 7 subsets, primarily based on domain organization: (1) Minimal domain: MMP-
7, MMP-26; (2) Simple hemopexin domain (collagenases, stromelysins, and others): 
MMP-1, MMP-3, MMP-8, MMP-10, MMP-12, MMP-13, MMP-18, MMP-19, MMP-20, 
MMP-22, MMP-27; (3) Gelatinases: MMP-2, MMP-9; (4) Furin activation, secreted: 
MMP-11, MMP-28; and Vitronectin insert: MMP-21; (5) Transmembrane 
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MMP/Membrane-type (MT-MMP; Type I Transmembrane): MMP-14 [Membrane-type-
1(MT1-MMP)], MMP-15 (MT2-MMP), MMP-16 (MT3-MMP), MMP-24 (MT5-MMP); (6) 
Glycosylphosphatidylinositol (GPI) anchored (Type I Transmembrane): MMP-17 (MT4-
MMP), MMP-25 (MT6-MMP); (7) Cys/Pro rich with Ig-like domain (Type II 
Transmembrane): MMP-23 (Fig. 1.2) (Cawston and Wilson, 2006; Yong, 2005; 
Stamenkovic, 2003).  Studies reveal that among these subsets and groups, despite 
distinct tissue expression patterns of individual MMPs, structural and functional overlap 
and interaction occurs, thus revealing a complexity that was once thought to be absent 
in MMPs (Cawston and Wilson, 2006; Sternlicht and Werb, 2001).  In addition to the 
standard eight subsets, there are other families of enzymes that share structural and 
functional similarities with MMPs, and are loosely included within the MMP family, such 
as the ADAMs motifs.  This sub-family of molecules will be discussed in further detail in 
a later section.  
Structurally all MMPs are multi-domain proteins, with each domain serving a 
specific function.  Secreted and membrane type-MMPs (MT-MMPs) contain the 
following common domains, unless otherwise noted: (1) N-terminal signal domain, 
which is removed upon insertion into the endoplasmic reticulum; (2) Propeptide domain 
(~80 amino acids) containing a “cystine switch” which helps maintain latency by 
blocking the catalytic zinc active site, and is cleaved to activate MMPs; (3) highly 
conserved Catalytic domain (~170 amino acids) containing three histadine residues 
bound to a zinc ion, calcium ions, and a conserved methionine residue, forming a 
structurally supportive “Met-turn” motif beneath the zinc ion active site; (4) Hinge region, 
which varies in length and composition and is involved in substrate specificity (absent in 
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MMP-7, -23, -26); and (5) C-terminal domain known as the hemopexin-like domain 
(~200 amino acids), or HLD, which is also thought to be involved in substrate specificity 
(absent in MMP-7, -23, -26) (Hernandez-Barrantes et. al, 2002; Nagase et. al, 2006; 
Sternlicht and Werb, 2001; Stramenkovic, 2003). Additional insert sequences are 
present and further dictate function in certain secreted and membrane-bound MMPs. 
Vitronectin and fibronectin-type II domain inserts are found in MMP-21; and MMP-2 and 
-9, respectively, while furin recognition sequences (RR(K/R)R)  are found at the C-
terminus of the propeptide domain in all MT-MMPs and MMP-11, -28, -21, and -23 
(Maskos and Bode, 2003; Nagase et. al, 2006; Cawston and Wilson, 2006; Fillmore et 
al, 2001).   According to current in vitro literature, this sequence allows for these specific 
MMPs to be activated intracellularly by serine proteases of the pro-protein convertase 
class (i.e.-furin) (Pei and Weiss, 1995; Illman et al., 2003; Sato et al., 1996; Kang et al., 
2002).  Despite slight subgroup variations, these general structural components create 
the foundation of the MMP family, and contribute to their multi-functional nature. 
As is true in all of science, structure dictates function.  MMPs are highly involved in 
tissue remodeling and reorganization during both development and disease, such as 
spinal cord injury (SCI), TBI, AD, stroke, Parkinson‟s disease (PD), and Multiple 
Sclerosis (MS) (as reviewed by Rosenberg, 2002, 2009; Yong et al., 2001; Nagase et. 
al, 2006).  Proper regulation of MMP function helps maintain a balance between tissue 
breakdown and preservation, and primarily occurs by three different mechanisms.  The 
first line of MMP regulation involves transcriptional control.  Generally, MMPs are 
expressed at low levels, but can be transcriptionally upregulated in response to 
increased tissue remodeling and events such as inflammation, injury, and cancer 
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progression (Nagase and Woessner, 1999). Synthesis of all MMPs as inactive 
zymogens (proMMP form) also serves as a regulatory mechanism.  Therefore, in order 
to achieve full function, MMPs must be activated by removal of the pro-domain (Sounni 
and Noel, 2005; Sternlicht and Werb, 2001). Finally, MMP activity can be regulated by a 
collection of endogenous tissue inhibitors of metalloproteinases (TIMPs), which bind 
and inactivate all MMPs in a 1:1 (MMP: TIMP) ratio.  Currently there are four identified 
TIMPs (TIMP-1, -2, -3, -4), each of which has different affinities for individual MMPs.  
These regulatory mechanisms act to balance MMP activation and inhibition, therefore 
maintaining normal development and remodeling in a healthy state (Nagase et. al, 
2006; Cawston and Wilson, 2006).   
While endogenous mechanisms are in place to ensure a physiological balance of 
secreted and membrane-bound MMP activity, regulation of MMPs has been shown to 
become unbalanced during pathological states.  Within the CNS, detrimental effects of 
persistent MMP activity include tumorigenesis, BBB disruption, neuroinflammation, 
demyelination, and neuronal death.  Therefore, MMPs have been shown to occur in 
neuropathologies such as SCI, TBI, AD, stroke, PD, MS (Rosenberg, 2002, 2009; Yong 
et al., 2001).  Laboratory and clinical studies have the used blocking/knockdown 
techniques and synthetic inhibitors in an attempt to control persistent MMP activity in 
these different neuropathologies.  Blocking antibodies, knockout or knockdown methods 
(transgenic mice, short interfering RNA), antisense methods, and pharmacological MMP 
inhibitors have all been used to not only investigate the roles of MMPs but to also limit 
disease progression and improve recovery.  For example, administration of broad- 
28 
 
 
 
 
 
 
 
 
 
Figure 1.2 Matrix Metalloproteinase (MMP) Structure and Subgroups.  a) Variable 
structure of MMPs including general domains (signal peptide, propeptide, catalytic, 
hinge region, and haemopexin) and unique inserts/domains (furin cleavage site, type II 
fibronectin repeats, MT-loop, transmembrane domain, cytoplasmic tail, N-terminal signal 
anchor, cysteine array, Ig-like domain, and GPI anchor; b) Seven subgroups based on 
MMP structure.  Note membrane-type MMPs possess additional structural 
domains/inserts that dictate position and function.
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spectrum MMP inhibitor GM6001 in a stroke model produced a significant reduction in 
infarct size following focal ischemia (Amantea et al., 2007).  Acute administration of 
GM6001 improved functional recovery following SCI and significantly limited the amount 
of apoptotic brain damage following TBI (Noble et al., 2002; Sifringer et al., 2007).  In 
most laboratory studies, inhibition or knockdown of overexpessed and active MMPs at 
appropriate times has limited their detrimental effects and pathology progression.  
Clinical MMP inhibition studies have not produced the same results, and have often 
been stopped early due to poor side effects in patients.  Both laboratory and clinical 
studies have historically focused on the inhibition of secreted MMPs such as MMP-2, -3, 
and -9.  However, the role of membrane-bound MMPs in development and disease has 
gained increased attention over the past decade due to the subgroup‟s unique structural 
features and ability to be an upstream mediator of other MMP activity.              
Membrane-bound MMPs 
Within the family of MMPs important structural differences have been uncovered, 
especially between the secreted and membrane-bound MMPs.  Membrane-bound 
MMPs possess unique structural features that dictate cellular localization and enzymatic 
function.  It is important to note the structural features that set this group apart from 
soluble MMPs, in order to better understand the roles they play in physiological and 
pathological processes. 
A truly unique feature of membrane- bound (membrane-type; MT) MMPs is the 
presence of a membrane anchoring domain following the HLD. This domain consists of 
a stem region (~30 amino acids) and a hydrophobic tether region (~20 amino acids). 
The tether region either exists as a transmembrane domain (TMD) with a short 
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cytoplasmic tail, as in MT1-, MT2-, MT3-, and MT5-MMP, or as a GPI anchor, as in 
MT4- and MT6-MMP (Hernandez-Barrantes et. al, 2002). The cytoplasmic tail in all MT-
MMPs, except MT4-MMP, may serve as a possible phosphorylation site, as is contains 
a cystine residue, with adjacent tyrosine and serine residues (Parks and Mecham, 
1998).  
All MT-MMPs, with the exception of MT4-MMP, contain an additional 8-amino 
acid insertion between β-strand II and III that forms a “MT-loop” within the catalytic 
domain, that is essential for proMMP-2 activation (Sounni and Noel, 2005; English et. al, 
2001).  The ability of MT-MMPs to activate proMMP-2 is best illustrated by the research 
focused on MT1-MMP activation of pro-MMP2.  The activation occurs through a series 
of specific bonds, where MT1-MMP, TIMP-2, and proMMP-2 form a ternary complex on 
the cell surface (Itoh and Seiki, 2005; Itoh, 2006; Itoh et. al, 2001). The process begins 
with the expression of an active, full length MT1-MMP protein (~60 kDa) on the cell 
surface binding to TIMP-2 at the “MT-loop”. Three dimensional analysis of the “MT-loop” 
structure reveals a pocket-like region which matches up with the Tyr-36 residue in the 
AB loop on the N-terminal domain of TIMP-2 (Fernandez-Catalan et. al, 1998).  
Mutations of MT1-MMP‟s “MT-loop” alter enzymatic activity of proMMP-2, further 
indicating its functional importance (Fernandez-Catalan et. al, 1998).  The binding of 
TIMP-2 inhibits any catalytic activity of MT1-MMP, which appears to be functioning 
more as a docking station rather than an enzyme in this situation. TIMP-2 possesses a 
C-terminal domain with a high affinity for the HLD domain of proMMP2. The proMMP-2 
“substrate” docks to the C-terminus of TIMP-2 and forms the ternary complex (Strongin 
et. al, 1995; Maskos and Bode, 2003). The binding of these three proteins is insufficient 
32 
 
to activate proMMP-2, thus an adjacent TIMP-free MT1-MMP is needed to initiate the 
first pro-MMP-2 cleavage. The primary cleavage site in proMMP-2 is not typically 
susceptible to MMPs, but a series of loops within the MT1-MMP catalytic domain may 
act to embrace this site and allow cleavage (Maskos and Bode, 2003). Following the 
initial cleavage, an additional MMP-2 molecule removes the remaining propeptide 
domain from the intermediate MMP-2 to yield a mature and fully-active MMP-2 molecule 
(Deryugina et. al, 2001).  While the majority of the current literature of is focused on 
MT1-MMP, other MT-MMPs are believed to carry out the same function (MT2-MMP, 
MT3-MMP, and MT5-MMP).  The unique “MT-loop” feature further implicates this 
subgroup of MMPs in physiological and pathological processes that require MMP-2 
activity.   
As previously mentioned, all MT-MMPs have a furin recognition sequence at the 
C-terminus of the propeptide domain, which serves as a cleavage site for activation (as 
reviewed by Cawston and Wilson, 2006). A second site in the propeptide, described as 
a stretch of 5 homologous amino acids, is present in addition to the furin recognition 
sequence in all MT-MMPs. This site may be essential to enzymatic functioning and act 
as an intramolecular chaperone by maintaining protein conformation (Fillmore et. al, 
2001; Cao et. al, 2000). Collectively, these structurally characteristics make MT-MMPs 
unique proteolytic enzymes within the MMP family (see again Fig 1.2).  
Based on advances made in uncovering these structural variations, MT-MMPs 
have emerged as important new players in ECM regulation due to their unique cellular 
localizations, structure, and involvement in a variety of physiological and pathological 
processes, such as tissue remodeling, tumor growth and metastasis, angiogenesis, 
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synaptic plasticity, and even activation of secreted proMMPs (Sato and Seiki, 1996; 
Jaworski, 2000, as reviewed by Sounni and Noel, 2005).  Although MT-MMPs possess 
functions similar to those of secreted MMPs, and cleave some of the same substrates, 
such as collagen, gelatin, laminin, glycoproteins and proteoglycans, they do possess 
structural and functional characteristics which set them apart from their secreted 
counterparts (Hernandez-Barrantes et. al, 2002). In contrast to secreted MMPs, which 
can migrate away from the cell to affect distant targets, MT-MMPs are specialized to 
affect a very focal area of the pericellular microenvironment.  As a result of their focal 
concentration, MT-MMPs have additional unique functions, some of which have direct 
and indirect effects on secreted MMP activity.  
In general, MT-MMPs contribute to the proteolysis of ECM components and the 
activation of proMMPs (proMMP-2, -13) or other zymogens (ADAMTS-4 p68), as well as 
influence a variety of extracellular and intracellular signaling pathways, alter cell-to-cell 
and cell-to-matrix relationships, control gene expression, and promote cell survival, 
migration and invasion, and angiogenesis, during phases of health and disease 
(Hernandez-Barrantes et. al, 2002; Sounni and Noel, 2005; Deryugina and Quigley, 
2006).  MT-MMPs are able to influence the above processes because of the different 
structural domains that make them unique.  The most distinguishing feature of an MT-
MMP is its position within the plasma membrane.  Prior to inserting in the membrane, 
most often the furin recognition sequence is cleaved by proprotein convertase in the 
Golgi during protein trafficking, and the MT-MMP becomes activated intracellularly.  
Blocking MT-MMP intracellular activation has been shown to be a prerequisite for MT-
MMP membrane insertion and position.  For example, when intracellular MT1-MMP 
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activation is blocked in vitro, MT1-MMP fails to be trafficked to the membrane and 
remains localized proximal to the Golgi compartment (Wu et al., 2007).  This level of 
intracellular regulation is thought to allow for proper protein folding and activation prior 
to membrane insertion, therefore ensuring that when the enzyme is upregulated, it is 
ready to function when and where it is needed in a timely manner.  There is also 
evidence of alternative methods of MT-MMP activation, including autoproteolysis, 
cleavage by a non-furin protease and extracellular activation by plasmin (Okumura et. 
al, 1997).  This characteristic of primary intracellular activation is in contrast to most 
secreted MMPs which are primarily activated extracellularly.   
Following activation, the cytoplasmic tail (domain) may be an important player in 
intracellular events such as trafficking and cell surface localization of the MT-MMP, 
therefore affecting MT-MMP functions such as sheddase activity and subsequent cell 
migration (Nakahara et. al, 1997). For example, in cancer cells MT1-MMP is localized at 
higher concentration in lamellipodia and invadopodia, possibly due to cytoplasmic tail 
activity (Nakahara et. al, 1997). This specific localization of MT1-MMP leads to an 
increase in pericellular ECM degradation and surface receptor cleavage, therefore 
enhancing cell migration (Hotary et. al, 2000; Mori et. al, 2002; Nakahara et. al, 1997). 
The mechanism of cell migration is not fully understood, but may involve MT1-MMP 
directed shedding of the membrane glycoprotein CD44, a widely expressed major 
hyaluronan receptor involved in cell-cell interactions, adhesion, and migration.  
Releasing the ectodomain of CD44 from the cell surface may alter the cell-matrix 
adhesion properties and permit cell migration (Naor et. al, 1997).  In order to fully 
promote cell migration, MT1-MMP must also be internalized by a clathrin-dependent 
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pathway, a process that is also mediated by the cytoplasmic tail (Anilkumar et. al, 
2005). Other MT-MMPs may also be able to influence cell migration in a similar fashion.  
In addition, the cytoplasmic tail may influence cell signaling pathways, as well as MT-
MMP dimerization and trafficking (as reviewed by Souni and Noel, 2005; Wang P et. al, 
2004).  
Once tethered to the membrane, the transmembrane or GPI anchor domains are 
responsible for maintaining the position of MT-MMPs, which in turn concentrates 
proteolytic activity to specific regions of the cell surface (Sternlicht and Werb, 2001). In 
this position, the catalytic domain is the integral structural component, and is necessary 
to carry out many MT-MMP functions.  MT-MMPs membrane localization, along with 
influence from the cytoplasmic tail domain, may also affect cell signaling pathways that 
involve cell survival, migration and invasion, and angiogenesis.  In pathological states, 
the spatial relationship of MT-MMPs and their cell surface substrates facilitates 
cleavage and shedding of either whole or fragmented proteins, resulting in modification 
of cell signaling pathways (Itoh and Seiki, 2006).  An example of this is the indirect 
activation of epidermal growth factor receptor (EGFR) signaling by MMP-2, -9 and MT1-
MMP.  EGFR activation affects downstream oncogenic pathways, such as the Sac, 
Ras, and extracellular signal-regulated kinase (ERK) pathways, and may also lead to 
increased expression of MT1-MMP in cultured glioma cells.  This suggests that EGFR 
and MT1-MMP may function together as mediators of glioma malignancy (Roelle et. al, 
2003).  MT-MMPs may also be involved in intracellular signaling through interaction with 
integrins. Integrins are cell adhesion molecules that mediate bi-directional signal 
transduction through the plasma membranes of neighboring cells.  Interaction between 
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MT1-MMP and αvβ3 integrin promotes cell adhesion and migration in vitro through the 
phosphorylation of the focal adhesion kinase (FAK) pathway (Deryugina et. al, 2002).  
In addition, MT2-MMP plays a role in the protection of tumor cells in vitro by altering 
apoptotic signals, therefore suggesting that it may protect tumor cells in vivo as well 
(reviewed by Deryugina and Quigley, 2006).  Through these signaling pathways and 
other mechanisms, MT-MMPs play very crucial roles in pathological states (Wang R et. 
al, 2004).  
Apart from its membrane-bound activities, the catalytic domain of some MT-
MMPs can be cleaved autocatalytically or non-autocatalytically, thereby releasing it into 
the surrounding microenvironment as a soluble enzyme.  Shedding of the catalytic 
domain from the membrane may be a point of MT-MMP regulation, and possibly result 
in further pericellular proteolysis and alteration of enzyme-inhibitor balance through 
TIMP binding (Osenkowski et. al, 2004; Hernandez-Barrantes et. al, 2002; Wang and 
Pei, 2001). Further investigation of cleaved and shed MT-MMP catalytic domains is 
needed to better define how they function as soluble proteinases.   
Membrane-bound-MMPs and the Nervous System 
Although MMPs are highly involved in both physiological and pathological events 
throughout the body,  their involvement in nervous system development, remodeling, 
and repair remains at the forefront of scientific investigation.  During nervous system 
development, MMPs are involved in dendritic and axonal formation and growth, 
synapse formation and stabilization, neuronal and glial migration, and structural 
reorganization. (Komori et. al, 2004; Sekine-Aizawa et. al, 2001; Monea et. al, 2006; 
Jaworski, 2000). In addition to their roles in development, MMPs act as major players in 
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a variety of neuropathological processes such as cancer, neurotoxicity, 
neuroinflammation, cerebral ischemia, TBI, AD, and MS (Sekine-Aizawa et. al, 2001; 
Sounni and Noel, 2005; Cunningham et. al, 2005; Yong et. al, 2001; as reviewed by 
Rosenberg, 2002).  While several soluble MMPs (e.g., MMP-2, -3, -9) have been shown 
to influence these processes, membrane-bound MMPs have emerged as important 
players based on their localization and ability to concentrate enzymatic activity.  Here 
we will detail a specific membrane-bound MMPs, MT5-MMP, in relation to central 
nervous system development and plasticity. 
MT5-MMP 
Nearly a decade ago, the fifth member of the MT-MMP subset was cloned, 
sequenced, characterized, and appropriately named MT5-MMP (MMP24) (Pei, 1999; 
Llano et. al, 1999). Structurally, MT5-MMP shows the greatest homology with MT3-
MMP, followed by MT1-MMP and MT2-MMP, maintaining overall sequence identities at 
64.4%, 53%, and 52.1%, respectively (Pei, 1999). Llano et al (1999), found similar 
homology between MT5-MMP and MT3-MMP at 63%. The molecular mass is ~65 kDa 
for the full inactive form of MT5-MMP, ~58 kDa for the full active form, ~52 kDa for the 
transmembrane-lacking form, and 28-34 kDa for shed forms (Pei, 1999; Sekine-Aizawa 
et. al, 2001, Wang X et. al, 1999). 
 A few structural variations are present in MT5-MMP, and may influence its 
functional abilities. Llano et al (1999) found a series of repeated sequences (CCG, 
CTG, and GCG) in the signal and propeptide domains of MT5-MMP. These sequences 
generate stretches of 8 Pro residues and 6 Leu residues in the signal sequence, and 6 
Ala residues in the propeptide domain, therefore making the N-terminal region of MT5-
38 
 
MMP significantly longer than the other membrane-bound MMPs. In the human 
genome, these nucleotide sequences are highly unstable and therefore usually 
polymorphic, which may suggest the existence of MT5-MMP protein variants with 
alternative structures and functions (Llano et. al, 1999; Ross and Fillmore, 2007). 
Another variation is present within the stem domain of MT5-MMP in mouse, rat, and 
human, where there is an additional furin recognition site, RRKERR. The RRKERR 
motif is necessary for cleavage and shedding of the soluble MT5-MMP form (Wang and 
Pei, 2001). Rapid shedding or fragmenting of MT5-MMP appears to be common at 
physiological temperatures, perhaps due to enzymatic instability (Pei, 1999; Wang X et. 
al, 1999). These structural differences influence MT5-MMP‟s functional role within the 
nervous system.  
Aside from structural additions, MT5-MMP has a very unique pattern of tissue 
expression when compared to the other membrane-bound MMPs, which are expressed 
in a variety of tissue types (Bernal et. al, 2005). MT5-MMP appears to be preferentially 
expressed in both rodent and human nervous systems, with mouse and human MT5-
MMP 95% homologous (Pei, 1999; Sekine-Aizawa et. al, 2001; Conant and Gottschall, 
2005). Within the rat brain MT5-MMP accounts for ~60% of all non-gelatinase type 
MMPs, whereas MT1-MMP and MT2-MMP account for 22.7% and 13%, respectively 
(Sekine-Aizawa et. al, 2001). Through reverse transcriptase polymerase chain reaction 
(PT-PCR) technology, MT5-MMP expression has been tested in a variety of tissues. 
Although expression remains the highest in the developing and adult brain and spinal 
cord, weak expression has been detected in tissues such as testis, liver, bone, 
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pancreas, lung and kidney (Pei, 1999; Llano et. al, 1999; Sekine-Aizawa et. al, 2001; 
Bernal et. al, 2005).  
Expression of MT5-MMP in the developing and adult CNS is primarily in regions 
that exhibit high neuronal plasticity, such as the hippocampus, olfactory bulbs, dentate 
gyrus (DG), ventricular zone, and cerebellum (Jaworski, 2000; Sekine-Aizawa et. al, 
2001; Hayashita-Kinoh et. al, 2001).  MT5-MMP has also been detected in PNS 
structures such as, isolated dorsal root ganglion neurons (DRG) and the trigeminal 
ganglion (Jaworski, 2000; Hayashita-Kinoh et. al, 2001).  Within these regions, MT5-
MMP is primarily expressed in neurons, including cerebellar purkinje and granule cells, 
hippocampal and cortical pyramidal cells, and granule cells in the DG (Hayashita-Kinoh 
et. al, 2001; Sekine-Aizawa et. al, 2001).  In the developing rat cerebellum, MT5-MMP is 
specifically localized in the soma and dendrites of Purkinje cells (Sekine-Aizawa et. al, 
2001).  Within isolated DRG cells of the developing mouse, MT5-MMP is localized in the 
soma and growth cone of neurites (Hayashita-Kinoh et. al, 2001). The localization and 
expression patterns of MT5-MMP in the nervous system suggest that MT5-MMP may 
be involved in normal development, morphogenesis, and neural plasticity.  In addition, 
MT5-MMP is indicated in neuropatholgies such as AD, brain cancer, and neurotrauma 
(Sekine-Aizawa et. al, 2001; Ahmad et. al, 2006; Llano et. al, 1999; Pei, 1999; Wang P 
et. al, 2004; Komori et. al, 2004).  
MT5-MMP‟s role in development has been investigated in both the rat and 
mouse nervous systems (Sekine-Aizawa et. al, 2001; Jaworski, 2000; Hayashita-Kinoh 
et. al, 2001).  Using in situ hybridization, MT5-MMP mRNA is first detected in the rat at 
embryo day 16 (E16), and is clearly expressed in neocortical areas by E20. Levels peak 
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at postnatal day 0 (P0), and although there is a steady decline into adulthood, MT5-
MMP remains highly localized to regions of postnatal plasticity (Jaworski, 2000).  In 
Purkinje cells of the postnatal rat cerebellum, Western blot analysis reveals a gradual 
increase in MT5-MMP protein levels between P1 and P35, with a dramatic increase 
during P14-35.  Immunohistochemistry supports these observations at different 
postnatal time points.  At P5, MT5-MMP is expressed in mature post-mitotic neurons 
within the inner granule cell layer, especially in the soma.  At P14, a time-point during 
which dendritic trees are developing, MT5-MMP protein is highly present in dendrites.  
MT5-MMP remains present in developed dendritic trees and cell bodies at P35, and is 
densely expressed within the Purkinje cells, as far out as postnatal week 10 (P10W) 
(Sekine-Aizawa et. al, 2001).  A varied expression pattern of MT5-MMP mRNA is 
observed within the developing mouse cerebellum.  Northern blot analysis reveals weak 
MT5-MMP mRNA expression at E14.  Levels increase in the mouse cerebellum from 
E18 through P0, at which time levels drop sharply and are practically undetectable at 
P30 (Hayashita-Kinoh et. al, 2001).  During this timeline of mouse development, several 
neocortical morphogenic events are occurring, including active neurogenesis, neuronal 
migration and differentiation, neurite outgrowth, and synaptic pruning (Brumwell and 
Curran, 2006).  Collectively, MT5-MMP‟s pattern of expression during rat and mouse 
brain development suggests that it may be involved in nervous system morphogenesis 
and plasticity, possibly through ECM degradation and remodeling.  
In the adult brain, MT5-MMP is an important player in both physiological and 
pathological processes.  As a member of the MMP family, MT5-MMP has inherent 
proteolytic abilities, and is active within the nervous system.  MT5-MMP cleaves and 
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fully degrades gelatin, chondroitin sulfate proteoglycans (CSPG), heparin sulfate 
proteoglycans (HSPG) and dermatan sulfate proteoglycans (DSPG), and partially 
degrades fibronectin in vitro (Hayashita-Kinoh et. al, 2001; Wang X et. al, 1999; as 
reviewed by Hernandez-Barrantes et. al, 2002).  In situ zymography shows MT5-MMP 
gelatinolytic activity in post-mitotic cells migrating to the cerebellar inner granule layer in 
P9 mice, and in adult cerebellar Purkinje and granule cells.  In mouse DRG cells of the 
PNS, recombinant MT5-MMP degrades CSPG and HSPG, both of which play an 
inhibitory role in neurite outgrowth (Hayashita-Kinoh et. al, 2001).  Cleavage of some 
proteoglycans is thought to release reservoirs of factors such as amphoterin and 
pleiotrophin, which may promote neurite outgrowth (Quinn et. al, 1999).  MT5-MMP is 
responsible for this proteolytic activity in vitro, because the activity is blocked by MMP 
inhibitors such as ethylenediamine tetraacetic acid (EDTA), BB94 and TIMP-2 
(Hayashita-Kinoh et. al, 2001; Wang X et. al, 1999).  MT5-MMP appears to be unable to 
degrade laminin and type I collagen (Wang X et. al, 1999).  The degradation of specific 
MT5-MMP substrates may contribute to normal tissue remodeling and reorganization, 
as well as influence synaptic plasticity within the nervous system.  
In addition to playing a role in normal tissue reorganization, MT5-MMP may be 
involved in pathologies such as cancer and AD.  The activation of proMMP-2 by MT1-
MMP/TIMP-2 is a key event in a variety of human carcinomas, including brain cancer.   
As previously mentioned, MT5-MMP is capable of activating proMMP-2 in vitro, and is 
believed to function similarly to MT1-MMP (Wang X et. al, 1999; Pei, 1999; Llano et. al, 
1999).  Therefore, MT5-MMP activation of proMMP-2 could play a role in tumor cell 
migration and invasion within the brain.  It is speculated that MT5-MMP forms a 
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homodimer, similar to that of MT1-MMP, during proMMP-2 activation as previously 
described.  This is supported by in vitro immunoprecipitation experiments that reveal 
what is thought to be a dimerized MT5-MMP 130 kDa form (Pei, 1999).  In human tissue 
samples, MT5-MMP mRNA is significantly over-expressed in brain tumors such as 
astrocytomas, anaplastic astrocytomas, and glioblastomas (Llano et. al, 1999).  
Recently, investigators have tried to target different proteins that interact with MT5-
MMP, as a possible means of treating these types of cancer.  For instance, activation of 
proMMP-2 appears to take place at the cell surface, therefore mechanisms that regulate  
MT5-MMP position and localization on the membrane may also be involved in cancer 
progression.  Typically, MT5-MMP proteins are internalized from the membrane and 
sent back through the Trans Golgi Network (TGN), and are then retrieved and 
repositioned on the cell surface.  Mint-3, which is capable of binding membrane 
proteins, is required for retrieval of internalized MT5-MMP back to the membrane, 
through interaction with the EWV motif in the carboxyl-end of MT5-MMP.  Theoretically, 
if Mint-3 were inhibited or knocked down, fewer internalized MT5-MMP proteins would 
be repositioned in the membrane, less proMMP-2 would be activated, and tumor cell 
migration and invasion would diminish (Wang X et. al, 2004).  Further investigation into 
the actual mechanism and efficiency of proMMP-2 activation by MT5-MMP is needed to 
gain greater insight into its role in human carcinomas of the nervous system.   
In addition to involvement in cancer progression, MT5-MMP may also play a role 
in neurodegenerative diseases, such as AD.  One of the hallmarks of AD is the 
presence of senile plaques, which primarily consist of mis-folded aggregates of amyloid 
β (Aβ), a proteolytic product of amyloid precursor protein (APP).  MT5-MMP interacts 
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with both Aβ and APP in the brain.  In human brains, MT5-MMP is co-localized with Aβ 
deposits near senile plaques, suggesting that cells may utilize MT5-MMP proteolytic 
abilities to remove fibrillar forms of Aβ peptides (Sekine-Aizawa et. al, 2001).  MT5-
MMP also induces cleavage and shedding of APP from the membrane in vitro, but only 
in the presence of the adapter protein Fe65.  MT5-MMP sheds a 120 kDa APP fragment 
from the membrane and induces Fe65-dependent transactivation, where Fe-65 remains 
bound to the cytoplasmic tail of APP and is translocated to regulate gene expression 
associated with APP (Ahmad et. al, 2006).  While Fe-65 is considered a scaffolding or 
adapter protein rather than a transcription factor, it has been found to influence protein 
expression and interact with a number of molecules, including APP, that are involved in 
nervous system development and tissue specific functions (Araki et al, 2004).  In 
relation to APP, MT5-MMP may either function to decrease the amount of Aβ 
aggregates and possibly protect against AD, or it may contribute to the progression of 
AD by cleaving APP into smaller fragments, ultimately leading to senile plaque 
formation.  Further investigation will help characterize MT5-MMP‟s involvement in AD.  
Aside from membrane bound activities, MT5-MMP may possess the ability to 
process ECM components and other proteins as a soluble species (Pei, 1999). When 
membrane-bound, MT5-MMP has a very short half-life, of ~ 30 min at 37°C in vitro, and 
is constantly being shed at rates higher than other MT-MMPs. The full length 
membrane-bound form is autocatalyzed into smaller fragments, which are released into 
the pericellular space.  Of these fragmented species, the ~28 kDa fragment retains the 
catalytic domain, and therefore may have new proteolytic abilities within the 
extracellular space (Wang X et. al, 1999).  The activity of the cleaved catalytic domain 
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of MT5-MMP is not fully understood, but may ultimately expand MT5-MMP‟s substrate 
profile in vivo.  
Based on previously discussed expression pattern within highly plastic regions of 
the brain, and specific localization in developing neurites and dendritic processes, MT5-
MMP is also thought to play a very important role in neural plasticity, or synaptogenesis, 
within the CNS and peripheral nervous system (PNS) following injury.  In the PNS, 
injury induced plasticity involves both collateral and regenerative axonal sprouting into 
the damaged or denervated regions (Fawcett et. al, 2003).  Following a peripheral nerve 
injury, such as transection of the sciatic nerve, it is normal to observe nerve fiber 
sprouting into Lamina II of the dorsal horn of the spinal cord.  MT5-MMP knockout mice 
are unable to structurally reorganization sprouting Aβ-fibers within the dorsal horn of the 
spinal cord following sciatic nerve injury (Komori et. al, 2004).  However, wild-type (WT) 
MT5-MMP mice exhibit the typical injury induced neuronal plasticity.  As a result of the 
lack of axonal sprouting into Lamina II, which contains a high percentage of nociceptive 
neurons, MT5-MMP knockout (KO) mice also do not develop the neuropathic pain with 
mechanical allodynia that typically accompanies such an injury.  Mechanical allodynia is 
feature of neuropathic pain, and is evoked by non-noxious mechanical stimuli.  The lack 
of Aβ-fiber sprouting and mechanical allodynia in KO MT5-MMP mice suggests that 
MT5-MMP plays an important role in laminar reorganization following peripheral nerve 
injury (Komori et. al, 2004).  MT5-MMP may influence reorganization through ECM 
degradation, or possibly through interaction with cell signaling pathways involved in 
nerve fiber outgrowth and migration to the appropriate target.  
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Following CNS injury, certain neurons retain their ability to sprout and form new 
synaptic connections within injured regions to enhance functional recovery, a process 
commonly referred to as reactive synaptogenesis (Hamori, 1990; Fawcett et. al, 2003; 
Phillips and Reeves, 2001).  MMPs and their substrates are major contributors to the 
process of reactive synaptogenesis, which involves collateral sprouting and synaptic 
reorganization and stabilization (Yong et. al, 2001; Fawcett et. al, 2003).  MT5-MMP is 
emerging as an important player in developmental and injury induced synaptogenesis. 
One mechanism of synapse modulation may involve the interaction between the 
enzyme-substrate pair of MT5-MMP and cadherin, which has mainly been studied in 
vitro (Monea et al, 2006).  Cadherins are cell-cell adhesion molecules that are present 
at a number of cell junctions, including synapses (Takeichi and Abe, 2005).  
Specifically, cadherins are present in extending dendritic filopodia and mature synapses 
of cultured hippocampal pyramidal cells (Togashi et. al, 2002).  During synaptogenesis, 
cadherins are active in pre- and post-synaptic terminals and help guide and stabilize 
new connections (Takeichi and Abe, 2005).  Interestingly, blockage of cadherin activity 
at the synaptic junction results in abnormalities in synaptic formation, suggesting that 
cadherins also regulate morphological changes within dendritic spines (Togashi et al, 
2002).  MT5-MMP shares a similar localization pattern to that of cadherin, and is 
present at the growth cone tips of developing cortical neurons, in both axons and 
dendrites, and remains present in the synapses of mature neurons, when bound to the 
palmitoylated α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor 
binding protein (ABP).  Palmitoylated ABP, which can be linked to cell-adhesion 
complexes, guides MT5-MMP to these locations and facilitates the interaction between 
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MT5-MMP and cadherins at the synapse (Monea et al, 2006).  Therefore, MT5-MMP 
may also affect synaptic stability though interaction with cadherins and other cell-cell 
adhesion complexes. Based on the current literature, MT5-MMP is considered an 
important factor in the process of synaptogenesis. However, additional in vivo and in 
vitro studies are needed to fully understand MT5-MMP‟s role in both developmental and 
injury-induced synaptogenesis.  
ADAMs 
ADAMs are type I transmembrane proteins of the adamylisin family that posses 
both proteolytic and adhesive functional capabilities (Black and White, 1998; White et 
al., 2003).  Due to similar domain structures and proteolytic capabilities, ADAM proteins 
are included within the MMP family of proteases previously described.  Currently, 40 
gene members of the ADAM family have been identified, 21 of which are thought to be 
functionally active in humans (Duffy et al., 2009).  The ADAM genes are divided into 
sub-families, based on their ability to exhibit or not exhibit proteolytic activity, and then 
further divided into smaller subsets based on specific tissue/cell expression (testis 
specific vs. non-testis specific).  ADAMs that exhibit proteolytic activity in humans 
include,   ADAMDEC-1 (decysin), ADAM-8, -9, -10, -12, -15, -17, -19, -20, -21, -28, -30, 
and -33.  The remaining human ADAM proteases, ADAM-2, -7, -11, -18, -22, -23, -29, 
and -32 lack one or more essential features in the catalytically active site, and are 
therefore grouped into the non-proteolytic sub-family (Edwards et al, 2008; White et al., 
2003).  These two sub-families are further divided based on tissue/cell expression 
patterns.  Studies have shown that ADAMs are expressed during development in 
different tissue and cell types throughout the body including, testis, lungs, intestines, 
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muscle, central and peripheral nervous system tissue, somatic tissue, bone, and 
hematopoietic cell types (Edwards et al., 2008).  Although the majority of expression 
studies investigate levels during development, selective ADAMs do remain present and 
functional throughout adulthood.     
Structurally, ADAMs are traditionally composed of eight basic domains: 1) N-
terminal signaling-domain; 2) pro-domain; 3) metalloproteinase domain; 4) disintegrin 
domain; 5) cysteine-rich domain; 6) EGF-like domain; 7) membrane-spanning domain; 
and 8) cytoplasmic domain (Fig. 1.3) (Black and White, 1998).  While most domains are 
present in all ADAMs, studies have indicated that in special cases some either remain 
inactive or are absent entirely.  Despite slight variations in structure, these general 
domains each have individual functions that dictate the role(s) ADAMs play during 
biological and pathological states.   
The N-terminal signaling domain is responsible for directing the protein through 
the secretory pathway.  The pro-domain, much like that of the MMPs, maintains enzyme 
latency through the same cysteine-switch mechanisms previously detailed, and also 
acts as an intramolecular chaperone (Roghani et al., 1999).  Removal of the pro-domain 
by a proprotein convertases (i.e.-furin or PC7) in the secretory pathway produces an 
active enzyme (Lum et al., 1998; Anders et al., 2001).  The metalloproteinase and 
disintegrin domains are the most studied of the ADAM domains, and are respectively 
responsible for the protease and adhesive properties that characterize most ADAMs.  
The metalloproteinase domain contains a Zn+2 dependent catalytically active site that is 
held latent by the pro-domain.  Sixty percent of ADAMs possess this domain, which 
contains the same HEXGHXXGXXHD sequence found in the catalytic domains of most 
48 
 
MMPs, indicating the ability for proteolytic activity (Takeda, 2009).  Major substrates that 
are proteolytically processed by the metalloproteinase domain include, signaling ligands 
and their receptors, cell-cell adhesion molecules, cell-matrix adhesion molecules, 
cytokines, and growth factors (White et al., 2003; Seals and Courtneidge, 2003).  The 
disintegrin domain contains a 14 amino acid stretch (CRXXXXXCDXXEXC) called the 
“disintegrin loop” which is believed to be responsible for integrin interaction and 
therefore the adhesive property of many ADAM molecules (White et al., 2003).  
Interaction with integrins has been shown to influence cell adhesion and cell-cell 
interactions.  It is important to note that not all ADAM family members have protease 
and/or adhesive capabilities. 
Unlike the metalloproteinase and disintegrin domains, the cysteine-rich domain is 
present in all ADAM molecules, and is found to be continuous with the disintegrin 
domain.  It has recently been described as having two segments, a “wrist” (Cw) and 
“hand” (Ch).  While Cw is continuous with the disintegrin domain, Ch is the most 
divergent and variable segment in the ADAM structure and therefore posses what has 
been termed a hyper-variable region (HVR).  The HVR is believed to be involved in 
substrate specificity, and may play a role in substrate binding to facilitate ectodomain 
shedding of the substrate by the metalloproteinase domain, therefore influencing 
protease activity (Takeda, 2009).  As a whole, the cysteine-rich domain has also been 
shown to interact with different molecules to promote cell spreading and migration 
(Hooper and Lendeckel, 2005).  The function of the EGF-like domain, which is absent in 
both ADAM-10 and -17, is not well understood in the current literature, but is thought to 
act as a rigid spacer connecting and orienting the metalloproteinase/disintegrin/cysteine 
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domains to the membrane-spanning domain (Takeda, 2009).   The membrane-spanning 
domain tethers the ADAM protein to the cell surface, which makes these molecules very 
similar to the MT-MMPs.  Therefore, they are presented with a limited pericellular 
environment which ultimately concentrates their activity to a specific zone.  It is 
important to note that although the majority of ADAMs are found tethered to the cell 
surface, ADAM-11, -12, -17, and -28 are susceptible to slicing that eliminates the 
membrane-spanning domain (Cerretti et al, 1999; Roberts et al, 1999; Howard et al., 
1999; Galliano et al., 2000).  These sliced variants are released as soluble proteins, and 
able to act at a distance from the cell surface.  It is not yet fully understood if all ADAMs 
are susceptible to this type of alternative splicing.  Nonetheless, the production of 
membrane-bound and soluble ADAM forms permits both focal and diffuse extracellular 
activity.  Among the membrane-bound ADAMs, the cytoplasmic domain varies in both 
length and composition and is often subject to alternative splicing.  At least one Src 
homology region-3 (SH3) binding site is present on the cytoplasmic domain for 
serine/threonine or tyrosine phosphorylation.  Phosphorylation of these sites and/or 
binding of other proteins to the cytoplasmic domain have been shown to influence 
ADAM maturation, trafficking, membrane localization, proteolytic activity, and 
association with cytoskeletal elements (Seals and Courtneidge, 2003).  Taken together, 
the general domains of ADAM molecules permit a variety of functions that have been 
shown to influence processes in development and pathology.   
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Fig 1.3 A Disintegrin and Metalloproteinase (ADAM) General Structure. Schematic 
representation of ADAM structure including prodomain, metalloproteinase domain, 
disintegrin domain, cysteine-rich region, EGF-like domain, transmembrane domain, and 
cytoplasmic tail domain.     
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Functionally, ADAM proteins are known primarily to proteolytically process the 
ectodomains of a variety of cell surface receptors and signaling molecules, and are 
often referred to as “sheddases".  Secondary to protease abilities, ADAMs possess 
adhesive properties that also influence their functional roles during biological processes.  
Expression patterns implicate ADAMs in biological processes such as neuronal cell 
migration, axon guidance, cell adhesion, fertilization, neurogenesis, myogenesis, 
branching morphogenesis in lung, and heart and bone development (as reviewed by 
Hooper and Ledeckel, 2005).  ADAMs have also been shown to play important roles in 
disease states including, cancer, rheumatoid arthritis, AD, Muscular Dystrophy, cardiac 
disease, and Multiple Sclerosis (Hooper and Lendeckel, 2005).   
It is evident that ADAMs play important functional roles in development and 
pathology.  During biological processes, ADAM activity has been shown to promote 
both extracellular and intracellular signaling (Reiss et al., 2005; Janes et al., 2005; 
Borggrefe and Oswald, 2009).  Ectodomain shedding of growth factors or cytokines by 
ADAMs can stimulate and/or inhibit extracellular signaling pathways, which in turn 
influence a number of biological processes.  This ectodomain cleavage of substrates by 
ADAMs has also been shown in many cases to be a prerequisite for intracellular 
signaling, involving molecules such as Notch and β-catenin (Pan and Rubin, 1997; 
Marambaud et al., 2003).  This process, referred to as Regulated Intramembrane 
Proteolysis (RIP) is a sequential proteolytic cascade that involves the primary 
ectodomain cleavage of a membrane-bound protein, followed by a secondary cleavage 
within the membrane by intramembrane-cleaving molecules such as presenilins (Brown 
et al., 2000; Buckingham, 2003).  The secondary cleavage can lead to subsequent 
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processing of intracellular fragments which act in intracellular signaling pathways to 
influence gene transcription.  Currently, ADAM-10 is the primary RIP molecule in the 
ADAM family (Saftig and Hartmann, 2005).  In addition to extracellular and intracellular 
signaling, ADAMs also influence cell adhesion and migration through binding to 
integrins and modulation of cell-cell and cell-matrix connections, respectively.  Cell 
adhesion and migration can also be affected by cleavage of cell adhesion or ECM 
molecules.  Therefore, in many cases, the metalloproteinase and disintegrin domains 
can work in concert to influence different biological processes.   
Successfully carrying out these functions requires a certain level of regulation.  
ADAMs are tightly regulated by a variety of means.  Regulation of these biological 
processes often involves controlling the protease activity, which can be influenced by 
adjacent and downstream domains.  Structural modifications such as Pro domain 
removal and alternative splicing of cysteine-rich and cytoplasmic domains can 
drastically affect the activity of ADAMs.  Binding of surrounding adapter proteins to or 
phosphorylation of the cytoplasmic domain may also impact protease activity.  Due to 
the homology of the catalytic site between MMPs and ADAMs, several ADAM family 
members have been shown to be regulated by the binding of endogenous TIMPs.  
While much regulation is in place to limit the proteolytic activity of ADAMs, other lines of 
regulation act to promote sheddase activity.  For example, ADAM-mediated shedding 
can be stimulated as a result of G-protein coupled receptors or protein kinase C (PKC) 
activation, changes in intracellular Ca2+ levels, and natural or experimental stimuli.  
Additionally, alterations to ADAM cell surface placement and localization can influence 
sheddase activity as well as change the pericellular environment of potential substrates 
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(Reiss and Saftig, 2009).  These levels of regulation of ADAMs influence the 
spatiotemporal expression and function of ADAMs, which is necessary during biological 
processes.  Loss of ADAM regulation has the potential to disrupt ADAM/substrate 
balance, and may lead to the progression of disease. 
    The importance of ADAMs in development and disease has been confirmed 
however specific nuances for each ADAM family member remain to be fully detailed.  
While ADAMs within small subsets may have overlapping structural and functional 
characteristics, it is important to delineate specific biological roles.  For the purposes of 
this study, we have chosen to highlight ADAM-10, and emphasize its expression and 
activity patterns within the nervous system.   
ADAM-10 and the Nervous System 
ADAM-10 was first isolated in 1989 in bovine brain myelin samples, but did not 
get its original vertebrate designation until 1996 (Howard et al., 1996). Today, ADAM-10 
has been identified as an essential protein in a number of vertebrates and is considered 
the principle „RIPing‟ sheddase of cell surface proteins such as APP and Notch.  Among 
the family of ADAMs, ADAM-10 shares the greatest sequence homology with ADAM-17 
(Maskos et al., 1998).  Both ADAM-10 and -17 lack the EGF domain and calcium I and 
III binding sites in the disintegrin domain, and possess additional disulfide bonds within 
their metalloproteinase and a shorter Ch segment in the cysteine-like domains (Takeda, 
2009).  Due to their sequence similarities, ADAM-10 and -17 have been shown to play 
compensatory roles in both development and disease.  While structural and functional 
similarities exist between ADAM-10 and -17, ADAM-10 appears to be expressed at 
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higher levels in the nervous system, therefore suggesting a greater role in nervous 
system development and disease (Marcinkiewicz and Seidah, 2000).     
Early vertebrate studies investigated expression patterns of ADAM-10 in 
developing and mature systems.  During development, ADAM-10 mRNA was found to 
be expressed ubiquitously throughout the dermatome, myotome, epidermis, gut 
ectoderm, epithelial tissue of the kidney and liver, heart and in neural crest cells of the 
chick embryo (Hall and Erickson, 2003).  In the developing mouse brain, ADAM-10 
mRNA was detected at E13 in cranial ganglia, and at E17 and P4, primarily 
concentrated within the superficial cortical layers and hippocampus.  In adult mouse 
brain, ADAM-10 mRNA expression was dampened, however more specifically localized 
to pyramidal cells in cortical layers II-VI, throughout the CA1 hippocampal region, 
dentate gyrus, and dorsal thalamus, and within non-neuronal cells including 
oligodendrocytes within the corpus callosum and choroid plexus cells (Marcinkiewicz 
and Seidah, 2000).  In human tissue, ADAM-10 was found to be highly expressed 
throughout the brain, in both neurons and glial cells, as well as in mesenchymal stem 
cells, placenta, bone marrow and blood myeloid cells, and bladder (Karkkainen et al., 
2000; Marcinkiewicz and Seidah, 2000; Edwards et al, 2008).   These expression 
patterns suggested a potential functional importance of ADAM-10 within the developing 
and adult nervous systems.  Further functional studies confirmed ADAM-10 as the 
principle sheddase involved in the Notch signaling pathway, and revealed it to be 
among a small group of ADAMs responsible for α-secretase cleavage of APP.  Although 
substrates Notch and APP have dominated ADAM-10 literature, there are additional 
potential substrates, including Ephrins, CD44, L1 adhesion molecule, N-cadherin, and 
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EGF, that may also influence nervous system physiology and pathology (Janes et al., 
2005; Nagano et al., 2004; Mechtersheimer et al., 2001; Reiss et al., 2005; Sahin et al., 
2004).  In the following sections, selective ADAM-10 substrates will be highlighted to 
demonstrate the involvement of ADAM-10 in development and disease.     
 ADAM-10 involvement in the Notch signaling cascade has garnered much 
investigation due to the importance of Notch in a number of biological processes.  
Within the nervous system, Notch is present from birth to death, and actively influences 
processes including neurogenesis, axonal and dendritic growth, synaptic plasticity, and 
neuronal death.  Notch has also been implicated in different neuropathologies, including 
ischemic stroke, AD, PD, Huntington‟s disease, and brain cancer through the Notch 
signaling pathway (Lathia et al., 2008).  Therefore, understanding ADAM-10/Notch 
interaction not only gives insight to nervous system development and maintenance, but 
it may also shed light on possible treatment options for the involved neuropathologies.  
The Notch signaling pathways involves the binding of the Notch receptor to its 
appropriate ligand (Delta-like, Jagged in mammals), which induces a set of proteolytic 
cleavages, the release of an intracellular Notch fragment, and subsequent regulation of 
gene transcription.  The released intracellular domain of Notch does not bind directly to 
DNA but rather acts as a transcriptional coactivator by binding recombination signal 
sequence-binding protein Jκ (RBP-J) and activates the transcription of genes that 
contain binding sites for RBP-J (Borggrete and Oswald, 2009).  Notch target genes 
include: transcription factors such as Hes and Hey proteins; developmental and immune 
genes such as CD25 and GATA3; genes associated with cell survival, proliferation, and 
migration such as c-myc and cyclinD1; and a variety of others such as NFκB2, bcl-2, 
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and ADAM-19 (as reviewed by Borggrefe and Oswald, 2009).  The downstream effects 
of Notch signaling on both development and disease are widespread, and partially 
dependent on ADAM activity.   ADAM-10 is capable of cleaving Notch at its first 
cleavage site, which in turn allows for additional cleavage by γ-secretase and release of 
an intracellular fragment (Pan and Rubin, 1997; Borggrefe and Oswald, 2009).  Without 
the ADAM-mediated cleavage event, Notch deficiency would occur, leading to a 
breakdown in gene transcription and downstream CNS processes.  Interestingly, 
ADAM-10 knockout mice exhibit multiple developmental malformations, including 
defective CNS and heart development, vasculogenesis and somitogenesis, similar to 
those seen in other Notch deficiency models such as Notch1/Notch4 and 
presenilin1/presenilin2 double knockout mice (Hartmann et al., 2002; Krebs et al., 2000; 
Herreman et al., 1999).  Based on these finding and observations it can be posited that 
ADAM-10 and Notch interaction is essential for CNS development, and may also be 
important in CNS disease processes.              
Amyloid precursor protein (APP) is another well-studied substrate of ADAM-10 
that is involved in cell motility and axonal vesicular transport under normal conditions 
(Sabo et al., 2001; Kamal et al., 2001).  Like Notch, APP is susceptible to proteolytic 
processing by a variety of secretases, and releases fragments that can act on 
downstream gene targets.  Within the brain, APP can be processed by α- (ADAM-10, -
17), β- (BACE1), and γ- (presenilin) secretases, and each cleavage product acts 
differently.  Cleavage of APP by ADAM-10 results in the release of an extracellular 
APPsα fragment, which has been shown to be neuroprotective and promote 
neuroplasticity (Bell et al., 2008).  This preliminary cleavage induces an intramembrane 
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γ-secretase cleavage and release of an intracellular fragment believed to have nuclear 
signaling functions.  In contrast, cleavage by β-secretase results in the release of an Aβ 
fragment that has been associated with AD plaques, neurotoxicity, and abnormal 
neurite size (LaFerla et al., 2007; Sastre, 2010).  Due to the protective qualities of the 
APPsα fragment and the detrimental nature of the Aβ fragment within the brain, ADAM-
10 has recently been targeted in AD studies.  In human post-mortem studies, ADAM-10 
mRNA was detected by northern blot analysis in AD brains throughout the frontoparietal 
cortex (Marcinkiewicz and Seidah, 2000).  ADAM-10 also showed moderate granular 
and vesicular staining in pyramidal and non-pyramidal neurons in cortical layers I-V and 
also around diffuse neuritic plaques (Bernstein et al., 2003).  Recall that MT5-MMP was 
also found to localize around neuritic plaques, which may indicate functional overlap 
between the two membrane-bound MMPs.  While ADAM-10 was present in AD brains, 
protein expression was significantly reduced when compared to age matched controls, 
indicating that perhaps a reduction in ADAM-10 results in decreased APPsα release, 
therefore giving way to Aβ processing and AD progression.  In vivo AD/ADAM-10 
studies support this hypothesis.  When AD mice were crossed with mice that 
moderately overexpressed ADAM-10 (APPV7171/ADAM10mo), results indicated 
decreased Aβ peptide levels, reduced plaque formation and improved LTP and 
cognitive scores when compared to singly transgeneic AD parent mice (Postina et al., 
2004).  In a separate study looking at excitotoxic stress induced by kainate injection, 
moderate ADAM-10 expression was shown to provide neuroprotection against 
excitotoxic stress in AD parent mice, but failed to protect against seizures and 
neurodegeneration.  Additionally singly transgeneic dominant negative ADAM-10 mice 
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showed shorter seizing times and less neuronal cell death and glial cell invasion 
following kainate injection when compared to wild-type mice.  These results suggest 
that while overexpression of ADAM-10 may limit excitotoxicity in mice that also 
overexpress APP, inhibition of ADAM-10 may be beneficial in controlling seizure activity 
and neuroinflammation in this model (Clement et al., 2008).  While these studies 
indicate a role for ADAM-10 in APP processing, it should also be noted that when 
ADAM-10 is deleted in cells, APP processing still occurred (Deuss et al., 2008).  
Although these are in vitro results, it is important to recognize the functional overlap 
between ADAM-10 and other ADAMs or MMPs.      
While much of the work done to investigate ADAM-10 interaction with ephrins 
has been conducted in Drosophila it may still reveal an important functional relationship 
that has potential influence on vertebrate nervous system processes.  Ephrins act with 
Eph receptors to form bi-directional signaling systems between membrane proteins 
involved in tissue compartmentalization processes such as somitogenesis, 
angiogenesis and axonal guidance (Saftig and Hartmann, 2005).  Within the nervous 
system, axonal guidance requires axon repulsion, which is activated when Eph 
receptor/ephrin connections are disrupted (Pasquale, 2005).  Studies indicate that 
ADAM-10 is capable of ephrin ectodomain cleavage, and disruption of Eph 
receptor/ephrin binding.  In Drosophila, KUZ (ADAM-10 orthologue) was found to be 
required for proper axonal extension during development (Fambrough et al., 1996).  
These observations were further investigated in primary cultured neurons that showed 
ectodomain cleavage of ephrin-A2 when full-length KUZ was present and inhibited 
cleavage when dominant negative KUZ was present (Hattori et al., 2000).  ADAM-10 
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was also found to associate with Eph3A and cleave ephrin-A5 to ensure signal 
termination and complex internalization in cultured cells (Janes et al., 2005).  These and 
other studies implicate ADAM-10 as a primary sheddase of ephrins within the nervous 
system, and suggest an important role for ADAM-10 in plasticity changes associated 
with axonal guidance and nervous system development.     
Finally, ADAM-10 can be tightly linked to nervous system development and 
plasticity through interaction with N-cadherin.  This interaction is similar to that between 
MT5-MMP and N-cadherin.  N-cadherin, which will be discussed in greater detail in the 
following section, is a transmembrane synaptic adhesion molecule that homophilically 
binds across the synaptic cleft to connect and stabilize pre- and post-synaptic elements 
(Benson and Tanaka, 1998).  In addition to maintaining synaptic structure and integrity, 
N-cadherin is important for synaptic efficacy and signaling.  ADAM-10 has been shown 
to regulate cell surface expression and availability of N-cadherin through ectodomain 
shedding (Uemura et al., 2006; Reiss et al., 2005).  Release of the extracellular N-
cadherin fragment has been shown to promote neurite outgrowth (Paradies et al, 1993; 
Utton et al., 2001).  N-cadherin ectodomain shedding not only promotes neurite 
outgrowth and modulates the synaptic stability extracellularly, but it also triggers 
downstream intracellular cytoskeletal changes and transcriptional events through the 
activity and translocation of β-catenin (Reiss et al., 2005).   
While MT5-MMP and ADAM-10 mediated N-cadherin cleavage, along with the 
downstream events will be detailed in later sections, these studies may be taken as 
evidence that these membrane-bound MMPs play a critical role in the process of 
synaptic plasticity.  To better understand the potential effects of N-cadherin proteolytic 
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cleavage, the following section will review characteristics of classic cadherins and 
highlight N-cadherin‟s role in the nervous system.      
 
CADHERINS 
Classic cadherins 
Classic cadherins constitute a well-established family of Ca+2 dependent, cell 
adhesion molecules, with as many as 20 members in a single vertebrate species 
(Takeichi and Abe, 2005).  Cadherins are classified as single-pass transmembrane, 
type I glycoproteins that typically form strong homophilic bonds in the presence of Ca+2, 
and are known to be associated with adherins junctions in a variety of cell types (Heupel 
et al., 2008; Benson and Tanaka, 1998).  Cadherin mediated cell-cell adhesion plays an 
important role in development and maintenance of tissue integrity in multicellular 
organisms (Halbleib and Nelson, 2006).  In addition to their adhesive properties, 
cadherins dynamically influence different intracellular signaling pathways that in turn 
affect downstream transcriptional events during embryological and adult processes 
(McCusker and Alfandari, 2009). 
Structurally, these cell-adhesion molecules possess a large extracellular segment, 
made up of tandemly repeated extracellular cadherin domains (Fig 1.4).  Based on 
extracellular domain number and organization, classic cadherins are further subdivided 
into two distinct groups: type I/II or type III cadherins.  Type I/II cadherins are found 
solely in vertebrates and ascidians and possess five extracellular domains.  Of the five 
extracellular domains, the distal most is responsible for specific binding, which is 
typically homophilic.  However, heterophilic binding can occur through formation of cis- 
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and trans-heterodimers between similar cadherins (Shan, WS et al., 2000).  This group 
can be further divided into type I: epithelial (E-), neural (N-), placental (P-), and retinal 
(R-) cadherins, and type II cadherins, which are designated numerically (ex: Cadherin-
11).  Type I cadherins possess a conserved HAV (histadine alanine valine) adhesion 
recognition sequence that is crucial for homophilic cadherin interactions (as reviewed by 
Suzuki and Takeichi, 2008; Noë et al., 1999).  Type II cadherins lack this HAV 
sequence, and are often found to bind heterophilically between cells.  Finally, type III 
cadherins exist in invertebrates and vertebrates such as fish and birds, but are not 
found in mammals.  In contrast to type I/II, their extracellular segment typically possess 
greater than five extracellular domains, as well as a unique primitive class cadherin 
domain (PCCD) that is situated between the extracellular domains and the plasma 
membrane (Oda and Tsukita, 1999; Tanabe et al., 2004). 
Despite variations in extracellular arrangement, all classic cadherins possess a 
highly conserved intracellular segment that contains juxtamembrane and cytoplasmic 
tail domains.  The juxtamembrane domain (JMD) contains a GGGEED sequence that 
permits interaction with members of the p120 catenin family.   The JMD also plays an 
important role in cell-cell adhesions and cell physiology by influencing cadherin 
clustering, cytoskeletal modifications, and the influx of calcium (Benson et al., 2000; 
Brusés JL, 2006).  The cytoplasmic tail domain (CD) serves as a binding site for 
catenins, such as β- and γ-catenin.  This protein cluster is linked to the actin 
cytoskeleton through α-catenin to not only ensure structural integrity of the tissue and 
full adhesive activity, but also to influence intracellular signaling pathways (see again 
Fig. 1.4) (Togashi et al., 2002; Lilien et al., 1999).   
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Figure 1.4 Classic Cadherin Structure and Interaction with Cytoplasmic Proteins.  
Classic cadherin structure includes tandemly repeated extracellular (EC) domains, a 
membrane spanning domain, and an intracellular domain that is further divided into 
juxtamembrane and cytoplasmic tail domains.  The intracellular domain interacts with 
cytoplasmic proteins such as β- and α-catenin, which anchor cadherin to the actin 
cytoskeleton.   
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Having knowledge of the general structure and function of classic cadherins 
allows us to understand the role they play in tissue development, maturation and 
maintenance.  While cadherins influence a variety of processes throughout an 
organism‟s lifespan, their role in nervous system development and disease has 
garnered tremendous attention and fostered important scientific inquiry.  In order to 
highlight the importance of cadherins in the nervous system, we will shift the focus of 
this review to the role that N-cadherin plays in nervous system development, 
neurophysiology and neuropathology.      
N-cadherin and the Nervous System 
Successful nervous system development requires coordinated temporal and 
spatial synthesis, regulation, and interaction of a number of essential proteins.  Of these 
proteins, N-cadherin (130 kDa) is one of the first present during the onset of nervous 
system development.  In vivo studies show that N-cadherin mRNA is typically 
expressed in two phases, an early embryonic phase and a late embryonic/postnatal 
phase.  In the early embryonic phase, N-cadherin mRNA is ubiquitously expressed 
throughout undifferentiated neuroepithelium.  During this phase the neuroepithelium is 
proliferating in the ventricular zone and the first neurons begin differentiation in the 
marginal zone (lamina I) of the cerebral cortex.  During the late embryonic/postnatal 
phase, when more neurons have differentiated and fiber tracts begin to form, N-
cadherin mRNA expression becomes restricted to particular subsets of neurons in cell-
rich layers or lamina within specific regions of the brain.  These specific brain regions 
include: deep neocortical layers, internal nuclear layer of the retina, parietal cortex, 
olfactory bulb, cerebellum, and several limbic system structures such as the 
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hippocampus proper and dentate gyrus (Bekirov et al., 2002; Redies and Takeichi, 
1993).  Within the rat hippocampus, the highest observed N-cadherin mRNA expression 
occurs from postnatal day 0-2, within cell-rich areas such as the granule cell layer of the 
dentate gyrus and the pyramidal cells of CA1 and CA3 fields.  It has also been observed 
that although N-cadherin is initially localized to both inhibitory and excitatory synapses, 
with time it selectively localizes to excitatory synapses within the hippocampus (Benson 
and Tanaka, 1998).  In addition to neuronal localization, N-cadherin mRNA has also 
been shown within the neuropil of the dentate gyrus molecular layer, which is 
suggestive of astrocytic or oligodendrocyte localization (Bekirov et al., 2002).  This 
observation is consistent with both in vivo and in vitro studies that have shown N-
cadherin mRNA within supportive cells of the nervous system, such as glial and 
Schwann cells (Wilby et al., 1999; Letourneau et al., 1990).  In the postnatal/adult 
phases of life, the distribution of N-cadherin is basically maintained, while its intensity of 
expression tends to decrease with age.   
  N-cadherin expression patterns indicate that it is functionally important during 
nervous system development, and remains necessary into later phases of life.  Studies 
show that N-cadherin is functionally involved in neural tube morphogenesis, 
development of left to right asymmetry through the Wnt signaling pathway, and 
formation of the alar region of the midbrain, hindbrain and posterior spinal cord (Lele et 
al., 2002; Thiery JP, 2003).  Interestingly, null-N-cadherin homozygotes display multiple 
nervous system defects, including malformations of somites and the neural tube, and 
typically die by day 10.5 of gestation due to heart defects (Thiery JP, 2003; Lou et al., 
2001).   Despite the cause of death, the nervous system malformations observed in 
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these animals would ultimately be detrimental to the process normal development, thus 
indicating the importance of N-cadherin during this stage.   
As nervous system development persists neurons differentiate, migrate to their 
final destination and extend axonal and dendritic processes in order to form synaptic 
connections and circuits within the brain.  Once established and throughout their 
existence, synapses experience a variety of modifications and changes.   Together 
these processes can be characterized as either activity-independent, which includes the 
“hard wired” events leading up to and including synaptogenesis, or activity-dependent, 
which can also include synapse formation as well as further synaptic modification (ex: 
strengthening; weakening; deletion).  N-cadherin plays important and distinct roles in 
both activity-independent and dependent processes.   
During the activity-independent phase of development, N-cadherin is upregulated 
and recruited to both pre- and post-synaptic compartments, as well as along axonal 
shafts.  Specifically, N-cadherin is recruited and inserted into the membrane of the 
symmetrical zone on the synapse, or puncta adherentia, which lies laterally to the 
asymmetric synaptic neurotransmitter release zone (Uchida et al., 1996).  Studies show 
that recruitment of N-cadherin to these compartments during development is important 
for neurite outgrowth, axon target recognition, pre-synaptic assembly, dendritic spine 
morphogenesis, and synaptic formation and specificity (Jontes et al., 2004; Bozdagi et 
al., 2000; Lilien et al., 1999).  In addition to a synaptic role, N-cadherin controls growth 
cone migration to Schwann cells, therefore influencing the process of axon myelination 
(Letourneau et al., 1990).   
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The aforementioned processes are guided and/or influenced by specific 
structural components of N-cadherin.  Studies have investigated the role(s) extracellular 
and intracellular domains of N-cadherin play in these processes.  As previously 
mentioned, the extracellular domain of cadherin is necessary for cell-cell adhesion.  It is 
not only responsible for the physical bond formed between cells, in this case neurons, 
but also is important for recruitment of N-cadherin to proper sites within the neuronal 
compartments.  Studies that look at the effect of mutant N-cadherin in both young and 
old neurons illustrate the importance of the extracellular domain.  For example, in older 
neurons, with pre-established synaptic contacts, extracellular domain deletion did not 
lead to synapse disassembly, but instead resulted in dendritic spine morphology 
changes (elongated or bifurcated spines) and significantly smaller synapses.  In both 
sets of neurons, although less dramatic in older transfected neurons, disruption of pre-
synaptic vesicle recycling and Synapsin and PSD-95 distribution was observed 
(Togashi et al., 2002).  These findings highlight the importance of the N-cadherin‟s 
extracellular domain for proper synaptic assembly, and potentially function. 
The intracellular domain of N-cadherin can also influence activity-independent 
events during neural development and synaptogenesis.  Recall that the intracellular 
domain possesses two distinct regions, the JMD and CD.  These regions serve primarily 
as binding sites for different synaptic proteins that are essential for synaptic formation 
and function.  A majority of these synaptic proteins belong to the catenin family.  The 
interaction between catenins and N-cadherin‟s intracellular domain is not only essential 
for the creation and maintenance of synaptic structure, but also important for 
intracellular signaling.     
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It is important to note that the JMD and CD have distinct roles when it comes to 
carrying out these essential synaptic functions.  The JMD has been shown to influence 
processes such as neurite outgrowth, functional coupling between pre- and post-
synaptic elements, synaptic adhesion, and synaptic stabilization through cadherin 
clustering.  These events are believed to involve the coupling and uncoupling of p120 
catenin to/from its surface (as reviewed by Brusés, 2006).  The relationship between the 
JMD and p120 catenin has also been implicated in intracellular signaling.  When p120 
becomes uncoupled from the JMD, it has been shown to influence transcription through 
nuclear translocation and subsequent interactions with a zinc finger transcription factor 
(Daniel and Reynolds, 1999).   
The CD appears to have more of a structural role during neural development and 
synaptogenesis, through its interaction with catenins and the actin cytoskeleton.  
Studies have implicated the CD/catenin complex in events such as neurite outgrowth, 
pre-synaptic vesicle assembly, dendritic spine stabilization, and synaptic adhesion and 
maturation (as reviewed by Brusés, 2006; Benson and Tanaka, 1998).  Proper 
orientation of N-cadherin, β-catenin, αN-catenin and cytoskeletal components is 
necessary for these events to occur successfully.   Multiple studies have shown that 
alterations to any one of the complex proteins during synaptogenesis in young neurons 
can lead to dendritic morphological changes and synaptic destabilization (Togashi et al., 
2002; Abe et al., 2004; Bozdogi et al., 2004).   More mature neurons tend to be affected 
less by these changes, which may indicate compensation by similar cadherins/catenins.   
The CD is also involved in intracellular signaling, primarily through interaction with β-
catenin which is influenced by phosphorylation.  β-catenin is in a dephosphorylated 
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state while bound to the CD, but is released into the cytoplasm when phosphorylated 
(Lilien et al., 1997).  Uncoupled β-catenin, which is well established as a Wnt signaling 
molecule, has the potential to influence a variety of signaling pathways and downstream 
transcription (McCusker and Alfandari, 2009).  For example, β-catenin can combine with 
the Tcf/LEF family of transcription factors to alter gene expression (Huber et al., 1996; 
Moon et al., 2004).  It is clear that both the JMD and CD play important roles in synaptic 
formation, structural integrity, and intracellular signaling during activity-independent 
developmental and synaptogenic events. 
Beyond development, N-cadherin has been found to be involved in activity-
dependent events, mainly activity-dependent synaptic plasticity.  Activity-dependent 
synaptic plasticity is a dynamic process that involves periods of neural activity at the 
synapse that have the potential to change synaptic structure and strength, and is 
essential to normal brain function.  Activity-dependent plasticity is also crucial in 
synaptic circuitry rewiring following CNS injury (Benson et al., 2000).  Neural activity has 
been shown to increase adhesive forces of N-cadherin and also recruit more N-cadherin 
to existing and nascent synapses at different stages of synaptic plasticity (Tanaka et al., 
2000; Bozdogi et al., 2000).  Decreasing or increasing neural synaptic activity using 
pharmacological agents can also alter the expression and localization of catenins that 
are associated with N-cadherin intracellularly (Abe et al., 2004).  Recall that the 
alteration of any of the cadherin-catenin components has been shown to correlate with 
changes in synaptic structure and function. 
The experimental model most often used to illustrate N-cadherin‟s involvement in 
synaptic plasticity is LTP.  To understand N-cadherin‟s role in synaptic plasticity, it is 
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important to first describe the LTP model.  LTP is the cellular model of long-lasting 
synaptic plasticity that is believed to contribute to learning and memory (Nagy et al., 
2006).  Because the hippocampus is crucial for learning and memory formation, 
hippocampal slice preparations is the dominant model used in these experiments, 
where the CA3 field Schaffer collateral afferent fibers are stimulated, and recordings of 
field excitatory postsynaptic potentials (fEPSP) are taken from the dendrites of the CA1 
field (Squire, 1992).  The high frequency stimulation administered to the slice triggers 
strong depolarization of neurons, which can lead to both short and long-lasting synaptic 
plasticity.  Short-lasting plasticity is fast and occurs during the induction and early 
phases of LTP (E-LTP), often lasting for approximately 60 minutes post-stimulation.  E-
LTP does not require new protein synthesis, but rather relies on modification to the 
synapse using existing and available stored proteins (Malenka and Bear, 2004).   Long-
lasting plasticity is slower to develop, occurs during the late phases of LTP (L-LTP), and 
involves gene transcription and protein synthesis, as well as the formation of new 
synaptic connections.  L-LTP can last hours to days, and sometimes weeks post-
stimulus (Benson et al., 2000; Bozdogi et al., 2000).  N-cadherin has been shown to 
play important and distinct roles in both E-LTP and L-LTP.   
Based on the synaptic localization of N-cadherin and its role in synaptic 
assembly and adhesion, it is clear to see how it can influence short- and long-term 
activity-dependent synaptic plasticity.  Alterations in short-term synaptic plasticity 
properties have been demonstrated in N-cadherin knockout embryonic stem cells, 
which displayed functional impairments in high-frequency pre-synaptic vesicle 
exocytosis (Jüngling et al., 2006).   
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In the case of E-LTP, which includes LTP post-stimulus induction, studies have 
shown an important role for N-cadherin.  In hippocampal slices pre-treated with N-
cadherin blocking antibodies, antagonists, or recombinant fragments, E-LTP either fails 
to be induced or displays a decreased E-LTP response that quickly returns to baseline 
(Tang et al., 1998).  N-cadherin also has been shown to be important in strengthening 
of existing and assembly of new synapses during L-LTP.  In a study by Bozdogi et al., 
spCAMP induced LTP resulted in a significant increase of N-cadherin protein levels at 
synaptic labeled puncta (2000).  In contrast to N-cadherin LTP studies, cadherin-11 
knockout mice display enhanced LTP in hippocampal neurons that appeared 
structurally sound.  This finding suggests that cadherins may influence different 
signaling cascades that contribute to synaptic plasticity, and that there are unique roles 
for cadherins localized within this region (Manabe et al., 2000).   
How does N-cadherin strengthen synapses during neural activity?   A possible 
mechanism involves the association for N-cadherin with N-methyl-D-aspartic acid 
(NMDA) type glutamate receptors (NMDAR).  Following strong stimulation of NMDAR, 
N-cadherin dimerizes and becomes increasingly resistant to being processed by MMPs.  
Dimerization promotes strong synaptic adhesion and therefore allows additional 
synaptic changes to take place without compromising synaptic stability (Tanaka et al., 
2000).  However, another study indicates that neural activity may decrease N-cadherin 
adhesive forces due to changes in [Ca+2].  It is well established that a threshold of 
neural stimulation causes an influx of Ca+2 through NMDAR channels, and leads to a 
decrease [Ca+2] at the synaptic cleft.  This decrease in extracellular Ca+2 limits the 
available Ca+2 needed for homophilic N-cadherin binding, therefore weakening its 
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adhesive properties and permitting structural remodeling.  It is estimated that [Ca+2] 
drops from 1.3mM to 0.8-.03 nM upon LTP induction, which in some cases may be 
sufficient to weaken N-cadherin synaptic adhesion (Heupel et al., 2008).  Despite 
varying reports, opposing N-cadherin responses to neural activity may be due to 
involvement of different signaling pathways that are activated during specific stages of 
development and disease.      
Neural activity can also lead to N-cadherin extracellular domain cleavage by 
enzymes such as MT5-MMP and ADAM-10, an event that is triggered by NMDAR 
stimulation (Fig 1.5) (Monea et al., 2005; Reiss et al., 2005; Uemura et al., 2006).  
Extracellular domain cleavage decreases N-cadherin‟s adhesive capabilities across the 
synapse, which may be beneficial during period synaptogenesis when the flexibility of 
synaptic elements is necessary.  Release of a 90 kDa N-cadherin N-Terminal Fragment 
(NTF) into the extracellular space can influence different biological events.  For 
example, NTF can associate with ECM molecules and potentially influence cell 
adhesion and neurite outgrowth.  In addition, extracellular cleavage of N-cadherin 
activates a cascade of events that results in additional cleavage and signaling 
intracellularly (McCusker and Alfandari, 2009).  Intracellular C-terminal Fragment 1 
(CTF1; 40 kD), which contains the transmembrane and entire intracellular domain of N-
cadherin, is generated following NTF shedding.  CTF1 is further modified by Presenilin-
1 (PS-1), which releases the intracellular domain from the transmembrane domain, and 
is renamed CTF2 (35 kD) (Uemura et al., 2006).  CTF2 can interact with both β-catenin 
and cAMP response element-binding (CREB) binding protein (CBP) to prevent their 
degradation, and in turn either promote or limit gene transcription (Marambaud et al., 
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2003; Reiss et al., 2005).  While the exact function(s) of these fragments remains 
elusive, it is clear that neural activity alters N-cadherin structure and function, and in 
turn affects different synaptic processes. 
Based on the current literature, N-cadherin serves a number of functions during 
synaptogenesis and throughout the life of a synapse.  N-cadherin is important during 
activity-independent events, such as neurite outgrowth and axon targeting, and during 
activity-dependent events such as synaptic plasticity and intracellular signaling.  Many 
of these studies have focused on the role(s) of N-cadherin during normal nervous 
system development and neurophysiological events.  There appears to be a need for 
further investigation of N-cadherin expression and function during various 
neuropathologies, such as TBI.  Therefore, we have designed this study to investigate 
the interaction between N-cadherin and two membrane-bound MMPs, MT5-MMP and 
ADAM-10, during injury-induced synaptogenesis following TBI. 
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Figure 1.5 Cleavage Products of N-cadherin.  MMP extracellular cleavage of full-
length (130 kDa) N-cadherin releases a 90 kDa N-terminal fragment (NTF).  
Extracellular cleavage is followed by intracellular processing of N-cadherin.  Intracellular 
fragments include a ~40 kDa C-terminal fragment 1 (CTF1) and a second ~35 kDa 
fragment (CTF2). 
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EXPERIMENTAL HYPOTHESES 
The following set of experiments and their results are divided into two main 
chapters.  The first chapter describes the spatial and temporal hippocampal expression 
of MT5-MMP, ADAM-10, and N-cadherin in models of adaptive (UEC) and maladaptive 
(TBI+BEC) synaptogenesis.  The second chapter describes the effects of in vivo 
pharmacological MMP inhibition on protein expression, physiological response, synaptic 
structural integrity and cognitive behavior during maladaptive synaptogenesis induced 
by (TBI+BEC).  The general hypotheses for both sets of experiments are: 
  
Hypothesis 1: Hippocampal MT5-MMP, ADAM-10 and N-cadherin protein and 
mRNA expression will be altered in UEC and TBI+BEC models during each phase 
of reactive synaptogenesis (2, 7, and 15d postinjury).  The comparison of spatial 
and temporal expression profiles for MT5-MMP, ADAM-10 and N-cadherin will 
reveal differences between models of adaptive (UEC) and maladaptive (TBI+BEC) 
plasticity, identifying aberrant changes linked to the extent of recovery achieved.  
 
To test Hypothesis 1, the spatial and temporal profile of hippocampal protein and mRNA 
expression was characterized using Western blot analysis, immunohistochemistry and 
qRT-PCR over select postinjury time intervals (2, 7, and 15d for protein; 7d for mRNA). 
 
Hypothesis 2: MMP inhibition during periods of enhanced MT5-MMP/ADAM-10 
expression will alter N-cadherin protein levels, as well as improve both synaptic 
efficacy and structure during synapse stabilization when examined 15d post-
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TBI+BEC.  These effects on synaptic plasticity will be reflected in progressive 
abrogation of injury-induced cognitive deficits when tested at 12-15d postinjury.  
 
To test Hypothesis 2, TBI+BEC cases were treated with either MMP inhibitor GM6001 
or vehicle at 6-7d postinjury.  The GM6001 treated and vehicle groups were then 
sacrificed during the period of synapse stabilization at 15d after injury.  Hippocampal 
protein expression was determined using Western blot analysis, while synaptic function 
was analyzed by in vitro electrophysiological measures, and synaptic cytoarchitecture 
determined using electron microscopic techniques.  A separate group of TBI+BEC 
animals was subdivided for either the same GM6001 or vehicle treatment and tested for 
cognitive performance in the Morris Water Maze at 12-15d postinjury.   
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Chapter 2 
 
 
 
Classification of MT5-MMP, ADAM-10 and N-cadherin during Adaptive and Maladaptive 
Injury-Induced Synaptogenesis 
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ABSTRACT 
Traumatic brain injury (TBI) leads to long-term impairments, often resulting from 
excessive neuroexcitation and axonal insult within vulnerable brain regions (Okonkwo 
and Povlishock, 2003; Povlishock and Katz, 2005).  Axon damage produces 
deafferentation and triggers an injury-induced synaptogenic response, involving matrix 
metalloproteinase (MMP) interaction with paired substrates within the deafferented 
region.  Two such MMPs are Membrane-Type 5 Matrix Metalloproteinase (MT5-MMP) 
and A Disintegrin and Metalloproteinase-10 (ADAM010), which  are highly expressed in 
the brain and may influence injury-induced synaptogenesis via cleavage of a shared 
substrate, neuronal cadherin (N-cadherin) (Reiss et al., 2005; Monea et al., 2006).  The 
present study examined the spatial and temporal profiles of hippocampal protein and 
mRNA for MT5-MMP, ADAM-10 and N-cadherin.  Models of adaptive (unilateral 
entorhinal cortex lesion; UEC) and maladaptive (combined central fluid percussion with 
bilateral entorhinal cortex lesion; TBI+BEC) plasticity were contrasted in order to identify 
differences in the expression of these matrix proteins during reactive synaptogenesis.  
Rats were subjected to UEC or TBI+BEC and hippocampal protein extracts prepared at 
2, 7, and 15d postinjury.  Western blot results showed significant elevation of MT5-MMP 
and ADAM-10 expression at 2 and 7d in both models, however, model differences were 
observed at 15d.  Each enzyme was decreased at 15d after UEC, but only MT5-MMP 
showed reduction following TBI+BEC, while ADAM-10 exhibited a persistently elevated 
expression .  Adaptive UEC recovery reduced N-cadherin at 2d, which returned to 
control levels at 7d, and increased expression at 15d.  Maladaptive plasticity induced by 
TBI+BEC also caused a significant decrease N-cadherin at 2 and 7d, but failed to show 
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the increase at 15d as was seen with UEC.  Preliminary qRT-PCR experiments 
sampling 7d deafferented molecular layer revealed increases in UEC transcript for MT5-
MMP and ADAM-10 consistent with the observed protein change, while in TBI+BEC 
only ADAM-10 transcript was altered, with an elevation matching 7d protein rise.  N-
cadherin mRNA showed an increase at 7d after UEC, prior to 15d protein increase.  By 
contrast, N-cadherin transcript was not altered at 7d after TBI+BEC, supporting absence 
of any rise in N-cadherin protein.  These inter model differences support distinct roles 
for each molecule in generating the maladaptive plasticity observed post-TBI+BEC.  In 
parallel immunohistochemical experiments, MT5-MMP, ADAM-10 and N-cadherin 
showed strong signal within reactive astrocytes of the deafferented dentate molecular 
layer, suggesting either a glial synthetic or phagocytotic role for processing matrix 
proteins during recovery.  Collectively, these results reveal spatio-temporal differences 
in MT5-MMP, ADAM-10 and N-cadherin expression when adaptive and maladaptive 
synaptic plasticity are compared, identifying specific molecules and times which might 
be targeted for improvement of synaptic recovery following TBI.  
 
INTRODUCTION 
Traumatic brain injury (TBI) is a widespread, commonly under-diagnosed 
neuropathology that affects roughly 1.7 million people each year in the United States 
alone (Faul et al., 2010).  Following TBI, many patients experience long-term physical, 
cognitive, and/or psychosocial impairments, which arise as a result the primary 
traumatic insult, as well as the subsequent cascade of secondary neuropathological 
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events (Povlishock and Katz, 2005; Langlois et al., 2006).  These secondary events 
often result in diffuse axonal damage, neuronal death, and deafferentation within the 
damaged brain region (Povlishock and Christman, 1995; Hayes et al., 1992; Okonkwo 
and Povlishock, 2003).  In an attempt to repair the damaged tissue and regain function, 
the brain exhibits properties of synaptic plasticity, where surrounding non-injured 
neurons sprout to create new synaptic connections.  However, the success of functional 
recovery is based on a variety of factors, including the complexity and severity of the 
injury. 
Experimental models of TBI have been designed to mimic the neuropathology 
and downstream reactive synaptogenesis observed following injury in humans.  
Following experimental TBI successful synaptic reorganization is evident, and postinjury 
events can be divided into three specific phases: degradation of injured axons (1-5 days 
post-lesion); regeneration of new synapses (6-15 days post-lesion); synaptic maturation 
(15-30+ days post-lesion) (Steward and Vinsant, 1983).  Of these models, the unilateral 
entorhinal cortex lesion (UEC) is well-established as a model of adaptive injury-induced 
synaptogenesis within the hippocampus (Steward et al., 1988).  The UEC eliminates 80-
90% of the afferent fibers that synapse in the outer molecular layer (OML) of the rat 
dentate gyrus.  It is an appropriate model for studying adaptive injury-induced 
synaptogenesis, because it results in predictable remodeling of the deafferented zone 
and recovery.  However, plasticity and functional recovery in the human TBI patient is 
less organized and predictable, and therefore the use of more complex and clinically 
relevant models is warranted.  In an attempt to reproduce the complex neuropathology 
and persistent cognitive deficits similar to those seen in human TBI, our lab developed a 
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rodent injury model that combines central fluid percussion with bilateral entorhinal 
cortex lesions (TBI+BEC). This model results in diffuse neuroexcitatory injury with 
bilateral focal hippocampal deafferentation, leading to maladaptive synaptic plasticity 
and persistent structural, functional and behavioral deficits (Phillips et al., 1994; Phillips 
and Reeves, 2001).  By contrasting models of adaptive and maladaptive plasticity (UEC 
vs. TBI+BEC), we can determine the expression profile of different proteins over time 
postinjury, focusing on candidates which may be responsible for the failure of 
successful synaptogenesis and functional recovery seen in the TBI+BEC model.     
Of the many proteins that change following injury, matrix metalloproteinases 
(MMPs) are among those upregulated in several models of central and peripheral 
nervous system injury  (Truettner et al., 2005; Rosenberg et al., 2007; Falo et al., 2006; 
Komori et al., 2004; Yong et al., 2001).  MMPs constitute a large family of zinc and 
calcium-dependent enzymes responsible for cleavage of a variety of extracellular matrix 
(ECM) substrates in response to different neuropathologies, including TBI (Sekine-
Aizawa et al., 2001; Sounni and Noel, 2005; Cunningham et al., 2005; Yong et al., 
2001).  During the early postinjury stages, MMPs play important roles in ECM 
degradation which can foster synaptic reorganization.  However, persistent MMP 
expression and activity has the potential to produce excessive ECM/substrate 
breakdown and poor synaptic functional recovery following TBI (Suehiro et al., 2004; 
Rosenberg et al., 1996a, 1996b, 1998, 2001; Kim et al., 2005; Shigemori et al., 2006).  
To better understand the role of MMPs in synaptic plasticity, we have characterized 
different MMP/substrate pairs in the adaptive UEC and maladaptive TBI+BEC models.   
We found that MMP expression after UEC was temporally correlated with different 
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phases of adaptive synaptogenesis.  However, selective secreted MMPs were 
persistently upregulated during post-TBI+BEC synaptogenesis, and failed to show 
consistency with expression patterns characteristic to adaptive plasticity (Falo et al., 
2006; Kim et al. 2005).  These findings reveal the importance of MMPs in the process of 
reactive plasticity, and suggest that manipulation of their expression may improve 
functional recovery following injury.  
While our lab and others have historically investigated the post-TBI role of 
secreted MMPs, the role of membrane-bound MMPs had not been studied in TBI 
synaptic plasticity models.  In contrast to their secreted counterparts, membrane-bound 
MMPs are specifically positioned adjacent to their substrates, which may permit lytic 
activity at neuronal membrane sites targeted for synaptic function.  In this novel study, 
we characterized the hippocampal protein profiles of two membrane-bound MMPs, 
Membrane-type 5 matrix metalloproteinase (MT5-MMP) and A disintegrin and 
metalloproteinase-10 (ADAM-10), along with their mutual substrate neural cadherin (N-
cadherin) during the period of reactive synaptogenesis induced by UEC and TBI+BEC.  
MT5-MMP and ADAM-10 are localized in and around hippocampal synapses and have 
been shown to cleave N-cadherin.  N-cadherin functions at synapses via homologous 
N-terminus interaction with adjacent cadherins to guide developing synapses and 
stabilize and strengthen mature connections (Jaworski, 2000; Marcinkiewicz and 
Seidah, 2000; Takeichi and Abe, 2005; Monea et al., 2006; Reiss et al., 2005).  N-
cadherin also forms intracellular complexes with catenin molecules, which are ultimately 
anchored to cytoskeletal structural elements to further ensure synaptic structural 
integrity (Takeichi and Abe, 2005).  Therefore proteolytic extracellular cleavage of N-
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cadherin by MT5-MMP and/or ADAM-10 activity may potentially modify synaptic 
structure and function during injury-induced synaptogenesis. 
In the present study, we investigated the spatio-temporal protein profiles of MT5-
MMP, ADAM-10 and N-cadherin within the deafferented hippocampus at 2, 7, and 15d 
postinjury.  This time course encompasses the three phases of injury-induced 
synaptogenesis previously described.  We hypothesized that the protein profiles of all 
three molecules would be significantly altered after TBI, and that these profiles would 
show differences between adaptive and maladaptive recovery, particularly during the 7-
15d period of synapse generation and stabilization.  Parallel changes in mRNA 
production for each molecule were also posited.   Finally, we also hypothesized that 
hippocampal MT5-MMP and ADAM-10 protein distribution would be altered during 
synaptogenesis, showing an elevation within the deafferented outer molecular layer.  
This elevation was posited to include increases within reactive astrocytes, positioned in 
close proximity to synaptic N-cadherin (Fig. 2.1).     
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Figure 2.1 Proposed Synaptic and Peri-Synaptic Protein Localization. Schematic 
representation of ADAM-10 (red) localization in post-synaptic density and surrounding 
glial processes; MT5-MMP (blue) in surrounding glial processes; and N-cadherin 
(yellow) spanning the synaptic cleft and localized in both pre- and post-synaptic 
elements.  Proximity of MMPs to N-cadherin favors molecular interaction/processing
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METHODS 
Experimental Animals 
Adult male Sprague-Dawley rats (300-400g) were used in this study.  Two rats 
were housed per cage, with food and water ad libitum, and subjected to a 12 hr dark-
light cycle at 22°C.  All protocols for injury and use of animals were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University.  At 
2, 7 and/or 15d postinjury time intervals, four randomly divided animal groups were 
used for biochemical assessment: (1) Unilateral Entorhinal Cortex (UEC, total n=41), (2) 
Combined Injury (TBI+BEC, total n=58), (3) Sham-injured (total n=53).  For all 
biochemical analysis, the contralateral hippocampus served as a paired-control for the 
UEC, while sham-injured animals served as controls for the TBI+BEC animals.   
Unilateral Entorhinal Cortex Lesion 
The entorhinal cortex lesion (UEC) protocol was a modification of the method of 
Loesche and Steward (1977).  A group of rats were anesthetized with isoflurane (4% in 
carrier gas of 70% N2O and 30% O2) delivered via nose cone and placed in a 
stereotaxic frame for surgical preparation.  During all surgeries, animal body 
temperature was maintained at 37°C via thermostatic heating pad (Harvard Apparatus, 
Holliston, MA).  Additionally, animal heart rate (beats per minute, bpm), arterial oxygen 
saturation (%), breath rate (breath per minute, brpm), pulse distention (µm), and breath 
distention (µm) were monitored via pulse oximeter during all surgical preparation 
(MouseOx; Starr Life Sciences, Oakmont, PA).  Briefly, an approximately 3 mm x 5mm 
portion of the skull was removed on the right side to expose the dura mater superior to 
the entorhinal cortex.  Electrolytic lesions were made by passing a 1.5 mA current (40 
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second duration) via 0.2 mm Teflon-insulated wire electrode, positioned 10° to the 
perpendicular plane, at eight separate stereotaxic sites:  1.5 mm anterior to the 
transverse sinus, and 3, 4, and 5 mm lateral to midline, 2 , 4 and 6mm ventral to the 
brain surface for the first two lateral measurements (3 and 4mm) and only 2 and 4mm 
ventral to the brain surface for the last lateral measurement (5mm) (see Appendix A, Fig 
A-1).  After lesioning, the electrode was removed, the scalp was sutured over the 
surgical site, and Bacitracin was applied.  Rats were closely monitored for recovery from 
anesthesia and lesion and then returned to their home cages. 
Surgical Preparation for Central Fluid Percussion TBI 
Animals were anesthetized (as above) and placed in a stereotaxic frame for 
surgical preparation 24hrs prior to injury.  Body temperature and physiological 
measurements were monitored throughout surgical preparation (as above).  As 
previously described (Phillips et al., 1994), rats received a 4.8 mm midline craniectomy 
midway between bregma and lambda, exposing but not breaching the underlying dura 
(see Appendix A, Fig A-2).  Two steel screws were implanted 1 mm caudal to the 
coronal suture on the left and 1mm rostral to lambdoidal suture on the right.  A modified 
Leur-Loc hub (2.6 mm inside diameter) was implanted in the craniectomy site and fixed 
with cyanoacrylate adhesive.  Dental acrylic was added around the hub and screws to 
secure the complex.  The scalp was sutured closed to cover hub and Bacitracin was 
applied to the wound.  Rats were monitored for recovery and returned to their home 
cages.   
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Central Fluid Percussion TBI 
Moderate central fluid percussion injury (2.0+0.1 atm) was performed as 
described by Dixon et al. (1987).  The fluid percussion injury device is made up of a 
Plexiglas cylinder (60cm long, 4.5 cm diameter) filled with double distilled water.  One 
end of the cylinder has a rubber-covered Plexiglas piston mounted on O-rings, and the 
opposite end is closed by a metal extra-cranial pressure transducer (Entram Devices, 
Inc., model EPN-0300-100A).  The end of the metal transducer (5mm tube, 2.6 mm 
inside diameter) has a male Leur-loc fitting that connects to the exposed female Leur-
loc hub implanted in the rat skull.  A metal pendulum is dropped from a determined 
height that coincides with injury severity, and strikes the rubber-covered piston, forcing 
a small injection of 2x distilled water into the closed cranial cavity, briefly displacing 
brain tissue (see Appendix A, Fig A-2).  Injury level is recorded by the extra-cranial 
transducer, and visualized and reported (atmospheres, atm) on an oscilloscope 
(Tektronix 5111: Beaverton, OR).  Twenty-four hours after surgical preparation, rats 
were re-anesthetized, connected to the fluid percussion device through the exposed 
hub, and subjected to injury.  Animals were monitored for recovery from anesthesia and 
injury by observation and timing of multiple reflexes (paw, tail, corneal, righting, pinna), 
and then returned to their home cages. 
Combined Central Fluid Percussion +Bilateral Entorhinal Lesion  
Animals that received the combined injury were surgically prepared for fluid 
percussion injury, and twenty-four hours later received moderate (2.0+0.1 atm) central 
fluid percussion injury.  These animals recovered for another twenty-four hour time 
period, and were then re-anesthetized and subjected to bilateral entorhinal cortex 
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lesions (Phillips et al., 1994).  Bilateral lesions were performed as described above in 
UEC protocol (see Appendix A, Fig A-2).  After lesioning, electrodes were removed, the 
scalp sutured, and Bacitracin was applied.  Animals were transferred to a recovery cage 
and monitored for at least 1 hr to ensure adequate recovery, and were then returned to 
their home cages. 
Western Blotting  
At 2, 7, and 15d following UEC or TBI+BEC a subset of animals (UEC n=24; 
TBI+BEC n=39; Sham-injured n=35) were selected for hippocampal protein analysis.  
Rats were anesthetized (4% isoflurane in carrier gas of 70% N2O and 30% O2) and 
sacrificed by decapitation.  Whole hippocampi were removed, homogenized in ice-cold 
TPER (Pierce), and centrifuged (8,000xg) for 5 min at 4°C.  Supernants were removed 
and assayed for protein concentration (Shimadzu UV-160, Shimadzu Scientific, 
Columbia, MD; FLUOstar Optima, BMG Labtechnologies, Inc., Durham, NC).  For blot 
preparation, a 1:5 dilution (5 μg sample:20 μg H2O) of each sample was mixed with XT 
Sample Buffer/Reducing Agent (Bio-Rad Laboratories, Hercules, CA) and heated at 
95°C. Proteins were resolved on a 4-12% Bio-Tris gel (Bio-Rad) and transferred to 
PVDF membranes.  Post-blotted gels were stained and analyzed for even protein load 
and transfer. Membranes were washed in dH2O twice and TBS once for 5 min each, 
and then blocked in 5% milk TBS-Tween (TBS-T) for 1 hour.  Membranes were then 
probed with primary antibody (MT5-MMP rabbit polyclonal n-terminus: 1:1,000, Abcam, 
Cambridge, MA; N-Cadherin mouse monoclonal c-terminus: 1:1,000, BD Transductions 
Laboratories, San Jose, CA; ADAM-10 rabbit polyclonal c-terminus: 1:1,000, Sigma, St. 
Louis, MO) in 5% Milk TBS-T. After overnight incubation at 4°C, blots were washed six 
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times with Milk TBS-T for 5 min each, incubated in secondary antibody (IgG goat anti-
mouse: 1:20,000, Rockland, Gilbertsville, PA; IgG bovine anti-rabbit: 1:20,000, Santa 
Cruz, Santa Cruz, CA; ) for 1 hour, and washed six times with TBS-T for 5 min each.  
Antibody binding was visualized with enhanced chemiluminescence substrate, 
SuperSignal (Thermo Scientific, Rockford, IL).  Positive blot bands were imaged on the 
Syngene G: BOX and densitometry was performed by GeneTools (Syngene, Frederick, 
MD).  β-actin (mouse monoclonal: 1:3,000, Sigma, St. Louis, MO) was used as a load 
control for TBI+BEC Western blot experiments (see Appendix B, Fig B-8), while post-
blot staining was used to assess loading consistency for UEC Western blot 
experiments. 
Immunohistochemistry 
At 2, 7 and 15d following UEC or TBI+BEC a subset of animals (UEC, n=7; 
TBI+BEC, n=13; Sham-injured, n=13) were selected for qualitative analysis.  Rats were 
anesthetized with a lethal dose of sodium pentobarbital (90 mg/kg, i.p.) and perfused 
first with 0.9% NaCl followed by aldehyde fixative (4% paraformaldehyde in 0.1M 
NaHPO4 Buffer or PBS, pH=7.4).  Brains were removed and stored in buffer overnight 
at 4°C. Coronal vibratome sections (30-40 μm) of the hippocampus and dentate gyrus 
were prepared for immunofluroescent visualization.  Briefly, vibratome sections were 
pre-incubated in 0.5% peroxidase for 30 min, and washed three times with PBS for 10 
min each.  PBS was removed, sections were placed in blocking buffer (fish gelatin in 
PBS + 0.05 % Triton X-100) for 30 min and then incubated overnight at 4° C in primary 
antibody (MT5-MMP rabbit polyclonal n-terminus: 1:250, Abcam, Cambridge, MA; N-
Cadherin goat polyclonal n-terminus: 1:100, Santa Cruz, Santa Cruz, CA; ADAM-10 
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goat polyclonal c-terminus: 1:500, Santa Cruz, Santa Cruz, CA; GFAP mouse 
monoclonal: 1:20,000, Millipore, Billerica, MA; CD-11 mouse monoclonal: 1:500, BD 
Biosciences, San Jose, CA; Iba-1 rabbit polyclonal: 1:250, Wako, Osaka, Japan).  
Antibody signal was optimized in preliminary experiments, and selected sections were 
incubated overnight in primary antibody in each experiment. After overnight incubation, 
sections were washed three times in PBS for 10 min each, and then blocked for 30 
minutes in buffer.  In a dark room, the secondary fluorescent antibody (Alexa 488 
donkey anti-goat or donkey anti-rabbit: 1:1,000; Alexa 594 donkey anti-mouse: 1:1,000, 
Invitrogen, Carlsbad, CA) was applied for 1-2 hours, followed by three PBS washes for 
10 min each.  Sections were then float-mounted in PB onto Probe On Plus glass slides 
(Fisher Scientific, Pittsburgh, PA) and cover-slipped (1.5 um thickness) using 
Vectashield (Vector Laboratories, Burlingame, CA).  Tissue was qualitatively analyzed 
for MT5-MMP, N-cadherin, and ADAM-10 co-localization with GFAP and CD-11 using 
the Leica TCS-SP2 AOBS confocal laser scanning microscope. 
Microarray Analysis 
At 7 d following UEC or TBI+BEC, subsets of animals (UEC n=5; TBI+BEC n=3; 
Sham n=3) were anesthetized (4% isoflurane in carrier gas of 70% N20 and 30% O2) 
and sacrificed via decapitation.  Both whole hippocampal (UEC n=1; TBI+BEC/Sham 
n=1) and dendrite-rich dentate molecular layer (ML) (UEC n=4 pooled; TBI+BEC/Sham 
n=2 pooled for each group) samples were prepared.  Following decapitation, 
hippocampi and dissections of enriched dentate molecular layers were quickly frozen in 
liquid nitrogen.   At the time of analysis, RNA extracts were prepared from frozen 
samples placed directly in Trizol reagent (InvitrogenTM, Life Technologies, Carlsbad, 
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CA).  A subsequent cleanup process with RNAeasy (QIAGEN, Valencia, CA) was 
performed according to the manufacturer‟s protocol.  RNA purity was judged by 
spectrophotometry (260, 270, 280 nm).  RNA integrity, as well as that of cDNA and 
cRNA synthesis products, was assessed by running 1µl of each sample in RNA 6000 
Nano LabChips® on a 2100 Bioanalyzer (Aligent Technologies, Foster City, CA).  
Affymetrix GeneChip Rat Genome 230 2.0 Arrays (Santa Clara, CA) were then used to 
screen for genomic transcript changes, including MT5-MMP, ADAM-10, and N-cadherin 
mRNA expression (see Dumur et al., 2009 for detailed methods description).  Once 
data was collected, background correction, normalization, and estimation of probe set 
expression summaries were performed using the log-scale Robust Multi-array Analysis 
(RMA) method.  Identification of altered gene expression for injured compared to control 
samples was assessed by applying the Significance score (S-score) method.  The S-
score method uses an error-based model to determine the variances for probe pair 
signals and follows a normal standard distribution.  The procedure produces scores 
centered at “0” (no change) with a standard deviation of 1.  Benjamin-Hochberg 
correction method was then used to correct for multiple testing and to obtain adjusted 
alpha-levels for each probe set (MT5-MMP, ADAM-10, and N-cadherin).   
qRT-PCR 
The 7d UEC and TBI+BEC samples used for microarray analysis were also 
analyzed using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
methods to assess gene expression levels for MT5-MMP, ADAM-10 and N-cadherin 
using TaqMan® chemistry.  Probes and primer sets for detection of MT5-MMP 
(Rn00582114 m1), ADAM-10 (Rn01530753 m1), and N-cadherin (Rn00580099 m1) 
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were obtained from Inventoried Assays (Applied Biosystems, Foster City, CA).  These 
gene specific probes were labeled in the 5‟ end with FAM (6-carboxyfluorescein) and 
the 3‟ end with a dark quencher.  Cyclophilin A from the Pre-developed TaqMan® Assay 
Reagents (Applied Biosystems) was used as an endogenous control for all samples.  
Experiments were performed in the ABI Prism 7500 Sequence Detection System 
(Applied Biosystems) using the TaqMan® One-Step PCR Master Mix Reagents Kit.  All 
samples were tested in triplicate under cycling conditions of 48°C for 30 minutes, 95°C 
for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute.  To calculate 
fold changes in expression levels for each gene, the 2-ΔΔCt method was used.  To 
calculate the efficiency of amplification for MT5-MMP, ADAM-10, and N-cadherin, 10-
fold serial dilutions of template samples were run (Dumur et al., 2009) 
In situ Hybridization  
At 7d following UEC or TBI+BEC, a subset of animals (UEC, n=5; TBI+BEC, n=3; 
Sham-injured, n=2) were selected for in situ hybridization (ISH) analysis.  Rats were 
anesthetized with a lethal dose of sodium pentobarbital (90 mg/kg, i.p.) and perfused 
first with 0.9% NaCl followed by aldehyde fixative (4% paraformaldehyde in 0.1M 
NaHPO4 Buffer or PBS, pH=7.4).  Brains were removed and stored in buffer overnight 
at 4°C.  Coronal vibratome sections (20-30 μm) of the hippocampus and dentate gyrus 
were prepared for ISH.  Sections were mounted on slides and stored at -20°C until 
riboprobe preparation was complete.  A rat MT5-MMP cDNA was generated by PCR 
cloning from nucleotides 408-931 of mouse MT5-MMP and using the following primers: 
F: 5‟-ATGTGGCGTCCCTGAT-3‟, R: 5‟-TGAAGTTGTGTGTCTCC-3‟ (Jaworski, 2000).  
Sense and antisense riboprobes were generated against a 500bp fragment of MT5-
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MMP using digoxigenin (DIG) labeled dNTPs (Roche, Mannheim, Germany) and the 
MAXI-Script In Vitro Transcription Kit (Ambion, Austin, TX). Probes were hydrolyzed to 
~250 nt.  Mounted vibratome sections were prepared and hybridized at 65°C as 
previously described (Yamagata et al., 2002).  Briefly sections were fixed with PFA, 
incubated in Proteinase K, acetylated, permeabilized in 1% Triton-X and hybridized.  
Bound riboprobes were detected by horseradish peroxidase (POD)-conjugated anti-DIG 
antibodies and fluorescent staining with Tyramide Signal Amplification (TSA) systems 
(PerkinElmer, Shelton, CT).  For immunofluroescent labeling, sections were blocked 
and primary antibody applied overnight at 4° C (GFAP rabbit anti-cow polyclonal 
antibody, DAKO; 1:1000).  Secondary antibody was applied to sections, which were 
coverslipped and sealed.  Images were obtained on a Leica TCS-SP2 AOBS confocal 
laser scanning microscope. 
Statistical Analysis 
Results were expressed as percent change from paired control samples.  The 
significance of differences in densitometric measures of Western blot immunobinding 
was analyzed using the Student‟s t-test.  Computer-based SPSS software was used for 
all analyses.  A probability of less than 0.05 was considered statistically significant for all 
experiments. 
 
RESULTS 
Physiological Measurements 
During surgical preparation and lesioning, all animals were monitored for heart rate (350 
+ 20bpm), arterial oxygen saturation (> 93%), breath rate (45 + 5bpm), pulse distention 
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(15 + 5µm), and breath distention (12 + 5µm) with pulse oximeter (MouseOx; Starr Life 
Sciences, Oakmont, PA).  Surgical procedures on all experimental animals produced no 
significant change in these physiological measures. 
 
Western Blot Analysis 
MT5-MMP, ADAM-10, and N-cadherin Protein Forms in Hippocampus 
Western blot (WB) results revealed predominant and additional lesser forms of 
MT5-MMP, ADAM-10 and N-cadherin following UEC and TBI+BEC (Fig. 2.2).  A 
predominant band was present for MT5-MMP at 80 kDa.  The active form of MT5-MMP 
is ~58 kDa, however this band was not detected in our MT5-MMP protein analysis.  
When the MT5-MMP membrane was re-probed, the 80 kDa band was found to co-
migrate with TIMP-2 (~24 kDa), the endogenous inhibitor of MT5-MMP (see Appendix B 
Fig.B-1).  Additionally, a less prominent and unbound TIMP-2 band was observed at 24 
kDa.  This result suggests that active MT5-MMP was bound to TIMP-2, and like other 
MT-MMPs, may participate in the downstream activation of other MMPs (e.g.- proMMP-
2).  An additional 85 kDa MT5-MMP form was present, which has yet to be 
characterized in the literature, but may represent a glycosylated form.  Immunopositive 
bands for ADAM-10 were observed at 100 kDa, 80 kDa, and 70 kDa.  These ADAM-10 
bands most likely represent an alternative TIMP-1 bound form (100 kDa), a “pro” or 
latent form (80 kDa), and a predominant active form (70 kDa), as described in the 
ADAM-10 literature.  Finally, bands for N-cadherin were visualized at 130 kDa and ~40 
kDa.  These N-cadherin bands represent a predominant full-length form (130 kDa) and 
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its intracellular fragment that includes the transmembrane domain (~40 kDa), which is 
produced following ectodomain cleavage. 
MT5-MMP, ADAM-10 and N-cadherin Protein Expression Post-UEC 
Western blot analysis of whole ipsilateral hippocampal extracts revealed significant 
injury-induced changes in MT5-MMP, ADAM-10 and N-cadherin protein between 2 and 
15d post-lesion, when compared to contralateral uninjured controls (Fig. 2.3).  The 
TIMP-2 associated 80 kDa form of MT5-MMP was significantly elevated at 2 and 7d 
postinjury (177.23 ±20.77, p<0.01; 202.06 ± 21.90, p<0.01).  The active 70 kDa form of 
ADAM-10 also showed significant elevation over control at 2 and 7d postinjury (213.15 
± 8.26, p<0.01; 200.89 ± 34.62, p<0.05).  Full length N-cadherin expression was 
significantly decreased at 2d (68.39 ±6.94, p<0.01), and increased at 15d (128.27 ± 
9.00, p<0.05).  At 7d, there was a trend towards a significant decrease in N-cadherin 
expression (74.23 ± 11.77, p=0.079).  At all three postinjury intervals, an inverse 
relationship was noted between both enzymes and N-cadherin, suggesting possible 
enzyme/substrate interaction during injury-induced synaptogenesis.  These results 
showed an up-regulation of two key MMPs during the degenerative (2d) and early 
regenerative (7d) phases of synaptogenesis, followed by a return to baseline during the 
stabilization phase (15d). These changes in MT5-MMP and ADAM-10 protein 
expression may correlate with changes in enzymatic activity, which could influence the 
early phases of injury-induced plasticity through interaction with N-cadherin following 
UEC.   
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Figure 2.2 Potential Hippocampal Molecular Forms of MT5-MMP, ADAM-10 and N-
cadherin Observed in Protein Analysis.  Schematic membrane-bound, structural 
depiction of active (58kDa) and TIMP-2 bound (80kDa) forms of MT5-MMP; TIMP-1 
bound (100kDa), pro- (80kDa) and active- (70kDa) forms of ADAM-10; Full-length form 
(130kDa) and cleaved intramembrane-cytoplasmic fragment (40kDa) of N-cadherin. 
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Figure 2.3 Hippocampal MT5-MMP, ADAM-10 and N-cadherin Protein Expression 
following UEC. Values expressed as percent of contralateral hippocampus over 2, 7, 
and 15d postinjury time intervals.  Following UEC insult, significant increases in MT5-
MMP (MT5) and ADAM-10 protein expression were observed at 2 and 7d with 
normalization of both MMPs at 15d.  By contrast, N-cadherin showed significant 
reduction at 2 and 7d and elevation at 15d. Note inverse relationship between enzymes 
and substrate over postinjury time course.  Representative blots shown below.  
I=ipsilateral hippocampus (injured); C=contralateral hippocampus (control); 2d: n=4-7; 
7d: n=4-7; 15d n=4-6. *p<0.05, **p<0.01. 
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In addition to the predominant protein forms of MT5-MMP, ADAM-10, and N-
cadherin, other alternative/minor bands were also visualized following UEC (see 
Appendix B, Fig B-2 through B-6).  Analysis of MT5-MMP showed that an 85 kDa 
species was significantly decreased over all time points (2d: 19.34 ± 3.15, p<0.02; 7d: 
22.84 ± 1.92, p=0.001; 15d: 60.25 ± 5.79, p<0.05) following injury.  This 85 kDa form 
has not been previously reported for MT5-MMP, and may represent an uncharacterized 
bound form or a post-translationally modified form that migrates differently in the gel 
system.  ADAM-10 protein analysis revealed two additional bands, 100 kDa and 80 
kDa. The 100 kDa band, an apparent TIMP-1 bound form, was significantly decreased 
at all time points (2d: 80.84 ± 1.69, p<0.01; 7d: 77.73 ± 5.18, p=0.05; 15d: 76.15 ± 6.19, 
p<0.05), as was the latent 80 kDa pro-form (2d: 32.03 ± 3.64, p<0.01; 7d: 45.85 ± 10.4, 
p<0.01; 15d: 67.11 ± 6.95, p<0.05).  These results showed that two regulated forms of 
ADAM-10, a TIMP-1 bound and latent form, were reduced with deafferentation 
remaining below control levels through all phases of reactive synaptogenesis.  With N-
cadherin, we also observed a ~40 kDa fragment at 2 and 15d, which was significantly 
decreased at 2d (65.27 ± 6.40, p<0.001).  These results show the presence of a 
cleaved form of N-cadherin, which may represent a product of acute postinjury ADAM-
10 and/or MT5-MMP proteolysis. 
MT5-MMP, ADAM-10 and N-cadherin Protein Expression Post-TBI+BEC 
Whole hippocampal extracts were also examined to determine changes in MT5-
MMP, ADAM-10 and N-cadherin protein expression, when compared to sham control 
(Fig. 2.4).  Western blot analysis revealed significant differences across all groups over 
the examined time intervals.  The 80 kDa form of MT5-MMP was significantly elevated 
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above sham at 2 and 7d postinjury (126.73 ± 9.85, p=0.05; 195.72 ± 11.01, p<0.001).  
The 70 kDa active-form of ADAM-10 showed significant elevation over control at all 
three intervals (2d: 156.34 ±18.18, p<0.01; 7d: 267.17 ±23.54, p<0.001; 15d: 230.78 ± 
30.41, p<0.001).  Full- length N-cadherin expression was significantly decreased at 2 
and 7d (75.11 ± 6.91, p<0.05; 81.03 ±4.80, p<0.05).  These results were similar to those 
found following UEC, including the inverse relationship between enzymes and substrate 
and similar MT5-MMP protein profiles.  Nevertheless, two important differences were 
observed when comparing adaptive to maladaptive expressional changes.  Notably, the 
significant up-regulation of ADAM-10 across all time intervals and the failure of N-
cadherin to significantly increase above control levels at 15d.    These results suggest 
that, of the two metalloproteinases, ADAM-10 and its proteolytic interaction with N-
cadherin may preferentially contribute to the maladaptive synaptic plasticity observed 7-
15d following TBI+BEC insult.      
Consistent with the UEC results, additional WB bands for all three proteins were 
also visualized after TBI+BEC.  For MT5-MMP, an 85 kDa species was found to 
significantly decrease over all time points (2d: 40.98 ± 6.84, p<0.001; 7d: 46.55 ± 6.46, 
p<0. 001; 15d: 59.23 ± 5.81, p<0.001) following injury.  ADAM-10 protein analysis 
revealed that a 100 kDa ADAM-10 form was significantly decreased at 2d (82.43 ± 3.36, 
p<0.001), and returned to sham levels at 7 and 15d.  An 80 kDa latent form of ADAM-10 
was also significantly reduced, but only at 2 and 15d (52.76 ±7.45, p<0.001; 79.66 
±4.98, p=0.05).  These additional forms of both MT5-MMP and ADAM-10 showed 
similar profiles to those in the UEC study, suggesting that they may be regulated and/or 
function similarly in both injury models.  Although a 40 kDa form of N-cadherin was  
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Figure 2.4 Hippocampal MT5-MMP, ADAM-10 and N-cadherin Protein Expression 
following TBI+BEC.  Values expressed as percent of sham controls over 2, 7, and 15d 
postinjury time intervals.  Following TBI+BEC, a significant increase in MT5-MMP (MT5) 
protein expression was observed at 2 and 7d, while ADAM-10 was significantly 
increased at all time-points.  By contrast, N-cadherin showed significant reduction at 2 
and 7d, and failed to elevate above control levels at 15d. Note inverse relationship 
between enzymes and substrate over post-injury time-course.  Representative blots 
shown below.  I=Injured; S=Sham (control); 2d: I=6-10, S=8; 7d: I=7-16, S=9-10; 15d 
I=7-8, S=8; *p<0.05, **p<0.01. 
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present over all post-TBI+BEC time intervals, there was no significant change from 
sham, whereas this form was significantly decreased at 2d after UEC.  Because this 40 
kDa form may be further cleaved into fragments that influence intracellular signaling 
pathways, such intermodel differences suggest that N-cadherin regulated cell signaling 
may contribute to the aberrant plasticity observed after the combined insult. 
Immunohistochemistry 
Immunofluorescent labeling was used to characterize cellular ADAM-10, MT5-
MMP and N-cadherin localization, as well as overall protein distribution within the 
dentate gyrus following UEC and TBI+BEC.  Tissue was double stained with MT5-
MMP/ADAM-10/N-cadherin and markers for astrocytes (GFAP) and microglia (CD-
11/Iba-1).  MT5-MMP, ADAM-10 and N-cadherin co-localized with the astrocytic marker 
in each injury model at 2, 7 and 15d postinjury (Fig. 2.5 and 2.6), but failed to show co-
localization with either microglial marker (see Appendix C, Fig. C-8).  Images double 
stained with GFAP and MT5-MMP/ADAM-10/N-cadherin from the 7d postinjury time 
interval are presented here to show protein localization and distribution.  Additional 
images for the 2 and 15d time intervals are shown in Appendix C (Fig. C-2 through C-6). 
ADAM-10 Immunohistochemistry following UEC and TBI+BEC 
Confocal imaging of hippocampus showed increased ADAM-10 signal throughout 
the deafferented molecular layer (ML) of both 7d UEC and TBI+BEC cases when 
compared with paired controls (Fig. 2.5 and 2.6).  The antibody signal was present as 
diffuse punctate sites within the neuropil, but the primary staining was localized within 
reactive astrocytes, co-labeled with GFAP.  The overall intensity of ADAM-10 was 
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greater in the combined insult cases.  In both models, ADAM-10 uniformly filled the cell 
bodies and processes of reactive astrocytes.  Diffuse staining was also present in glial 
processes surrounding granule cell (GC) somata.  When 2, 7, and 15d cases were 
compared, the greatest signal and cellular labeling was observed at 2 and 7d postinjury 
in both models, consistent with WB results showing greatest expression of ADAM-10 at 
those times.  While these experiments cannot confirm whether ADAM-10 is produced by 
astrocytes or simply being degraded within them, it is clear that astrocytes play a role in 
the processing of ADAM-10 following during both adaptive and maladaptive 
synaptogenesis.     
MT5-MMP Immunohistochemistry following UEC and TBI+BEC 
In contrast to ADAM-10, hippocampal confocal imaging showed a different 
pattern for MT5-MMP ML distribution in 7d UEC and TBI+BEC animals relative to paired 
controls (Fig. 2.5 and 2.6).  Overall intensity of signal was lower in the UEC than for 
TBI+BEC, where, in the latter, MT5-MMP showed a strong diffuse staining throughout 
the ML.  Like ADAM-10, the overall intensity of MT5-MMP was also greater in the 
combined insult cases.  In both models the primary signal was again localized within 
GFAP positive astrocytes.  Following UEC, the MT5-MMP signal filled the somata and 
processes of these reactive astrocytes.  By contrast, MT5-MMP labeling in the 
combined model formed a cluster-like staining pattern within astrocytic cell bodies and 
their primary processes.  A dense punctuate MT5-MMP labeling was seen surrounding 
granule cells.    Comparison of all three postinjury time intervals showed the greatest 
labeling at 2 and 7d in both models.  WB results did show greatest increase in MT5-
MMP at 7d, approximately equivalent for each injury.  Interestingly, our  
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Figure 2.5 Molecular Layer Localization of ADAM-10, MT5-MMP and N-cadherin 
with GFAP at 7d following UEC.  Confocal imaging revealed co-localization of ADAM-
10, MT5-MMP and N-cadherin with astrocytic marker GFAP in molecular layers.  Single-
channel confocal images showed pronounced signal within the deafferented OML, with 
a cell-filling pattern for ADAM-10 and N-cadherin.  MT5-MMP displayed a punctate 
staining throughout the neuropil and clustered signal within reactive astrocytes.  
Contralateral (control) overlays display a dampened injury response, but similar 
expression pattern for each protein.  ADAM-10, MT5-MMP and N-cadherin (green); 
GFAP (red).  40x magnification.  OML = outer molecular layer; IML= inner molecular 
layer; GC= granule cell layer.  Arrowheads indicate examples of co-localization for each 
protein.
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Figure 2.6 Molecular Layer Localization of ADAM-10, MT5-MMP and N-cadherin 
with GFAP at 7d following TBI+BEC.  Confocal imaging revealed co-localization of 
ADAM-10, MT5-MMP and N-cadherin with astrocytic marker GFAP in combined injured 
animals.  Overlays of injured animals showed pronounced astrocytic response and 
signal within the deafferented outer molecular layer.  ADAM-10 exhibited a cell-filling 
pattern, while MT5-MMP revealed punctate neuropil staining and somatic clustered 
intracellular signal reaching into proximal processes.  N-cadherin had similar punctate 
neuropil pattern, and primarily astrocytic somatic clustering.  Sham-injured (control) 
overlays display a dampened injury response, but similar spatial expression pattern.  
ADAM-10, MT5-MMP and N-cadherin (green); GFAP (red).  40x magnification.  OML = 
outer molecular layer; IML= inner molecular layer; GC= granule cell layer.  Arrowheads 
indicate examples of co-localization. 
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immunohistochemistry supported the higher ML MT5-MMP signal for combined cases.  
As for ADAM-10, strong glial labeling suggests a possible role of the reactive astrocyte 
in either MT5-MMP synthesis or phagocytotic processing.   
N-cadherin Immunohistochemistry following UEC and TBI+BEC 
Confocal imaging of hippocampal N-cadherin revealed more subtle model 
differences at 7d postinjury (Fig 2.5 and 2.6).  Following UEC, N-cadherin and GFAP 
were co-localized within the ML, with increased signal throughout the deafferented 
neuropil relative to paired controls.  Fine, punctate label was seen around GC somata.  
The overall pattern of N-cadherin staining was similar for the 7d post-TBI+BEC cases,  
however, signal was more punctuate and concentrated within the astrocyte cell bodies 
with minimal process labeling.  These subtle model differences may indicate variations 
in astrocytic processing of N-cadherin during adaptive and maladaptive synaptogenesis.  
The results of these experiments show an increase in ML expression of N-cadherin at 
7d postinjury.  This is in contrast to the reduced expression assessed by WB 
measurements.  It is important to note that due to technical limitations, antibody 
recognizing an N-terminal sequence of N-cadherin was used for immunohistochemical 
experiments, while a C-terminal recognizing antibody was employed for WB analysis.  
Application of the different antibodies most likely accounts for differences in N-cadherin 
expression detected by the two methods.  We interpret our WB results as illustrating a 
decrease in overall C-terminal signal due to MT5-MMP or ADAM-10 cleavage of intact 
N-cadherin.  By contrast, the confocal experiments appear to show cleaved and shed N-
terminal fragments of N-cadherin, which are potentially internalized for processing within 
reactive astrocytes of the ML.     
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DNA Microarray analysis  
At 7d post-UEC and TBI+BEC, RNA extracts of whole hippocampus (UEC n=1; 
TBI+BEC/Sham n=1) and enriched molecular layer (ML) (UEC n=4 pooled; 
TBI+BEC/Sham n=2 pooled) were used to generate cDNAs for microarray gene 
expression screening.  The 7d postinjury time interval was selected because it was the 
period exhibiting greatest WB MT5-MMP and ADAM-10 hippocampal protein expression 
and we wanted to determine if this protein peak was matched by an elevation in mRNA 
synthesis.  A rise in mRNA expression at 7d would also help us interpret changes in 
protein expression occurring during the subsequent synaptic stabilization phase of 
recovery at 15d.  For this study, changes in gene expression of ±50% or more from 
control were considered significant.  Results did reveal potential injury effects in some 
cases, although overall changes in MT5-MMP, ADAM-10, and N-cadherin transcripts at 
7d postinjury were not significant using our ±50% cutoff (Table 1).  Among the three 
genes, the most pronounced UEC transcript shift occurred with ADAM-10, where we 
found a 45% and 47% increase relative to control in ML and hippocampus, respectively.   
MT5-MMP and N-cadherin transcripts at 7d after UEC revealed no significant change 
(0-5%).  For post-TBI+BEC gene expression, the greatest shifts were seen in ML 
samples, where ADAM-10 and N-cadherin transcripts increased 20% and MT5-MMP 
decreased 20% in expression.  In the whole hippocampus, ADAM-10 mRNA was 15% 
higher than control, while MT5-MMP and N-cadherin transcripts were not altered.  
Microarray results revealed potential transcript changes in both hippocampus and ML 
for each model. These indications of possible mRNA shifts after injury were 
subsequently probed and verified in the ML samples using qRT-PCR methods.                   
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Table 1. Microarray Analysis of MT5-MMP, ADAM-10 and N-cadherin Transcripts 
at 7d post-UEC and TBI+BEC.  Transcript values reported as a relative change from 
control (UEC: contralateral molecular layer or whole hippocampus; TBI+BEC: sham).  
Post-UEC values show greatest change in ADAM-10 for molecular (+45%) and whole 
hippocampal (+47%) sample(s), while N-cadherin and MT5-MMP show no change (NC). 
Post-TBI+BEC values show small shifts in transcript for MT5-MMP (-20%) molecular 
layer, ADAM-10 molecular layer (+20%) and whole hippocampal (+15%), and N-
cadherin molecular layer (+20%) samples.  UEC molecular layer n=4 rats, ipsilateral 
sides pooled and contralateral sides pooled; whole hippocampus n=1 rat ,ipsilateral  
and contralateral side separately analyzed; TBI+BEC molecular layer n=2 rats, all 
pooled from both animals; Sham molecular layer n=1rat, two sides pooled; n=2 rats; 
TBI+BEC whole hippocampus n=1rat , injured hippocampi pooled; Sham hippocampi  
n=1 rat, two sides pooled.
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Table 1. Microarray Analysis in Adaptive & Maladaptive TBI models 
 
 
UEC 
 Molecular layer 
(n=4, pooled) 
Whole Hippocampus 
   (n=1)   . 
MT5-MMP NC NC 
ADAM-10 1.45+ 1.47+ 
N-cadherin NC NC 
   
TBI+BEC 
 Molecular layer 
(n=2, pooled) 
Whole Hippocampus 
(n=1 injured, 1 sham) 
MT5-MMP 1.20- NC 
ADAM-10 1.20+ 1.15+ 
N-cadherin 1.20+ NC 
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Quantitative RT-PCR 
Aliquots from the same 7d UEC and TBI+BEC ML RNA extracts used for 
microarray analysis were subjected to qRT-PCR with specific primers to MT5-MMP, 
ADAM-10, and N-cadherin mRNA (Fig. 2.7).     
MT5-MMP, ADAM-10 and N-cadherin mRNA Expression after UEC 
Quantitative RT-PCR analysis of ipsilateral ML samples at 7d post-UEC revealed 
higher mRNA expression for MT5-MMP, ADAM-10 and N-cadherin when compared to 
contralateral control.  While experimental design prevented statistical analysis in this 
situation, MT5-MMP transcript did show a modest 31% increase, while ADAM-10 mRNA 
was elevated 112% over control.  These results are temporally consistent with our WB 
results which showed significant elevation in both MT5-MMP and ADAM-10 protein at 
7d postinjury.  N-cadherin mRNA had the most pronounced change, a 117% elevation 
over control, indicating active transcription during a period of reduced N-cadherin 
protein expression, and just prior to the 15d increase in N-cadherin during UEC synapse 
stabilization.        
MT5-MMP, ADAM-10 and N-cadherin mRNA Expression after TBI+BEC 
In 7d TBI+BEC ML samples subjected to qRT-PCR we observed an apparent 
elevation of ADAM-10 mRNA expression compared to sham-injured control.  Transcript 
was increased by 83% during the period of sprouting and synaptogenesis, consistent 
with post-TBI+BEC WB protein expression.  These results suggest that matched 
changes in ADAM-10 transcript contribute to the large 7d rise in protein seen after 
combined insult, and may also support the persistent elevation of ADAM-10 protein at  
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Figure 2.7 Quantitative RT-PCR Molecular Layer mRNA Expression of MT5-MMP, 
ADAM-10 and N-cadherin post-UEC and TBI+BEC.  Values expressed as a percent 
of control (UEC: contralateral ML; TBI+BEC: Sham) at 7d following injury.  ML samples 
showed elevated MT5-MMP, ADAM-10, and N-cadherin transcript post-UEC, and only 
elevated ADAM-10 transcript post-TBI+BEC.  Shifts in initial ADAM-10 microarray data 
(see Table 1) consistent with ADAM-10 ML transcript expression in both models.  ML 
=Molecular Layer. UEC ML n=4 rats, ipsilateral sides pooled and contralateral sides 
pooled; TBI+BEC ML n=2 rats, all pooled from both animals; Sham molecular layer 
n=1rat, two sides pooled. 
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15d with maladaptive plasticity.  MT5-MMP and N-cadherin mRNA expression in the ML 
were not different from control at 7d.  These results suggest that if transcript elevation 
was responsible for the 7d WB rise in MT5-MMP protein, it likely occurred prior to the 
time of tissue sampling.  Absence of change in N-cadherin transcript at 7d after 
TBI+BEC would be consistent with the observation that the protein was not elevated 
over controls at either 7 or 15d after injury.  
In situ hybridization 
MT5-MMP RNA localization at 7d following UEC and TBI+BEC 
Preliminary in situ hybridization experiments were conducted to determine the 
cellular site of MT5-MMP synthesis within the hippocampus.  The MT5-MMP probe 
used in this experiment was a gift generously provided by Dr. Diane Jaworski.  This 
probe was designed for the characterization of MT5-MMP expression within the 
developing brain (Jaworski, 2000).  Based on results from immunohistochemical 
experiments, we predicted that MT5-MMP synthesis occurs within hippocampal glial 
cells, specifically reactive astrocytes.  Preliminary trials using 20-30 μm thick coronal 
brain sections revealed MT5-MMP anti-sense signal within reactive astrocytes in the 
deafferented dentate ML at 7d after UEC and TBI+BEC, as indicated by MT5-MMP 
probe co-localization with astrocytic marker GFAP (see Appendix D Fig. D-1).  Anti-
sense signal was found predominantly within astrocytic processes and around the cell 
body perimeter, closely matching the distribution of the protein in our 
immunohistochemical study.   While MT5-MMP signal was present in both injured and 
control slices, increased labeling and astrocytic response was also observed in both 
UEC and TBI+BEC animals.   
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Unfortunately, we also observed non-specific fluorescent signal with the sense 
control sequence in some of our experiments.  This signal was found within the same 
reactive astrocytes targeted by the antisense label.  In troubleshooting this result, we 
identified several possible sources of the aberrant control signal:  1) the use of different 
restriction enzymes for cDNA cuts than those of the original published technique, 
potentially causing non-specific binding of the extended vector DNA sequences, 2) the 
use of 20-30 µm thick vibratome tissue slices as opposed to thinner 8-10 µm frozen 
sections, and 3) insufficient permeability of probe into the tissue, generating surface 
adhesion artifact.  We plan to conduct additional experiments to address these possible 
complications, and will generate clean sense controls before proceeding with further in 
situ hybridization analysis of MT5-MMP, ADAM-10 and N-cadherin mRNA in our injury 
models. 
DISCUSSION 
The current study examined the spatial and temporal profile of MT5-MMP, 
ADAM-10 and N-cadherin protein expression during reactive synaptogenesis (2-15d 
postinjury) within the dennervated hippocampus.  Expression of the membrane type 
MMPs and their common ECM substrate were compared in two different TBI models, 
directly contrasting adaptive (UEC) versus maladaptive (TBI+BEC) synaptic plasticity.  
These protein data were complemented by assessment of mRNA expression for each 
molecule at 7d postinjury, the period of active sprouting and synapse formation.  In our 
Western blot analyses, we found that MT5-MMP and ADAM-10 protein was elevated at 
the 2 and 7d postinjury intervals for both models, times marking acute degenerative 
change and early synaptic growth.  The greatest increase in MMP expression was seen 
122 
 
with ADAM-10 at 7d.  This data was supported by large 7d elevations in ADAM-10 
versus MT5-MMP transcript in both models.  We also observed a consistent decrease in 
N-cadherin expression at 2 and 7d after injury in each model.  Notably, the main 
differences between adaptive and maladaptive plasticity were seen at 15d, when 
synapse stabilization is underway.  Here, adaptive UEC plasticity showed reduced MMP 
protein and an increase in N-cadherin expression over that of controls. By contrast, the 
maladaptive plasticity of TBI+BEC was marked by a persistently elevated ADAM-10 
protein level and the absence of any rise in N-cadherin expression.   Interestingly, 
immunohistochemistry for each MMP and N-cadherin showed primary localization in 
reactive astrocytes of the deafferented molecular layer and the intensity of this 
localization was increased following injury.  These results show that membrane-bound 
MMPs are involved in the both adaptive and maladaptive synaptic plasticity and, given 
the distinct recovery-dependent differences in MT5-MMP, ADAM-10, and N-cadherin 
expression, likely participate through interaction with N-cadherin to affect synapse 
stabilization.  Elevated ADAM-10 and reduced N-cadherin expression was most 
correlated with the maladaptive response.  Such enzyme/substrate interactions could 
critically influence cell-cell and ECM-cell interaction and the organization of intact 
synapse structure.  Overall, these results confirm that membrane-bound MMP response 
is influenced by the type and complexity of neuropathology induced by TBI. 
Postinjury Time Course of Membrane-bound MMPS and N-cadherin Expression    
Our Western blot analysis of hippocampal MT5-MMP, ADAM-10 and N-cadherin 
protein expression during reactive synaptogenesis revealed the following:  1) both 
membrane-bound MMPs were increased early postinjury (by 2d) and peaked in 
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expression at the 7d sprouting period, suggesting a prominent role in the earlier phases 
of recovery, 2) both membrane-bound MMPs were matched by a reduction in their 
target substrate N-cadherin, observed for adaptive and maladaptive conditions alike, 
and 3) the principal forms of these proteins indicate different roles for each enzyme, 
MT5-MMP expressed in a TIMP bound, non active form and ADAM-10 changes 
primarily linked to the 70 kDa active enzyme.  Overall, the profiles of MT5-MMP and 
ADAM-10 expression in the adaptive UEC model are consistent with our previous 
analyses of secreted MMPs, where both transcription and translation of MMPs 2, 3 and 
9 are rapidly elevated at the onset of synaptogenesis (Kim et al., 2005, Falo et al., 
2006).  In contrast to those studies, where released MMPs were reduced at later stages 
of synaptic recovery, our current results suggest that persistent expression of active 
membrane bound ADAM-10 can aberrantly influence the long-term stabilization of new 
synapses generated after TBI.  A prominent role for ADAM-10 during TBI-induced 
synaptic plasticity would be expected from the literature, where it has been shown to 
influence axonal guidance, cortical synapse development and synaptic modulation 
through interaction with molecules like ephrin, APP, and N-cadherin (Hattori et al., 2000; 
Bell et al., 2006; Reiss et al., 2005). The active form of this enzyme appears to target 
the synaptic adhesion protein N-cadherin during the early, more plastic phases of 
synapse regeneration, but this enzyme/substrate interaction is attenuated during 
synapse maturation and stabilization.  Such interaction would be predicted since 
reduced adhesion would be required for the morphing of synaptic structure in the acute 
postinjury period, and elevated N-cadherin needed for transmembrane anchoring of the 
synaptic junction complex and binding of synaptic proteins to the pre- or postsynaptic 
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cytoskeleton.  The presence of high levels of ADAM-10 would foster the cleavage of N-
cadherin at its extracellular/membrane interface, resulting in shedding of the N-terminal 
sequence into the matrix space. Other studies have also demonstrated that synaptic 
stabilization and functional efficacy are mediated through N-cadherin extracellular 
binding, transmembrane placement, and intracellular association with catenin molecules 
(Gottardi and Gumbiner, 2004).  In addition, the intracellular N-cadherin fragmentation 
can signal the transcription of genes involved in cell survival, migration and synapse 
adhesion/stabilization (McCusker and Alfandari, 2009).  Thus, N-cadherin is involved in 
synaptogenesis, through direct physical binding and indirect effects on downstream 
transcription.  Our results provide further evidence that these membrane-bound MMPs 
and N-cadherin are an important enzyme/substrate pairing for successful synaptic 
reorganization following TBI. 
From the literature, MT5-MMP can be linked with neuroplasticity, where 
reorganization of Aβ fibers after sciatic nerve injury, synaptic modulation through N-
cadherin cleavage, and neurite outgrowth with proteoglycan cleavage are all promoted 
by its activation (Komori et al., 2004; Monea et al., 2006; Hayashita-Kinoh et al., 2001).   
By contrast, we did not find MT5-MMP in its active form, rather expressed at a higher 80 
kDa band, a size predicted for enzyme bound to endogenous inhibitor.  Blot re-probing 
experiments suggest that this high kDa band represents active MT5-MMP bound to its 
endogenous inhibitor TIMP-2.  Such a result opens the possibility that the enzyme may 
play a very different role from the predicted N-cadherin modulation during reactive 
synaptogenesis.  Rather, TIMP-2 bound MT5-MMP may be part of a ternary complex 
that activates pro-MMP-2, and leads to downstream gelatinase activity.  Activated MMP-
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2 would then be available to interact with ECM molecules present in the damaged 
neuropil to influence early phases of reactive synaptogenesis.  We know that shifts from 
pro- to active MMP forms occur following CNS injury (Ashi et al., 2000; Noble et al., 
2002; Li et al., 2009) and that focal activation of these enzymes can occur in a complex 
formed by TIMP/MT-MMP/pro-MMP binding at the cell membrane (Strongin et. al, 1995; 
Sternlicht and Werb, 2001; Maskos and Bode, 2003; Nagase et al., 2006).  Such focal 
MMP activation could be particularly important when new synaptic sites are being 
organized along reforming dendrites within the deafferented molecular layer. 
In addition to the significant changes found in predominant forms of MT5-MMP, 
ADAM-10 and N-cadherin, secondary signals for each protein were also observed 
following injury.  These additional forms showed temporal shifts consistent with the 
expression of the principal kDa forms.  For example, ADAM-10 probed blots contained 
both 100 kDa TIMP-1 bound and 80 kDa pro-enzyme forms which were significantly 
reduced in tandem with the elevation of active ADAM-10 enzyme.  Further, we also 
observed a 2d increase in a 40 kDa N-cadherin form, consistent with the intracellular C-
terminal fragment produced by ADAM-10 cleavage.  Generation of a 35 kDa N-cadherin 
C-terminal fragment has been associated with intracellular signaling pathways which 
facilitate gene transcription (Marambaud et al., 2003; Reiss et al., 2005; McCusker and 
Alfandari, 2009; Jang et al., 2009).  While our peptide did not migrate exactly at 35 kDa, 
it remains possible that injury has generated the same intracellular fragment, although 
not fully processed for its role in downstream cell signaling. Given the known roles for 
MMP and N-cadherin interaction, these findings are not surprising, however, they are 
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novel in the context of reactive synaptogenesis, providing further insight into the time 
and recovery-dependent roles of these two membrane-bound MMPs.  
Model Differences in Membrane-bound MMP and N-cadherin Expression  
Direct comparison between adaptive and maladaptive models of reactive 
synaptogenesis revealed three major differences in MT5-MMP, ADAM-10 and N-
cadherin expression.  Compared to adaptive synaptic recovery, the maladaptive 
condition showed:  1) attenuated MT5-MMP and ADAM-10 expression at 2d after injury, 
2) a higher level of ADAM-10 protein at 7d, which remained significantly elevated at 15d 
postinjury and 3) a failure to generate elevated full-length N-cadherin at 15d during 
synapse stabilization.    
Following UEC lesion, TIMP-bound MT5-MMP and active ADAM-10 protein 
levels were significantly elevated during the acute degenerative (2d) and early 
regenerative (7d) phases of recovery.  With TBI+BEC, a similar 2d rise over control 
occurred, but was reduced in extent by approximately 28%.  Lower enzyme expression 
at 2d may limit the amount of MMP/substrate interaction required to promote the 
necessary degeneration and clearance of damaged axon terminals following combined 
injury.   This result is similar to that seen for secreted MMP-3 at 2d, where the TBI+BEC 
insult generated a lower level of enzyme than the UEC (Phillips et al., unpublished 
observations).  By contrast, at the 7d interval, where axonal sprouting and synapse 
formation is most rapid, ADAM-10 expression was 25% higher than seen in adaptive 
recovery, and remained elevated up to 47% over UEC levels at 15d postinjury. Again, 
this result is in agreement with a persistent elevation of MMP-3 protein at 7d in the 
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maladaptive TBI+BEC model (Phillips et al., unpublished observations).  Together they 
support a differential response for MT5-MMP and ADAM-10 between the two models.  
Combined injury pathology had a lesser effect on MT5-MMP, which was most 
associated with the early periods of debris removal and organization for axonal 
sprouting.  By contrast, maladaptive plasticity was clearly linked to higher ADAM-10 
response and a persistent elevation of the enzyme past the time period when it is 
attenuated in the adaptive UEC model.  Such persistent MMP elevation under 
conditions of failed recovery is in agreement with long-term increase in transcript levels 
for secreted MMPs 2, 3 and 9 previously reported for the TBI+BEC model (Phillips and 
Reeves, 2001; Kim et al., 2005; Falo et al., 2006). 
Another important model difference was observed regarding the expression of 
full-length N-cadherin, which showed a significant 15d elevation over control levels 
during adaptive UEC recovery.  This would be predicted for the phase of 
synaptogenesis when nascent synapses are selectively pruned and junction complexes 
stabilized by N-cadherin adhesion.  A similar elevation of the synaptic protein agrin was 
described 7d following UEC, which paralleled the reduction of MMP-3 (Falo et al., 2006; 
Falo et al., 2008).  With TBI+BEC maladaptive plasticity, full length N-cadherin was 
attenuated by 30% at 15d relative to the UEC model, a result predicted from the 
observation that active ADAM-10 was elevated at the same time point.  A persistent 
ADAM-10 proteolysis of N-cadherin at newly developing synapses would limit synaptic 
stabilization and possibly alter downstream signals regulating gene transcription critical 
to recovery.  Notably, this same pattern of persistently elevated enzyme and 
significantly reduced substrate was seen with MMP-3 and its synaptic target agrin 
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following TBI+BEC (Falo et al., 2006; Falo et al., 2008).  Moreover, reduced N-cadherin 
and agrin protein expression in the maladaptive model is consistent with the poor 
synaptic reorganization seen in earlier ultrastructural studies (Phillips et al., 1994; Falo 
et al., 2006).   
Model differences were also found with some of the additional forms identified for 
each protein.  The 100kDa TIMP-1 bound and 80kDa pro-enzyme forms of ADAM-10 
were significantly reduced at all three postinjury intervals after UEC, however, they each 
returned to control levels at 7d post-TBI+BEC.  While the reason for a normalization of 
these ADAM forms during the phase of sprouting and synapse formation is not clear, it 
may represent a compensatory shift towards latent enzyme expression as a control for 
the extent of ADAM-10 activity generated in the maladaptive model.   The one case 
where a model difference was not observed was the 85kDa form of MT5-MMP which 
was significantly reduced at all time intervals for UEC and TBI+BEC, suggesting that 
this MT5-MMP form may play a similar role in the adaptive and maladaptive recovery 
processes. 
 Tissue Distribution of Membrane-bound MMPs and N-cadherin after Injury  
Tissue localization provides important correlative data for the accurate 
interpretation of quantitative changes in MMPs and their target substrates during 
reactive synaptogenesis.  Based on current literature, MT5-MMP, ADAM-10 and N-
cadherin clearly display spatial expression patterns that would favor interaction at the 
synaptic interface and support active roles in synaptic reorganization (Jaworski, 2000; 
Sekine-Aizawa et al., 2001;, Hayashita-Kinoh et al, 2001; Benson and Tanaka, 1998; 
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Monea et al., 2006; Marcinkiewicz and Seidah, 2000; Marcello et al., 2007).  Our 
immunohistochemical analysis of MT5-MMP, ADAM-10 and N-cadherin support such a 
relationship in several ways:  1) the deafferented molecular layer in UEC and TBI+BEC 
cases shows elevation of each enzyme and N-cadherin relative to paired controls, 2) 
the 7d increase in MMP protein is more profound for the combined insult cases, 
correlating with the quantitative blot results, and  3) astrocytes are the primary sites of 
tissue localization for all three proteins, with subtle differences in neuronal distribution 
noted between MT5-MMP and ADAM-10. 
Adaptive and maladaptive synaptogenesis showed several similarities in enzyme 
and N-cadherin protein distribution.  In each TBI model, dentate MT5-MMP, ADAM-10 
and N-cadherin were elevated relative to uninjured controls.  Proteins showed principal 
localization within reactive astrocytes in the deafferented molecular layer during all 
phases of reactive synaptogenesis.  This pattern is entirely consistent with our earlier 
studies with MMPs 2, 3 and 9, where endogenous glia appear to be the primary site for 
production or processing of these enzymes (Phillips and Reeves, 2001; Kim et al., 
2005; Falo et al., 2006).  Moreover, secreted MMPs are consistently reported to be 
localized within the glia affected by a variety of CNS traumas (Rosenberg, 1995).  
Diffuse neuropil localization is also consistent with the proposed high concentration of 
these three molecules at synaptic sites either around granule cell (GC) bodies or along 
their dendrites.  A notable difference in membrane-bound MMP distribution between 
models was the stronger intensity of this latter pattern in the combined cases.  This was 
particularly true for MT5-MMP, which might be explained by it potential role in activation 
of MMP-2 within the ML extracellular space.  More profound damage in the TBI+BEC 
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model would require greater matrix fluidity to facilitate debris removal.  Localization of 
N-cadherin within reactive astrocytes and throughout the ML supports glial uptake and 
processing of its cleaved extracellular domain during a time of increased active ADAM-
10 expression.  Again, the combined maladaptive model showed subtle differences, 
with slightly more signal in a diffuse pattern relative to cellular localization than the UEC.  
The TBI+BEC model exhibits slow debris clearance (Phillips et al., 1994), suggesting 
that perhaps this shift in N-cadherin distribution represents a lesser degree of glial 
response to phagocytose the cleaved adhesion protein.  Over the 2-15d time course, 
we found a similar pattern of MT5-MMP, ADAM-10 and N-cadherin distribution in the 
dentate, with the principal difference being relative intensity of signal.  This pattern was 
consistent with model and temporal differences seen in our WB results.  N-cadherin was 
the only exception, where, as described above, we can attribute the higher tissue signal 
versus lower blot signal to differences in antibody recognition used for the two 
experiments.  As with our other histological time course studies, the more acute 
increases are followed by long-term decreases as synaptogenesis proceeds.  Taken 
together, these results support local interaction between membrane-bound 
MMPs/substrates during synaptic remodeling, a site where glial processes intimately 
interface with pre- and post-synaptic membranes (Benson et al., 2000).   
Our immunohistochemical results not only illustrate the spatial profile of these 
matrix proteins, but also point to a major astrocytic role in their regulation during 
reactive synaptogenesis.  The data suggests that this role may be different as a function 
of membrane-bound MMPs.  A primary clue here was the distinct structural appearance 
of antibody signal for MT5-MMP and ADAM-10.  We found similar punctate somatic and 
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process labeling in reactive astrocytes for both MT5-MMP and N-cadherin, supporting a 
common link to phagocytosis and internalization after injury.  By contrast, ADAM-10 
uniformly filled the astrocyte cell bodies and did not directly match with the N-cadherin 
pattern.  Although most published studies show ADAM-10 localized within neurons, 
there is also evidence that ADAM-10 may have an astrocytic origin (Kieseier et al., 
2003; Bandyopadhyay et al., 2006).  While this difference is an interesting observation, 
our data cannot fully discriminate between the possibilities.  It should be noted that our 
WB data does show major changes in active enzyme, supporting lytic astrocytic activity 
for ADAM-10 as well.  
The magnitude and direction of astrocytic response may be dependent on the 
severity and complexity of TBI, and therefore influence the level of recovery.  Reactive 
astrocytes can exhibit detrimental, as well as stimulatory effects on injury-induced 
plasticity.  Traditionally, reactive astrocytes are proposed to contribute to the formation 
of inhibitory glial scars adjacent to damaged tissue, therefore preventing or limiting 
recovery postinjury (Liuzzi and Lasek, 1987; Rudge and Silver, 1990).  Conversely, 
some studies argue that astrocytic scars play a protective role, restricting additional 
tissue damage following injury, as well as synthesizing and releasing local 
cytokines/growth factors (White and Jakeman, 2008; Su et al., 2009).  Reactive 
astrocytes also produce and release MMPs to aid in the removal of damaged 
tissue/cells from the injured region, a necessary step prior to the regenerative phase of 
synaptogenesis.  We know that MMP-3 expression during post-UEC synaptogenesis 
contributes to adaptive recovery.  However, overproduction and release of MMPs could 
lead to upregulated activity and additional tissue damage.  For example, lytic activity of 
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both MMP-3 (Kim et al., 2005) and the gelatinases MMPs 2, and 9 (Phillips, 
unpublished results) is persistently elevated during maladaptive synaptic plasticity, 
negatively affecting recovery in the TBI+BEC model.  In these cases, MMPs are 
predominantly located within CNS glia and are likely released to influence 
synaptogenesis.  Thus, a tight spatial and temporal regulation of MMP expression 
appears necessary for adaptive plasticity to occur.  Despite their dual role, targeted 
manipulation of reactive astrocytes during maladaptive plasticity has potential to 
improve recovery by limiting the overexpression and release of MMPs postinjury. 
RNA Expression of Membrane-bound MMPs and N-cadherin During Sprouting and 
Synaptogenesis 
To better understand the profile of postinjury MT5-MMP, ADAM-10, and N-
cadherin protein expression, we used microarray and qRT-PCR methods to screen for 
transcript changes at 7d after UEC and TBI+BEC.   Microarray results from whole 
hippocampus and enriched ML samples revealed the greatest change to be in ADAM-
10 transcript, which occurred following adaptive UEC.  In contrast, slightly more modest 
shifts were seen after TBI+BEC.  Increased ADAM-10 transcript did not appear to differ 
between ML and hippocampal samples, further supporting its prominent role in reactive 
synaptogenesis.  These findings are paralleled by increases in hippocampal ADAM-10 
protein expression values at 7d for both models and the persistent rise in the enzyme 
at15d following TBI+BEC.  Microarray screening of MT5-MMP and N-cadherin failed to 
show post-UEC changes in gene expression and only a modest rise in N-cadherin ML 
transcript with TBI+BEC.  While these results do not specifically match our hippocampal 
WB profile, they do provide details regarding the synchrony of transcription and 
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translation in these models.  No change in ML UEC MT5-MMP and N-cadherin 
transcript at 7d suggests that these genes are regulated at either earlier or later time 
intervals to produce the protein changes we have observed.  In the maladaptive model, 
ML gene expression patterns were attenuated, consistent with the slower start for 
membrane-bound MMP response and slower lysis of synaptic proteins like N-cadherin.  
The strongest cross-model synchrony of transcript and protein change was seen for 
ADAM-10, which might be predicted since the 7d time point showed the most increase 
in protein expression. 
Quantitative RT-PCR analysis of the same 7d ML samples, revealed greater 
changes in MT5-MMP, ADAM-10 and N-cadherin mRNA expression, as is commonly 
the case when samples are shifted from array to PCR analysis.  Elevated ADAM-10 
mRNA in both models remains consistent with our hippocampal WB results.  Again, this 
tight synchrony of protein and mRNA expression for ADAM-10 shows that its up 
regulation is important during dentate synaptic reorganization. The principal asynchrony 
between message and protein was seen with the combined model MT5-MMP and N-
cadherin.  As indicated above, we interpret this pattern to mean that our 7d sampling 
missed an earlier peak in MT5-MMP transcript.  Alternatively, the use of ML for the PCR 
may introduce unknown differences when compared to hippocampal WB results.  We 
also interpret the lack of effect on 7d transcript for N-cadherin in the maladaptive model 
as an expected result, since the protein does change at the later 15d time point with 
TBI+BEC.  It should be noted that reported protein expression was determined from 
whole hippocampal samples, while the greatest changes in mRNA expression were 
derived from ML samples.  The fact that 7d whole hippocampal mRNA analysis showed 
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minimal to no change relative to controls tends to support synthesis of these proteins by 
non-neuronal cells, such as reactive astroglia concentrated in the deafferented zone, a 
conclusion consistent with our immunohistochemical and preliminary in situ 
hybridization findings.  Taken together, the PCR analysis further supports the 
involvement of membrane-bound MMPs in the acute phases of synaptic regeneration, 
as well as the notable persistent expression of active ADAM-10 and reduced N-cadherin 
during stabilization of nascent synapses. 
Role of MT5-MMP, ADAM-10 and N-cadherin in Synaptic Recovery after TBI   
The spatial and temporal patterns of MT5-MMP, ADAM-10, and N-cadherin 
expression during adaptive and maladaptive recovery provide insight into potential 
mechanisms underlying their role in injury-induced synaptogenesis.  While membrane-
bound MMPs like MT5-MMP and ADAM-10 may be either directly or indirectly capable 
of modifying ECM-cell and cell-cell structure within the CNS, they may also act as 
upstream mediators of plasticity.  At this time, our view of postinjury mechanisms is 
strongly based on evidence that MMP lysis of N-cadherin has downstream effects on 
plasticity-related events.  The present results show that elevation of active ADAM-10 is 
paralleled by decreased full length N-cadherin expression postinjury.  Additionally, a 
persistent elevation of active ADAM-10 at 15d post-TBI+BEC is correlated with reduced 
N-cadherin expression when compared to the pattern in UEC, further suggestive of a 
critical ADAM-10/N-cadherin interaction during synaptogenesis.  There is evidence that 
ADAM-10 and MT5-MMP cleavage of N-cadherin has both extracellular and intracellular 
downstream effects that can potentially influence synaptic plasticity (Uemura et al, 
2006; Reiss et al., 2005; Monea et al., 2006).  For example, in vitro studies show 
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ectodomain shedding of N-cadherin releases an N-terminus fragment (NTF) that 
promotes neurite outgrowth in cultured neurons (Paradies and Grunwald, 1993; Utton et 
al., 2001).  Additionally, MMP-driven ectodomain shedding of N-cadherin is required for 
its further intracellular cleavage, which releases a 40kDa C-terminus fragment (CFT1), 
similar to the form we observed in our WB analysis.  The release of CTF1 alters the 
structural integrity of the synapse by changing the intracellular binding properties of the 
protein, thereby permitting structural synaptic modifications during times of heightened 
plasticity (i.e., acute degenerative and regenerative phases of reactive synaptogenesis) 
(Jang et al., 2009).  Release of intracellular N-cadherin fragments has also been shown 
to alter synaptic Ca2+ conductance and therefore affect synaptic function.  This N-
cadherin fragmentation is linked to changes in submembrane interaction with proteins 
such as the AMPA receptor family and p120 catenin, resulting in a decreased Ca2+ 
conductance (Silverman et al., 2007; Malenka and Bear, 2004; Brusés, 2006; McCusker 
and Alfandari, 2009; Jang et al., 2009).   CFT1 undergoes further processing into a 
35kDa fragment (CTF2), which can inhibit the AKT signaling pathway, therefore 
potentially leading to neuronal death in pathological states (Jang et al., 2009).  
Additionally, CTF2 may affect synaptogenesis by binding CREB binding protein (CBP) 
and preventing downstream transcription of CREB-dependent genes that are critical for 
nervous system function and plasticity (Marambaud et al., 2003; Lonze and Ginty, 
2002).  Further, CTF2 also associates with the Wnt signaling molecule β-catenin, which 
promotes transcription of genes that are important for cell proliferation and survival, 
such as cyclin D1, c-myc, c-jun, and N-cadherin (Reiss et al., 2005).  Clearly the 
literature points to the signaling events produced by the proteolytic processing of N-
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cadherin as critical to the efficient reorganization of the synaptic junction.  We believe 
our aggregate data provide evidence that this is true, and that the success or failure of 
injury-induced synaptic recovery may depend upon MMP directed generation of 
substrate fragments at specific phases of synaptogenesis. Indeed, the altered ADAM-10 
and N-cadherin expression we observed during the later stages of aberrant injury-
induced synaptogenesis support this conclusion. 
     
SUMMARY 
The current study examined MT5-MMP, ADAM-10 and N-cadherin protein and mRNA 
expression during adaptive and maladaptive plasticity as a first step in better 
understanding the role of these matrix molecules in postinjury recovery.  It is clear that 
the neuropathology generated by UEC and combined TBI+BEC are different, and 
therefore recruit different responses from these membrane-bound MMPs to either foster 
or inhibit structural and functional recovery.  The results presented here raise several 
questions about postinjury mechanisms that may affect MMP regulation, expression, 
and, in turn, injury-induced plasticity.  Our results implicate MT5-MMP and ADAM-10 as 
important enzymes in the plasticity process, potentially through activation of other 
proteases or interaction with N-cadherin.  Although we show MT5-MMP and ADAM-10 
influence on synaptic plasticity in two different TBI models, it remains unclear what 
specific event(s) regulate their differential postinjury expression patterns.  Future studies 
are needed to determine MT5-MMP and ADAM-10 functional activity over the time 
course of reactive synaptogenesis.  In addition, detailed behavioral and functional 
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assessments are necessary to further understand model differences and reveal 
possible therapeutic targets to improve synaptic plasticity and recovery following TBI.  
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Chapter 3 
 
 
 
MMP Inhibition Improves Synaptic Efficacy and Stabilization during               
Maladaptive Injury-Induced Synaptogenesis 
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ABSTRACT 
In our prior studies we have reported that a variety of matrix metalloproteinases 
(MMPs) influence the success of reactive synaptogenesis induced by traumatic brain 
injury (TBI).  The first portion of this dissertation has shown that specific membrane-
bound MMPs, MT5-MMP and ADAM-10, are spatially and temporally correlated with 
adaptive synaptic plasticity, specifically the period of recovery when new synapses are 
stabilized.  The success of this process appears to be linked to reduced MMP levels 
and elevated expression of their common substrate, N-cadherin, an adhesion molecule 
critical to the organization and stabilization of the synaptic junction.  Such observations 
suggest that membrane bound MMPs may act in concert with N-cadherin to support 
functional recovery seen with adaptive synaptic plasticity.  Our earlier studies indicate 
that attenuation of secreted MMP activity at 6-7d postinjury improves the structural 
integrity of newly formed synapses in the TBI+BEC model of maladaptive 
synaptogenesis.  Here, we posit that inhibition of membrane bound MT5-MMP and 
ADAM-10, targeting their elevation during onset of regenerative axonal sprouting in that 
model, will enhance N-cadherin related stabilization of synaptic structure and promote 
functional recovery.  Adult male rats subjected to TBI+BEC (combined fluid percussion 
+ entorhinal lesion insult) were treated with the broad spectrum MMP inhibitor GM6001 
(10mg/kg i.p.) or vehicle at 6 and 7d postinjury, targeting both the onset of synapse 
reorganization and the period of highest hippocampal MT5-MMP and ADAM-10 protein 
expression.  Assessment of drug effect was made at 15d postinjury, the period when 
these two MMPs and their substrate N-cadherin were most prominently altered during 
maladaptive plasticity.  Relative to sham-injured controls, GM6001 treatment decreased 
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ADAM-10 protein levels and increased in N-cadherin protein expression.  Functional 
effects of MMP inhibition were also evaluated at 15d postinjury, using brain slices for in 
vitro electrophysiological recordings of long-term potentiation (LTP), long-term 
depression (LTD), and paired pulse facilitation (PPF) in the Schaffer collateral input to 
CA1.  This pathway was selected based upon its widespread use as a model for 
probing hippocampal synaptic efficacy, and the fact that its components remain intact 
following the TBI+BEC insult.  Combined injury resulted in the delayed induction of LTP, 
which was partially restored with GM6001 treatment.  By contrast, LTD failed to show 
any drug-related change.  Further, PPF trials showed no significant effects of either 
injury or drug, suggesting that functional deficits associated with this hippocampal 
pathway did not involve defects in pre-synaptic terminals.  To assess behavioral 
plasticity following MMP inhibition, a subset of injured-untreated and injured-treated 
animals were tested for spatial memory performance using the Morris Water Maze.  Our 
results showed the profound, persistent deficits associated with the TBI+BEC model, 
however, GM6001 treatment failed to alter behavioral outcome.  Finally, qualitative 
ultrastructural analysis of injured animals treated with GM6001 revealed dendritic 
cytoarchitecture and synaptic integrity consistent with adaptive synaptic recovery, 
supporting the hypothesis that GM6001 MMP inhibition also protects synaptic structure 
after TBI.  Collectively, these results suggest that membrane-bound MMPs and their 
substrate N-cadherin interact during reactive synaptogenesis to influence synapse 
stabilization, contributing to enhanced synaptic function following TBI. 
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INTRODUCTION 
Two principle features of traumatic brain injury (TBI) are excessive 
neuroexcitation and diffuse axonal injury, which lead to neuronal deafferentation in 
vulnerable brain regions (Okonkwo and Povlishock, 2003; Povlishock and Katz, 2005).  
Injury-induced deafferentation results in reactive synaptogenesis, which serves to 
replace degenerated synaptic connections and restore function.  This plasticity is 
influenced by a number of extracellular matrix (ECM) molecules, including members of 
the matrix metalloproteinase (MMP) family and their targeted substrates (Phillips and 
Reeves, 2001).  MMPs constitute a large family of zinc and calcium dependent 
enzymes that are capable of substrate cleavage at cell surfaces, including the majority 
of ECM shaping molecules (Rosenberg, 2002).  Clearly, MMP proteolytic modification of 
cell-ECM and cell-cell connections is critical for the formation and maintenance of 
neural circuitry, as well as for synaptic replacement, reorganization, and recovery 
following TBI (Sternlicht and Werb, 2001; Treuttner et al., 2005; Falo et al., 2006; 
Szklarczyk et al, 2002).  While MMPs promote a variety of plasticity processes including 
axonal guidance and synaptogenesis during nervous system development and disease, 
MMP activity is tightly regulated to avoid the negative consequences of excessive lysis 
(Yong et al., 2001).           
Our lab has demonstrated MMP involvement in reactive synaptogenesis 
following TBI, which suggests an integral MMP role in recovery (Reeves et al., 2003; 
Kim et al., 2005; Falo et al., 2006).  Studies revealed aberrant MMP protein expression 
and activity when the plasticity process is maladaptive.  This work contrasts the 
adaptive synaptic recovery induced by unilateral entorhinal cortex lesion (UEC) with a 
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model which combines moderate central fluid percussion injury and bilateral entorhinal 
cortex lesions (TBI+BEC), resulting in poor synaptic recovery.  We posit that these 
persistent recovery deficits are due, in part, to the unregulated expression and activity of 
MMPs within damaged brain regions.  Therefore, to improve synaptic recovery and 
uncover potential treatment paradigms for human TBI, we have explored the efficacy of 
pharmacological MMP inhibition postinjury in producing enhanced synaptic recovery.  In 
the TBI +BEC model, MMP inhibition with the hydroxyamate compound FN-439 at 6-7d 
postinjury reduced spatial learning deficits and improved synaptic cytoarchitecture (Falo 
et al., 2006).  Interestingly, we also found that FN-439 administration 30 minutes after 
UEC attenuated both structural and functional recovery at 7d postlesion (Reeves et al., 
2003).  These results suggest that, while regulated MMP expression and activity is 
required for successful synaptic recovery, excessive MMP response can attenuate this 
recovery and result in maladaptive reorganization following brain injury. 
  Recently, two membrane-bound MMPs, Membrane-type 5 MMP (MT5-MMP) and 
A Disintegrin and Metalloproteinase-10 (ADAM-10), have emerged as important players 
in the plasticity process.  MT5-MMP and ADAM-10 may influence the outcome of 
reactive synaptogenesis by targeting the neuronal adhesion molecule, N-cadherin 
(Monea et. al, 2006; Reiss et al., 2005).  In the CNS, N-cadherin ligates pre- and post-
synaptic elements extracellularly, stabilizes intracellular synaptic structure, and 
influences the organization and function of mature synapses (Benson and Tanaka, 
1998).  MT5-MMP and ADAM-10 are localized in and around synapses, in close 
proximity to N-cadherin, permitting concentrated proteolytic activity at synaptic junctions 
(Jaworski, 2000; Marcinkiewicz and Seidah, 2000; Takeichi and Abe, 2005).  Interaction 
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between MT5-MMP, ADAM-10 and N-cadherin has the potential to influence reactive 
synaptogenesis following TBI through modification of synaptic adhesion and 
stabilization.   
The first study in this dissertation has shown that specific membrane-bound 
MMPs, MT5-MMP and ADAM-10, are spatially and temporally correlated with adaptive 
synaptic plasticity, specifically the period of recovery when new synapses are stabilized 
(Warren et al., 2009).  We observed an inverse relationship between levels of enzyme 
and substrate in both models, as well as recovery-dependent changes in protein 
expression postinjury.  Relative to the adaptive UEC model, maladaptive plasticity 
showed a reduced MT5-MMP response at 2d postinjury and a persistently elevated 
ADAM-10 expression at 15d.  Synaptic adhesion protein N-cadherin was reduced at 2 
and 7d postinjury, but showed elevation above normal levels of expression at 15d with 
adaptive recovery.  With maladaptive synaptogenesis, N-cadherin failed to increase at 
15d.  We conclude that these altered patterns of 2d MT5-MMP and 15d ADAM-10/N-
cadherin expression contribute to the poor synaptic recovery seen in the TBI+BEC 
model.  Further, we posit that the inhibition of MT5-MMP or ADAM-10 activity at 6-7d 
postinjury, the interval of its maximum expression, will attenuate enzyme expression 
and elevate N-cadherin at 15d after injury.  Moreover, these shifts will reduce structural 
and functional pathology which characterizes the maladaptive synaptic plasticity of the 
TBI+BEC model.  
In this present study we investigated the effect of MMP inhibition on MT5-MMP, 
ADAM-10 and N-cadherin protein expression by administering the broad-spectrum 
MMP inhibitor, GM6001, at 6 and 7d following TBI+BEC insult.  Assessment of drug 
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effect was made at 15d postinjury, the period when these two MMPs and their substrate 
were most prominently altered during maladaptive plasticity.  GM6001 inhibits MMP 
activity by chelating zinc at the active site of secreted and membrane-type MMPs, 
including MT5-MMP and ADAM-10.  Substrate binding is prevented, rendering the 
MMPs inactive (Grobelny et al., 1992; Schultz et al., 1992).  We chose to use GM6001 
in our study based upon its ability to cross the blood brain barrier to inhibit MMPs in vivo 
and published evidence for its in vitro inhibition of MT5-MMP and ADAM-10 (Gijbels et 
al., 1994; Leib et al., 2000; Bendeck et al., 1996; Monea et al., 2006; Reiss et al., 2005).  
We chose to administer GM6001 at 6 and 7d for several reasons:  1) to target the 
period where we observed maximal postinjury MT5-MMP and ADAM-10 elevation, 2) to 
manipulate MT5-MMP and ADAM-10 activity during the period of axonal sprouting and 
3) to match our prior protocols which showed enhanced synaptic recovery with FN-439, 
a MMP inhibitor with high selectivity for secreted MMP-3 (Falo et al, 2006).  In these 
studies we first assessed hippocampal MT5-MMP, ADAM-10 and N-cadherin 
expression at 15d postinjury with Western blots.  In a parallel set of experiments, 
functional effects of MMP inhibition were evaluated with in vitro electrophysiological 
recordings of long-term potentiation (LTP), long-term depression (LTD), and paired 
pulse facilitation (PPF) in the Schaffer collateral input to CA1.  To assess behavioral 
plasticity following MMP inhibition, a subset of injured-untreated and injured-treated 
animals were tested for spatial memory performance using the Morris Water Maze.  At 
the end of behavioral assessment, a subset of animals from each group was prepared 
for ultrastructural analysis of drug effect on synaptic cytoarchitecture.  Our results show 
that MMP inhibition significantly affected ADAM-10 and N-cadherin protein expression, 
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improved measures of synaptic efficacy, and enhanced the integrity of hippocampal 
synaptic ultrastructure.    
 
METHODS 
Experimental Animals 
Adult male Sprague-Dawley rats (300-400g) were used in this study.  Two rats 
were housed per cage, with food and water ad libitum, and subjected to a 12 hr dark-
light cycle at 22°C.  All protocols for injury and use of animals were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University.   
Rats were randomly divided into three groups and subjected to either: 1) TBI+BEC 
injured-untreated (n=25), 2) TBI+BEC injured-GM6001 treated (n=20), 3) TBI+BEC 
injured-vehicle treated (n=10), 4) sham-injury (n=25).  Animals were allowed to survive 
for 15d, at which time subgroups were again randomly selected for biochemical, 
electrophysiological or ultrastructural assessment.  In all analyses, sham-injured 
animals served as paired-controls and results were expressed as percent change from 
this group.  A subset of injured-treated, injured-untreated and sham-injured rats 
underwent behavioral testing (MWM) on days 12-15 postinjury before being sacrificed at 
15d. 
Surgical Preparation for Central Fluid Percussion TBI 
Animals were anesthetized (isoflurane 4% in carrier gas of 70% N2O and 30% O2 
delivered via nose cone) and placed in a stereotaxic frame for surgical preparation 
24hrs prior to injury.  Body temperature was maintained at 37°C using a thermostatic 
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heating pad (Harvard Apparatus, Holliston, MA) and physiological parameters (heart 
rate, arterial oxygen saturation, breath rate/distension and pulse distension) monitored 
throughout surgical preparation using pulse oximetry (MouseOx; Starr Life Sciences, 
Oakmont, PA).  Rats received a 4.8 mm midline craniectomy midway between bregma 
and lambda, exposing but not breaching the underlying dura.  Two steel screws were 
implanted 1 mm caudal to the coronal suture on the left and 1mm rostral to lambdoidal 
suture on the right.  A modified Leur-Loc hub (2.6 mm inside diameter) was implanted in 
the craniectomy site and fixed with cyanoacrylate adhesive.  Dental acrylic was added 
around the hub and screws to secure the complex.  The scalp was sutured closed to 
cover hub and Bacitracin was applied to the wound.  Rats were monitored for recovery 
and returned to their home cages.   
Central Fluid Percussion TBI 
Moderate central fluid percussion injury (2.0+0.1 atm) was performed as 
described by Dixon et al. (1987).  The fluid percussion injury device is made up of a 
Plexiglas cylinder (60cm long, 4.5 cm diameter) filled with double distilled water.  One 
end of the cylinder has a rubber-covered Plexiglas piston mounted on O-rings, and the 
opposite end is closed by a metal extra-cranial pressure transducer (Entram Devices, 
Inc., model EPN-0300-100A).  The end of the metal transducer (5mm tube, 2.6 mm 
inside diameter) has a male Leur-loc fitting that connects to the exposed female Leur-
loc hub implanted in the rat skull.  A metal pendulum is dropped from a determined 
height that coincides with injury severity, and strikes the rubber-covered piston, forcing 
a small fluid injection into the closed cranial cavity, briefly displacing brain tissue.  Injury 
level is recorded by the extra-cranial transducer, and visualized and reported 
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(atmospheres, atm) on an oscilloscope (Tektronix 5111: Beaverton, OR).  Twenty-four 
hours after surgical preparation, rats were re-anesthetized, connected to the fluid 
percussion device through the exposed hub, and subjected to injury.  Animals were 
monitored for recovery from anesthesia and injury by observation and timing of multiple 
reflexes (paw, tail, corneal, righting, pinna), and then returned to their home cages. 
Combined Central Fluid Percussion +Bilateral Entorhinal Lesion (TBI+BEC) 
Animals that received the combined injury were surgically prepared for fluid 
percussion injury, and twenty-four hours later received moderate (2.0+0.1 atm) central 
fluid percussion injury.  These animals recovered for another twenty-four hour time 
period, and were then re-anesthetized and subjected to bilateral entorhinal cortex 
lesions (Phillips et al., 1994).  Briefly, a small portion of the skull was removed on the 
right and lefts sides to expose the dura mater superior to the entorhinal cortex (see 
again Appendix A, Fig. A-2).  Electrolytic lesions were made by passing a 1.5 mA 
current (40 sec each) via 0.2 mm Teflon-insulated wire electrode, positioned 10° to the 
perpendicular plane, at eight at eight separate stereotaxic sites:  1.5 mm anterior to the 
transverse sinus, and 3, 4, and 5 mm lateral to midline, 2 , 4 and 6mm ventral to the 
brain surface for the first two lateral measurements (3 and 4mm) and only 2 and 4mm 
ventral to the brain surface for the last lateral measurement (5mm) (see again Appendix 
A, Fig. A-1).  After lesioning, electrodes were removed, the scalp sutured, and 
Bacitracin was applied.  Animals were transferred to a recovery cage and monitored for 
at least 1 hr to ensure adequate recovery, and were then returned to their home cages. 
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MMP Inhibitor (GM6001) Administration 
Inhibition of MT5-MMP and ADAM-10 activity was achieved using a commercially 
available MMP inhibitor, GM6001 (Millipore, Billerica, MA).  This hydroxamate 
compound chelates the active site zinc atom within a variety of MMPs, preventing 
substrate binding and rendering the enzyme inactive (Grobelny et al, 1992; Schultz et. 
al, 1992).  Although it targets a broad-spectrum of MMPs, GM6001 has been shown to 
inhibit both MT5-MMP and ADAM-10 in vitro (Monea et. al, 2006; Reiss et. al, 2005).  
Animals within the TBI+BEC Injured-treated group received GM6001 (10mg/kg i.p.) 
once daily, at 6 and 7d postinjury, delivered in vehicle consisting of  4% 
carboxymethlycellulose (CMC sodium salt, Sigma, St. Louis, MO) suspension as 
described.  GM6001 dose, suspension, and delivery was based on previous in vivo 
studies which showed effective inhibition of MMPs in neurotrauma models (Wang and 
Tsirka, 2005; Sifringer et al., 2007).  The timeframe for dosing was selected to coincide 
with the period where we observed maximal postinjury MT5-MMP and ADAM-10 
elevation.  A separate injured-vehicle group received 4% CMC with the same dosing 
paradigm to assess effects of vehicle on biochemical outcome.  No significant 
differences were detected between injured-untreated and injured-vehicle animals (data 
not shown), therefore the two groups were combined into one for subsequent 
experimental analyses.   
Western Blot Analysis 
At 15d following injury, a subset of rats (TBI+BEC injured-treated: n=6; TBI+BEC 
injured-untreated: n=7-8; sham-injured: n= 8) were subjected to hippocampal protein 
analysis.  Rat were anesthetized with isoflurane (4% in carrier gas of 70% N2O and 30% 
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O2) and quickly decapitated.  Whole hippocampi were removed, homogenized in ice-
cold TPER (Pierce), and centrifuged (8,000xg) for 5 min at 4°C.  Supernatants were 
removed and assayed for protein concentration (Shimadzu UV-160, Shimadzu 
Scientific, Columbia, MD; FLUOstar Optima, BMG Labtechnologies, Inc., Durham, NC).  
For blot preparation, a 1:5 dilution (5 μg sample:20 μg H2O) of each sample was mixed 
with XT Sample Buffer/Reducing Agent (Bio-Rad Laboratories, Hercules, CA) and 
heated at 95°C. Proteins were resolved on a 4-12% Bio-Tris gel (Bio-Rad) and 
transferred to PVDF membranes.  Post-blotted gels were stained and analyzed for even 
protein load and transfer. Membranes were washed in dH2O twice and TBS once for 5 
min each, and then blocked in 5% milk TBS-Tween (TBS-T) for 1 hour.  Membranes 
were then probed with primary antibody (MT5-MMP rabbit polyclonal n-terminus: 
1:1,000, Abcam, Cambridge, MA; N-Cadherin mouse monoclonal c-terminus: 1:1,000, 
BD Transductions Laboratories, San Jose, CA; ADAM-10 rabbit polyclonal c-terminus: 
1:1,000, Sigma, St. Louis, MO) in 5% Milk TBS-T. After overnight incubation at 4°C, 
blots were washed six times with Milk TBS-T for 5 min each, incubated in secondary 
antibody (IgG goat anti-mouse: 1:20,000, Rockland, Gilbertsville, PA; IgG bovine anti-
rabbit: 1:20,000, Santa Cruz, Santa Cruz, CA; ) for 1 hour, and washed six times with 
TBS-T for 5 min each.  Antibody binding was visualized with enhanced 
chemiluminescence substrate, SuperSignal (Thermo Scientific, Rockford, IL).  
Immunopositive bands were imaged on the Syngene G:BOX and densitometry was 
performed using GeneTools software (Syngene, Frederick, MD).  β-actin (mouse 
monoclonal: 1:3,000, Sigma, St. Louis, MO) was used as a load control for Western blot 
experiments (see again Appendix B, Fig B-8).   
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Electrophysiological Recording  
A randomly selected subset of rats from TBI+BEC injured-treated (n=9), 
TBI+BEC injured-untreated (n=8), or sham-injured (n=12) groups were prepared for in 
vitro electrophysiological recording.  Each rat was anesthetized with 4% isoflurane for 4 
min, and the brain rapidly removed.  Coronal 450 μm slices were cut into artificial 
cerebrospinal fluid (ACSF; 2-4 ºC) containing (in mM): NaCl 124, KCl 3, MgSO4 2, CaCl2 
2, NaH2PO4 1.3, NaHCO3 26, glucose 10; pH 7.4; saturated with 95% O2/5% CO2 gas. 
All slices containing the mid-dorsal hippocampus were saved, which yielded 4 to 6 
slices per brain.  Slices were then transferred to a holding chamber containing 
oxygenated ACSF, gradually brought to 34°C, and were allowed to equilibrate under 
these conditions for at least 1 h prior to recording.  For electrophysiological recording, a 
slice was gently transferred from the holding chamber to a submersion-type recording 
chamber, and perfused with oxygenated ACSF (34°C) at a rate of 2-3 ml / min. 
A bipolar stimulating electrode (teflon-insulated tungsten, with intertip distance 
(0.2-0.3 mm) was lowered into the stratum radiatum of CA1 in order to stimulate the 
fibers of the Schaffer collateral system. This hippocampal projection was selected for 
study in lieu of the perforant path projection to the dentate gyrus, which is bilaterally 
ablated in the TBI+BEC model.  The Schaffer-collateral projection to CA1 also 
represents a downstream component of the hippocampal trisynaptic loop and is often 
used for studies of synaptic efficacy after CNS injury.  A recording electrode (glass 
micropipette filled with ACSF; resistance 6-8 MegOhm) was also placed in the stratum 
radiatum, approximately 0.5-0.7 mm medial to the stimulating electrode, to measure the 
evoked population excitatory postsynaptic potentials ("field EPSPs" or fEPSPs).  The 
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initial depth of electrodes was approximately 200 micron below the surface of the slice, 
however, fine adjustments were made in the depths of both stimulating and recording 
electrodes to achieve maximum fEPSP amplitude. 
Unless otherwise noted, stimulation used for evoked potentials was constant 
current stimulus-isolated square wave pulses (0.20 msec duration) delivered at one 
pulse each 30 sec (0.033 Hz).  All evoked field potentials were amplified (bandpass = 
d.c. to 5 kHz), digitized at 20 kHz, and stored on hard disk for off-line analysis.  For off-
line quantification of digitized waveforms, fEPSP slopes were measured as rate of 
descent over a 0.5 msec interval in the initial negative-going phase of the fEPSP 
(ClampFit v.8.2 software, Axon Instruments, Inc., Union City, CA). 
An input-output function was generated for each slice by varying stimulus 
intensity in ten equal steps from subthreshold level to the stimulus intensity which 
evoked a maximum fEPSP.  To assure measurement stability, all evoked potentials 
were repeated 4 times, at each separate level of stimulation intensity, and statistical 
analyses were performed only on the averaged signals.    Following the determination of 
the input-output function, three paradigms of neural functional plasticity were 
implemented:  long-term potentiation (LTP), long-term depression (LTD), and paired-
pulse facilitation (PPF). 
Stimulus amplitude was adjusted to evoke a fEPSP response which was 50% of 
maximum, based on the prior input-output analysis (see above).  Using this constant 
level of stimulation intensity, a 30 minute period of baseline recording was obtained by 
evoking fEPSPs at a stimulus rate of 0.033 Hz.  LTP was then induced by theta-burst 
high frequency stimulation (HFS) consisting of a total of ten bursts of four pulses at 100 
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Hz, with 200 msec separating the onset of each burst.  The magnitude of LTP was then 
evaluated for a period of 60 minutes, using the same stimulation parameters (0.033 Hz) 
as used during the pre-HFS baseline sample. Following the 60 minute period of post-
HFS monitoring, LTD was induced using 15 minutes of 1 Hz stimulation. The effects of 
the 1 Hz stimulation were then evaluated by acquiring responses at the low stimulation 
rate (0.033 Hz) for 20 minutes. 
A subset of rats (n=6) within each group were further assessed for paired-pulse 
facilitation (PPF).  In the PPF procedure, two identical stimulus pulses, subthreshold for 
target cell discharges (i.e., not evoking population spikes) and separated by either 50, 
100, or 150 msec, usually evoke non-identical responses.  The second augmented 
response has been interpreted as due, in large part, to residual Ca2+ loaded into pre-
synaptic terminals during the first response, which has not been buffered or cleared 
prior to the second response (Leung and Fu, 1994).  Paired-pulse plasticity was 
calculated at each interpulse interval (50, 100, and 150 msec) using the ratio of the 
second fEPSP slope to the first (fEPSP2/fEPSP1).    
Morris Water Maze Assessment 
The Morris Water Maze (MWM) was used to assess spatial memory function as 
previously described (Hamm et al, 2001; Phillips et al., 1997).  TBI+BEC injured-treated 
(n=7), TBI+BEC injured-vehicle (n=8) and sham-injured (n=5) groups were subjected to 
4 trials per day for 4 days (12-15d post-injury).  In each block of trials, rats were placed 
in the pool, facing the wall and commenced testing once from each of the start locations 
(north, south, east west ordinates).  The order of start locations was randomized and 
the hidden goal platform was consistently positioned 45 cm from the outside of the pool 
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wall.  A digital camera was mounted above to pool to record all trials.  For each trial, 
rats were given up to 120 sec to find the hidden platform.  If the rat failed to reach the 
platform after 120 sec, it was placed on the platform for 30 sec, removed from the pool, 
and returned to a heated chamber between trials.  All trials were separated by 4 min 
intervals.  A mean daily latency to find the platform (in sec) was calculated for each 
animal and group mean comparisons were made as described previously (Phillips et al., 
1997).   
Electron Microscopy 
At the end of MWM testing (15d postinjury), a subset of rats (n=3/injured group) 
were randomly selected for qualitative EM analysis.   Rats were anesthetized with a 
lethal dose of sodium pentobarbital (90 mg/kg, i.p.) and perfused with 0.9% NaCl 
followed by mixed aldehyde fixative (4% paraformaldehyde and 0.2% glutaraldehyde) in 
0.1M Phosphate Buffer (PB), pH 7.2. Brains were then removed and stored in buffer 
overnight at 4°C. Coronal vibratome sections (40 μm) containing the hippocampus and 
dentate gyrus were collected in 0.1M PB and prepared for EM processing as previously 
described (Phillips et al., 1994). Briefly, sections were first placed in 1% osmium (in 
0.1M PB, pH 7.2), processed in resin and flat-embedded on plastic slides.  After curing, 
hippocampi were excised and a series of semi-thin (0.5µm) and ultrathin (silver, 600Å) 
sections cut on a Leica EM UC6i ultramicrotome (Leica Microsystems, Wetzlar, 
Germany).  The semi-thin sections were photographed as a guide for ultrastructural 
sampling. Ultrathin sections were collected on membrane-coated slotted grids and 
observed on a Jeol JEM-1230 electron microscope equipped with a Gatan UltraScan 
4000SP CCD camera.  A series of 5,000 x images were collected at regular intervals 
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across the dorso-ventral extent of CA1 radiatum and the dentate molecular layer for 
subsequent qualitative cytoarchitectural analysis.  
Statistical Analysis   
For Western blot data, results were expressed as percent of control and group 
means calculated.  Changes in protein expression were first evaluated for significance 
by comparison of relative optical density measures within TBI+BEC injured-untreated 
and injured -treated samples to that of paired sham-injured control cases.  Subsequent 
comparisons were also made for optical density measures between TBI+BEC injured-
untreated and injured-treated cases.  The effects of injury and drug treatment on protein 
level were determined using the Student‟s t-test. 
Electrophysiological results were evaluated with mixed-model ANOVAs, using 
the MANOVA software routines in SPSS v. 11.5, with between-subjects factor of 
analytic group (uninjured control, TBI+BEC (untreated), and TBI+BEC (treated)).  In 
LTP analyses, the repeated measures factor was time relative to application of the high-
frequency stimulation (theta-burst), and in PPF analyses the repeated measures factor 
was interpulse interval.  Contrasts between specific groups were evaluated using simple 
effects based on planned comparisons (Keppel, 1991; Levine, 1991).   
For behavioral measures, group means were first analyzed using ANOVA, with 
specific group differences evaluated using the Fisher Least Significant Difference test.  
A probability of less than 0.05 was considered statistically significant for all experiments.  
All results are reported as mean + SEM.  
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RESULTS 
Physiological Measurements 
During surgical preparation and lesioning, all animals were monitored for heart rate (350 
+ 20bpm), arterial oxygen saturation (> 93%), breath rate (45 + 5bpm), pulse distention 
(15 + 5µm), and breath distention (12 + 5µm) with pulse oximeter (MouseOx; Starr Life 
Sciences, Oakmont, PA).  Surgical procedures on all experimental animals produced no 
significant change in these physiological measures. 
 
Western blot analysis 
Effect of MMP Inhibition on MT5-MMP, ADAM-10 and N-cadherin Protein Expression  
In order to test the effect of MMP inhibition on MT5-MMP, ADAM-10 and N-
cadherin expression during the period of synapse stabilization, we sampled 
hippocampal protein extracts at 15d postinjury.  We specifically targeted GM6001 
treatment at the 6-7d postinjury interval to affect the period when enzyme levels are 
highest and N-cadherin substrate decreased.  The primary 80 kDa MT5-MMP 
expression at 15d was neither significantly affected by GM6001 treatment when 
compared with injured vehicle cases, nor was it different from sham-injured controls 
(104.55 + 9.75, p=0.65) (Fig. 3.1).  These results suggest that MT5-MMP protein 
expression was not a major player at 15d postinjury, consistent with our prior Western 
blot results.  However, we did observe a significant drug effect on active 70 kDa ADAM-
10 protein expression at 15d postinjury relative to injured-untreated animals (Fig. 3.1).  
Injured-untreated cases showed an increase (230.78 ±30.41, p<0.001), while injured-
treated cases were not different from controls (109.74 ±14.86, p=0.64).  Further, when 
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injured-untreated and injured-treated were directly compared, there was a 48% 
reduction in 70 kDa ADAM-10 following GM6001 which proved to be significant 
(p<0.01).  While 15d full length N-cadherin (130 kDa) within the injured groups was not 
different from sham-injured controls (p=0.15), GM6001 treatment significantly elevated 
130 kDa N-cadherin in the injured-treated animals when compared with the injured-
vehicle cases at 15d (injured-untreated: 88.69 + 5.47 p=0.24; injured-treated: 122.29 + 
12.87; p<0.05) (Fig. 3.1).  Notably, the relative expression of MT5-MMP, ADAM-10 and 
N-cadherin in the GM6001 treated TBI+BEC cases was now similar to that seen at 15d 
following UEC, shifting the profile toward that present during adaptive synaptic plasticity.   
Further, these results show that GM6001 administration at the time of sprouting 
and synapse formation selectively affects ADAM-10 during synapse stabilization phases 
of synaptogenesis.  Moreover, significant increase in N-cadherin after GM6001 
treatment supports a direct enzyme/substrate interaction between ADAM-10 and N-
cadherin during this synapse stabilization. 
Blot signal for the additional forms of MT5-MMP (85 kDa), ADAM-10 (100 kDa, 
80 kDa) and the 40 kDa N-cadherin fragment following GM6001 treatment was not 
different from that of the injured-vehicle group at 15d postinjury (data not shown).  
These results indicate that MMP inhibition did not affect the expression of these 
additional forms of MT5-MMP, ADAM-10 and N-cadherin. 
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Figure 3.1 Comparison of MT5-MMP, ADAM-10 and N-cadherin Hippocampal 
Protein Expression in TBI+BEC-untreated and TBI+BEC GM6001-treated animals 
at 15d.  Values expressed as percent of sham controls.  GM6001 treatment at 6 and 7d 
postinjury significantly decreased ADAM-10 and increased N-cadherin protein 
expression relative to injured-untreated group when measured at 15d.There was no 
change noted between groups for MT5-MMP (MT5) expression. Representative blots 
shown below. I=Injured; S=Sham (control); Injured-Vehicle n=7-8, Injured-Treated n=6, 
Sham n=8; *p<0.05, **p<0.01 
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Electrophysiology 
Effect of MMP Inhibition on Long-Term Potentiation and Long-Term Depression  
 Application of the theta-burst high-frequency stimulation (HFS) generally 
elevated fEPSP slopes during the 60 minute post-HFS period.  Example evoked 
waveforms from each group are shown in Fig. 3.2, illustrating potentials acquired during 
pre-HFS baseline period, and during the post-conditioning period.  Also illustrated is the 
fEPSP measurement, taken early in the downstroke of the fEPSP.  In comparison to 
fEPSP measurements based on peak amplitude, a slope measurement early in the 
fEPSP waveform is less affected by population spikes.  As indicated in Fig. 3.2, the 
standardized current intensity (50% of maximum, based on input-output functions) 
evoked moderate fEPSP waveforms, having small population spikes, or lacking them 
altogether.  After HFS, the evoked fEPSPs often developed large population spikes (see 
example, marked „p.s.‟ in Fig. 3.2).  Within the LTP literature, there is a widespread 
agreement that the „early-slope‟ measurement approach reflects current fluxes initiated 
by the population EPSP, prior to contamination by target cell discharges. 
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Figure 3.2 Representative field potentials evoked in the Schaffer collateral 
afferent input to CA1.  Traces are shown from a sham control rat, from a TBI+BEC 
(vehicle) rat, and from a TBI+BEC (GM6001-treated) rat.   A sample waveform is shown 
during the baseline recording period, prior to the application of high frequency 
stimulation (HFS) used to induce LTP, and from 10 min and 60 min after HFS.  Within 
each row stimulus current was held constant.  The method of measuring the initial 
fEPSP slope is illustrated in two of the baseline waveforms.  In addition to usually 
increasing fEPSP slope, HFS often also induced a population spike (p.s.) which 
persisted during the post-HFS recording period
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In uninjured control rats, the HFS trains induced a significant 58.0+8.6% increase 
in fEPSP slope, when averaged across the 60 minute post-HFS monitoring period 
(p<0.001).  However, as measured at 15 d after the TBI+BEC injury, LTP was weak and 
quite variable.  Again averaging across 0-60 minutes post-HFS, the TBI+BEC 
(untreated) group exhibited a 36.1+15.5% elevation of fEPSP slope, but this narrowly 
missed significance (p=0.077).  In contrast HFS induced a significant 45.8+10.8% 
average increase in TBI+BEC (treated) rats (p<0.01).  Figure 3.3 panel A shows, mean 
fEPSP slope measurements, normalized to pre-HFS baseline, for each group.  These 
results indicated that the HFS was effective in inducing a functional plasticity:  a 
significant 58% and 46% enhancement for controls and injured-treated rats, 
respectively, and a (non significant) 36% change in injured-untreated rats.  A separate 
issue was whether these magnitudes of LTP were statistically different among the three 
groups.  As a first approach to this question, we analyzed whether the mean fEPSP, 
averaged over entire 60 minutes of post-HFS monitoring, was significantly different 
among the three groups.  This analysis indicated that there were no statistically 
significant differences among any of the three groups (p=0.198), probably due to the 
highly variable responses in rats subjected to TBI+BEC. 
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Figure 3.3 Effects of TBI+BEC injury and GM6001 treatment on LTP and LTD.  (A).  
Rats with TBI+BEC injuries showed weak and highly variable LTP, significantly below 
control levels during the first 15 minutes post-conditioning (Period 1 (P1) interval).  Time 
of application of high-frequency stimulus (HFS) trains is marked with filled arrow.  
Injured rats treated with GM6001 exhibited a level of LTP intermediate between the 
control and injured-untreated groups.  LTD (induction time marked with open arrow) was 
not significantly altered by injury or GM6001 treatment. ).  For clarity data points are 
averages of 2-minute epochs.  (B)  Mean level of LTP was significantly suppressed in 
injured rats from 0-15 min post-HFS (p<0.05).  LTP in GM6001-treated rats was not 
different from control levels.  No significant injury or drug effects were observed from 
16-60 minutes post-HFS (P2). 
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Inspection of Figure 3.3 panel A, suggested a possible systematic difference 
among groups during the first 15 minutes post-HFS.  Specifically, the rate of post-HFS 
response increases in the injured-untreated group tended to be retarded in comparison 
to the control and to injured-treated groups.  Accordingly, analyses were also conducted 
separately for this early period (Period 1 = 0-15 minutes post-HFS), and for P2=16-60 
minutes post-HFS.  While this division is arbitrary, for theoretical reasons it is useful to 
explore indications that injury or drug treatments may preferentially impact activity-
dependent plasticity at early stages.  For example, and as discussed below, molecular 
cascades and structural modifications, initiated by HFS, may be quite labile during the 
early phases of plasticity, and especially susceptible to neuropathological conditions 
during this time.  Analyses targeted at period P1, revealed that the average LTP 
induced in TBI+BEC (untreated) rats was significantly below that of uninjured control 
rats (p<0.05) (see Figure 3.3 panel B).  In contrast, during this same interval (0-15 
minutes post HFS) the level of LTP in TBI+BEC (treated) rats was not different from 
uninjured controls (p=0.183), or from TBI+BEC (untreated) rats (p=0.323).  To the 
extent that a significant effect of injury was only observed in the TBI+BEC (untreated), 
and not in the TBI+BEC (treated), groups, these results are consistent with a 
neuroprotective effect of GM6001 on LTP induction under these injury conditions.   
However, any neuroprotective benefit was limited to this early interval, because no 
statistically significant differences were noted among the groups during 16-60 minutes 
post-HFS (see Figure 3.3 panel B). 
Although application of the low-frequency (1 Hz) stimulation appeared to induce 
some degree of long-term depression (LTD), the mean fEPSP slopes in all groups 
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trended back to the potentiated level during the 20 minutes of LTD monitoring (75-95 
minutes in Figure 3.3 panel A).  Although the TBI+BEC (untreated) group exhibited an 
especially unstable pattern during this interval, statistical analyses did not reveal any 
significant between-group differences of mean fEPSP slopes, induced by the LTD 
procedure.   
Effect of MMP Inhibition on Paired-Pulse Facilitation  
 Studies of LTP have documented the involvement of multiple postsynaptic 
mechanisms including specific kinase activities, translocation and modification of AMPA 
receptors, morphological changes to spines and postsynaptic densities, protein 
synthesis, and gene activation.  Less evidence has accumulated for a presynaptic role 
in LTP induction (e.g., reviewed by Malenka and Bear, 2004), although important 
questions remain in this area. Because N-cadherin participates in the linkage and 
stabilization of presynaptic terminals with postsynaptic structures, it is useful to consider 
if TBI+BEC injury, and GM6001 treatment, alter presynaptic functional plasticity in a 
manner comparable to their effects on LTP.  To approach this issue we also 
implemented the paired-pulse facilitation (PPF) procedure.  While a postsynaptic role in 
this form of short-term plasticity cannot be entirely ruled out, there is a substantial 
consensus that, using low levels of stimulus current as presently implemented, PPF is 
predominantly mediated presynaptically.  Multiple authors have interpreted the 
augmentation of the second response to reflect residual Ca2+ loaded into presynaptic 
terminals during the first response (Lomo, 1971; Creager et al., 1980; Zucker, 1989; 
Leung and Fu, 1994).  
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 In the present study, all groups showed a similar pattern of responses to the 
paired stimulus presentations.  An example set of paired fEPSPs, obtained from a 
control rat, are shown in Fig. 3.4 panel A.  Note the similar amplitude and waveform of 
the first field potential in each pair.  This was expected because 30 seconds were 
allowed to pass between each paired pulse presentation.  This permitted a recovery of 
the ionic status of the presynaptic compartment, presumably including a return of 
intracellular calcium to basal levels.  Note also that the amplitude and waveform of the 
second field potential in each pair were contingent on the interpulse interval, with the 
greatest augmentation of fEPSP2 seen at an interval of 50 msec.  Stimulus currents 
were held constant during this procedure, set individually for each slice to ensure that 
fEPSP1 was stimulated below the threshold for a population spike.  However, it was 
commonly observed that a population spike was visible in fEPSP2, especially at 50 and 
100 msec intervals (see example „p.s.‟ in Fig. 3.4 panel A). 
 At interpulse intervals of 50 msec, fEPSP2 was elevated over fEPSP1 by an 
average of 69.55+7.30%, for all slices tested.  The mean magnitude of PPF, at the 50 
msec interpulse interval, ranged from 81.92+13.82% (injured untreated) to 
59.47+14.52% (injured-treated), with controls showing an intermediate 67.24+9.46%.  
However, these differences did not reach statistical significance.  All groups showed the 
predicted pattern of decreased PPF as interpulse interval was increased to 100, and 
then to 150 msec (Fig. 3.4 panel B).  However, the same lack of statistically significant 
group differences were noted also at these longer intervals, with overall PPF 
magnitudes of 51.69% and 33.16% observed at 100 and 150 msec, respectively.  
Taken together, analysis of the PPF data indicated that neither the TBI+BEC injury nor 
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Figure 3.4 Effects of TBI+BEC injury and GM6001 treatment on PPF.  (A)  
Representative paired-pulse waveforms for interpulse intervals 50, 100, and 150 msec, 
from a sham-injured control rat.  Dotted portion of waves abbreviates period between 
evoked responses.  In the PPF protocol, stimulus current is set below threshold for 
population spikes (first response in each pair).  Characteristically, the second response 
is augmented (steeper descent of fEPSP), and a population spike is often induced at 
interpulse intervals of 50 or 100 msec (p.s. in example).  (B)  Mean paired-pulse ratios 
(fEPSP2 / fEPSP1) for the analytic groups exhibited similar decreases as interpulse 
interval was increased from 50 to 150 msec.  Neither the TBI+BEC injury, nor the 
GM6001 treatment, was associated with a statistically significant effect on PPF 
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 the GM6001 compound significantly altered this form of short-term plasticity (p=0.482).   
Morris Water Maze Testing 
MMP Inhibition and Cognitive Behavioral Outcome  
Cognitive performance of injured-untreated and injured-treated animals was 
assessed at 12-15d postinjury using the Morris Water Maze (Morris et al., 1981) task 
(Fig. 3.5).  Group latencies (measured in seconds) to locate the hidden platform were 
analyzed using ANOVA, which revealed significant differences in main effect of group 
(p<0.001).  Following ANOVA analysis Fisher Least Significant Difference (LSD) tests 
were conducted to determine specific group differences.  Post Hoc analysis using the 
Fisher LSD test indicated significant differences between injured-untreated and sham 
groups, as well as between injured-treated and sham groups (p<0.001).  GM6001 
treatment at 6-7d postinjury failed to produce significant differences in performance 
between the injured-untreated and injured-treated groups (p=.294).  These results 
indicate that the GM6001 dosing used in this study, while altering ADAM-10 and N-
cadherin expression and affecting the induction of LTP, did not significantly improve 
spatial memory deficits associated with maladaptive plasticity.  
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Figure 3.5 Effect of TBI+BEC injury and MMP Inhibition on Cognitive Recovery.  
Spatial learning and memory was assessed using the Morris Water Maze task.  Pre-
trained sham-injured (open circle), injured-vehicle (black square) and injured-treated 
(gray triangle) groups underwent testing on days 12-15 postinjury.  Average latency to 
goal scores (measured in seconds) for each group are presented across postinjury 
testing days.  Injured-vehicle and injured-treated animals displayed significantly longer 
latency to goal times when compared to sham-injured animals at all postinjury day 
intervals, indicating an injury effect.  However, MMP inhibition by GM6001 treatment 
(i.p., 10 mg/kg, 6 and 7d postinjury) did not improve cognitive recovery in the injured-
treated group when compared to sham control. p<0.001. 
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Ultrastructural Analysis 
MMP Inhibition and Hippocampal Synaptic Structure  
Following MWM assessment, a subset of15d postinjury untreated and GM6001 
treated animals were prepared for ultrastructural analysis.  Qualitative observations of 
ultrathin sections from both dentate gyrus molecular layer and CA1 stratum radiatum 
revealed differences in dendritic and synaptic cytoarchitecture between the two groups.  
Injured-untreated animals showed evidence of persistent hippocampal dendritic and 
synaptic pathology (Fig. 3.6).  Their dendrites were of small diameter, irregular in form 
and often containing disrupted cytoskeleton.  Synapses appeared immature, with 
thinned post-synaptic densities and atypically large separation at the synaptic cleft.  In 
contrast, GM6001 treated animals displayed dendritic and synaptic cytoarchitecture 
more consistent with control 15d postinjury cases.  Overall, treated cases appeared to 
have larger diameter dendrites, with intact cytoskeletal networks.  Synaptic profiles 
revealed well-developed junctions, with mature pre-and post-synaptic organization.  
Although qualitative in nature, these observations do suggest that MMP inhibition during 
the initiation of sprouting and synapse formation can foster a shift toward the generation 
of normal synaptic structure in a model of maladaptive synaptic recovery.  While these 
observations do not follow the absence of GM6001 effect on cognitive outcome, they do 
compliment our 15d protein and electrophysiological analyses, which show that the 
MMP inhibitor increases expression of the neuronal adhesion molecule N-cadherin and 
elicits a reversal of field potential deficits during the induction of LTP. 
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Figure 3.6 Effect of TBI+BEC injury and GM6001 Treatment on Dendritic and 
Synaptic Cytoarchitecture at 15d.  Ultrastructural profiles of the dentate molecular 
layer and hippocampal CA1 stratum radiatum following vehicle (A/C) or GM6001 (B/D) 
treatment.  Qualitative assessment of GM6001 cases (B/D) suggest increased dendritic 
integrity, with larger diameters and more intact cytoskeleton.  Synapses appeared more 
frequently and had normal structural organization (see inset arrows) when compared to 
vehicle (A/C). The GM6001 profile is consistent with our 15d observations of increased 
expression of N-cadherin and partial restoration of CA1 LTP following MMP inhibition.  
Bar = 2µm. 
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DISCUSSION 
 The current study examined the effects of MMP inhibition on MT5-MMP, ADAM-
10, and N-cadherin protein expression, synaptic function, synapse cytoarchitecture and 
cognitive recovery in the TBI+BEC model of maladaptive plasticity.   Following injury, 
the broad-spectrum MMP inhibitor GM6001 was administered on days 6 and 7 
postinjury, targeting both the onset of synaptic reorganization and the period of most 
elevated MT5-MMP and ADAM-10 expression. Assessment of drug effect was made by 
comparing injured-treated and injured-vehicle animals at 15d survival, when stabilization 
of regenerated synapses begins.  Our results showed that GM6001 treatment produced 
the following: 1) a reduction in ADAM-10 and increase in N-cadherin hippocampal 
protein expression, generating a profile similar to that found at 15d post-UEC, 2) an 
enhancement of synaptic efficacy, evidenced by effects on the early induction phase of 
LTP, and 3) improved structural reorganization of dendritic and synaptic 
cytoarchitecture.  In the present experimental design, GM6001 MMP inhibition failed to 
produce improvement in cognitive performance.  Collectively, this study provides 
evidence that targeted MMP inhibition promotes a more adaptive environment for 
reactive synaptogenesis, thereby improving postinjury recovery in the maladaptive 
condition.  In following sections, we will discuss how these results support a prominent 
role for membrane bound MMPs and N-cadherin in the enhancement of functional and 
structural synaptic recovery.  
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MMP Inhibition and Protein Expression 
Western blot (WB) analysis at 15d postinjury, the onset of synapse stabilization, 
revealed that MMP inhibition produced differences in hippocampal ADAM-10 and N-
cadherin protein expression.  When injured-treated and injured-vehicle groups were 
compared, drug treatment significantly decreased ADAM-10 protein by 48%, while N-
cadherin was significantly elevated by 38%. This resulted in a pattern of relative 
expression which matched that of the adaptive UEC described in the previous chapter, 
supporting the hypothesis that appropriate balance of MMP/substrate interaction is key 
to the final stabilization of regenerated synapses.  While we have studied the effects of 
other MMP inhibitors (e.g., FN-439) on behavioral and structural outcome in the 
combined model (Falo et al., 2006), this is the first study to show that MMP inhibition 
has a direct effect on the expression of membrane bound MMPs and N-cadherin during 
the stabilization phase of synaptogenesis.  These results are also consistent with prior 
studies in our laboratory which show that manipulation of recovery in the combined 
model alters the expression of MMPs.  For example, postinjury administration of the 
NMDA antagonist MK-801 significantly reduced MMP-2 activity and MMP-3 protein 
expression (Phillips and Reeves, 2001; Falo et al., 2006).    
Our WB results also revealed differential effects of GM6001 on the two 
membrane bound MMPs.  Here, MMP inhibition failed to affect the TIMP-2 bound MT5-
MMP protein expression at 15d post-TBI+BEC.  This result might be explained by the 
fact that a majority of MT5-MMP signal was seen at 80 kDa, consistent with TIMP-
2/MT5-MMP binding at the catalytic site, likely in the context of proMMP-2 activation.  
This arrangement would then act to hinder GM6001 binding and inhibition.  While MT5-
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MMP protein expression remained unchanged at 15d, our current  interpretation of 
MT5-MMP response is supported by prior findings showing  shifts in hippocampal MMP-
2 protein after TBI+BEC, similar to our observed MT5-MMP changes (Phillips and 
Reeves, 2001).  Based on the concomitant elevation MT5-MMP and MMP-2 at 2-7d 
postinjury, targeting earlier time points for MMP inhibition of MMP-2 would be warranted 
to provide further evidence for this proposed relationship, as well as further delineate 
specific MMP role in postinjury recovery.  Taken together, these data support our 
proposed role for MT5-MMP as an activator of proMMP-2 during the earlier phases of 
injury-induced synaptogenesis.    Our WB results show that MMP inhibition can 
significantly affect protein expression following injury in a TBI model of maladaptive 
plasticity, and promote a molecular environment similar to that found with adaptive 
plasticity.   
One important consideration for interpretation of our results would be how 
inhibition of MMP activity leads to changes in protein expression following injury.  
Postinjury MMP inhibition may influence protein expression by reducing the capacity for 
MMPs to modify ECM and cell to cell connections.  Such modification would affect the 
initiation of a number of signaling pathways which regulate cell survival and death, often 
through altering gene transcription and protein translation.  In the context of this study, 
persistent ADAM-10 lysis of synaptic N-cadherin between 7-15d postinjury may be 
linked to anoikis, or cell death by loss of cell anchorage (Grossman, 2002).  Inhibition of 
this ADAM-10 activity would reduce cleavage of synaptic N-cadherin, maintain synaptic 
contact, attenuate loss of anchorage, and potentially allow for a more stable 
transcriptional regulation of ADAM-10 and N-cadherin expression in surviving cells. 
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Inhibition of MMPs has also been shown to decrease downstream neuronal 
degeneration and improve recovery in other neurotrauma models, potentially by limiting 
excessive loss of cell anchorage and preventing anoikis (Ashi et al., 2000; Wang and 
Tsirka, 2005; Zhao et al., 2006; Sifringer et al., 2007).  Additionally, injury-induced 
alteration of ECM and cell to cell connections can provide feed forward signals that 
influence downstream pathways within the cell and lead to MMP upregulation (Conant 
and Gottschall, 2005).  For example, post-ischemic alterations of hippocampal ECM-cell 
contacts have been shown to trigger intracellular signaling by protein focal adhesion 
kinase, pp125FAK, which leads to upregulation of MMP-2 and -9 (Zalewska et al, 2003).  
Potentially, increased MMP expression may lead to continued alteration in ECM/cell 
interaction, activation of these signaling pathways, and further MMP upregulation.  In 
the context of our Chapter 2 results, this endogenous feedback mechanism may have 
mediated the injury-induced increases in active ADAM-10 expression that were 
observed over the postinjury time course.  Therefore, postinjury inhibition of MMP 
activity may further decrease ECM/cell alterations, thereby limiting the effects of 
downstream signaling through such pathways.  This may explain our observations that 
GM6001 decreased ADAM-10 protein expression at 15d postinjury.  Finally, MMP 
inhibition may influence N-cadherin expression through β-catenin, which can indirectly 
decrease N-cadherin protein upon its release from the cadherin/catenin complex and 
subsequent nuclear translocation to act as a transcription factor (McCusker, 2009).  Our 
results suggest that MMP inhibition may help to maintain β-catenin submembrane 
binding in the cadherin/catenin complex, therefore limiting its release to affect a down 
regulation of N-cadherin.  The result would be enhanced synapse stabilization.  While 
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MMP inhibitors are designed to limit protease activity, our results provide further 
evidence they can also influence the process of injury-induced synaptogenesis through 
downstream regulation of the expression of plasticity-associated proteins, and therefore 
improve recovery.  
MMP Inhibition and Synaptic Functional Recovery 
In order to examine the effect of MMP inhibition on recovery of synaptic function 
we conducted a series of in vitro electrophysiological experiments including assessment 
of LTP, LTD and PPF.  We chose to record the synaptic response in CA1 stratum 
radiatum following Schaffer Collateral fiber stimulation.  This choice was made for two 
reasons: 1) the absence of a homotypic perforant path projection in the combined 
animals subjected to BEC insult and 2) the presence of synaptic reorganization in CA1 
dendrites following cFPI alone.  Results from these experiments showed an injury effect 
on the capacity for LTP during the first 15 minutes (P1) following conditioning stimulus.  
These experiments were the first in vitro assessment of LTP, LTD and PPF in the 
TBI+BEC model and were consistent with our prior in vivo studies showing persistent 
deficits in the capacity to elicit LTP up to 15d postinjury (Reeves et al., 1997).  A key 
finding in the present electrophysiological assessments was that the GM6001 treatment 
partially restored the injury-induced LTP deficit noted in the first 15 minutes post-
conditioning.  This suggests that dampening of MMP activity during the 6-7d period of 
sprouting and synapse formation can improve synaptic function in the context of 
maladaptive plasticity.  While this was the first investigation to examine the effects of 
MMP inhibition on TBI+BEC synaptic efficacy, the consequences of postinjury MMP 
inhibition on synaptic function have been examined in the UEC model of adaptive 
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plasticity.  In that study, the MMP inhibitor FN-439 was applied at 30 min after lesion 
and outcome assessed at 7d postinjury (Reeves et al., 2003).  Results showed a 
reduced capacity to elicit LTP and aberrant spatial reorganization of synapses along 
deafferented dendrites when compared to vehicle controls.  In contrast to MMP 
inhibition at 7d, the latter study suggests that acute inhibition of MMPs during the 
degenerative phase of synaptogenesis can reduce functional recovery, even within an 
adaptive environment.  Similarly, non-injured (naïve) hippocampal slices treated with 
FN-439 failed to produce LTP induction and maintenance, further suggesting that 
inhibition of MMPs under normal conditions is also detrimental (Meighan et al., 2007). 
Thus, our collective data support a key role for MMPs in shaping the environment 
around reorganizing synapses to foster their growth, as well as support stabilization for 
synaptic efficacy in the new circuits generated.  The findings also clarify the requirement 
for increased MMP activity during the more acute postinjury periods and the subsequent 
attenuation of this activity as synapses mature and regain their functional status.  
In addition to LTP, we also investigated the effect of GM6001 treatment on LTD 
and PPF.  Despite observing significant changes in LTP, we found no group differences 
in LTD and PPF measurements.  Interestingly, PPF abnormalities have been observed 
within the central (Reeves et al., 2000) and lateral (Cao et al., 2006) fluid percussion 
(cFPI, lFPI), persisting for up to seven to nine days postinjury, respectively.  Such model 
differences show that pathophysiological processes influencing pre-synaptic plasticity 
are altered when cFPI is combined with targeted deafferentation in the TBI+BEC model.  
This result provides further support for our hypothesis that neuroexcitation insult and 
deafferentation are interactive in the context of maladaptive synaptic reorganization.  
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Collectively, these electrophysiological data suggest that postsynaptic vulnerability may 
be a preferential contributor to deficits in synaptic efficacy following TBI+BEC.  Further, 
by documenting that these deficits can be attenuated with MMP inhibition, we provide 
support for the hypothesis that MMPs and their synaptic substrates participate in the 
recovery of functional synapses following TBI.  
 The current LTP findings with GM6001 treatment point to several possible 
mechanisms by which MMPs might affect functional recovery during reactive 
synaptogenesis.  One such LTP-associated synaptic mechanism may involve the 
adhesive and stabilization roles of N-cadherin.  N-cadherin functions extracellularly to 
bind pre- and post-synaptic elements and establishing intracellular connections to 
stabilize the synapse and permit efficient function (Takeichi and Abe, 2005).  Pre- and 
post-synaptic adhesion is essential for synaptic growth, maturation and resistance to 
disassembly (Bozdogi et al., 2004).  Based on these roles, N-cadherin is linked to 
synapse potentiation and plasticity during early and late LTP (E-LTP, L-LTP), where in 
vitro blocking N-cadherin results in the failure to produce LTP induction and/or 
maintenance (Tang et al., 1998; Bozdogi et al., 2000).  The current study shows that 
MMP inhibition mediates increased N-cadherin expression and attenuates E-LTP 
induction deficits at 15d after TBI+BEC insult.  All LTP monitoring conducted in this 
study, and certainly the P1 period, would fall within the E-LTP phase which may last for 
~1 to 3 h (Blitzer et al., 2005).  Recall that, following GM6001 treatment 15d N-cadherin 
protein expression in TBI+BEC is very similar to what was seen at that time interval 
after UEC, a period which represents the onset of the synaptic stabilization.  Similar 
levels of N-cadherin protein in these two groups suggests the potential for similar 
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maturation and stabilization of hippocampal synapses.  Therefore, N-cadherin may 
directly influence the successful synapse stabilization or synaptic efficacy during E-LTP.   
An additional N-cadherin associated mechanism that may be enhanced by MMP 
inhibition involves modification of the post-synaptic density (PSD) during E-LTP.  E-LTP 
does not require new protein synthesis, but rather, relies on modification and re-
organization of existing synapses using available stored proteins (Malenka and Bear, 
2004; Issac et al., 1995; Liao et al., 1995).  Modifications made to existing synapses 
include the trafficking and placement of additional AMPA receptors into the PSD, which 
is regulated by N-cadherin in cultured neurons, therefore indicating a link between 
structural and functional plasticity (Bredt and Nicoll, 2003; Malenka and Nicoll, 1999; 
Nuriya and Huganir, 2006).  Based on current literature, the interaction between AMPA 
receptors and N-cadherin appears to enhance synaptic efficacy as measured by LTP.  
Our finding of functional improvement, associated with increased hippocampal N-
cadherin following GM6001 treatment, would be consistent with prior reports of an N-
cadherin role in receptor and PSD stabilization.  A preservation of N-cadherin function, 
after GM6001 treatment, conceivably permitted enhanced synaptic transmission and 
LTP-associated plasticity in our maladaptive model.       
In addition to its role in post-synaptic density organization and function, N-
cadherin affects synaptic Ca2+ conductance through other binding partners at the 
synapse.  In the previous chapter, we provided evidence that MMP lysis of the N-
cadherin extracellular domain mediates the cleavage and release of an intracellular 
~35-40 kDa cytoplasmic tail fragment-1 (CTF1).  This 40 kDa N-cadherin fragment was 
detected in both the UEC and TBI+BEC models.  Although we did not find significant 
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change in this fragment with GM6001 treatment, it is important to consider its possible 
influence on Ca2+ conductance on synaptic function.  The intracellular release of CTF1 
can indirectly affect Ca2+ conductance by interacting with one of its binding partners, 
p120 catenin, which subsequently releases and activates RhoA.  Through interaction 
with myosin-actin cytoskeleton, soluble, active RhoA ultimately decreases synaptic Ca2+ 
influx through action on voltage activated Ca2+ channels (VACC) (Marrs et al., 2009).  
Therefore, extensive lysis of N-cadherin by a persistently activated ADAM-10 can serve 
as an upstream mediator of RhoA signaling, leading to decreased Ca2+ conductance 
and attenuated synaptic efficacy.  Our LTP results suggest that MMP inhibition may limit 
N-cadherin cleavage, thereby preventing RhoA driven decrease in synaptic Ca2+ influx, 
and decreasing the injury-induced deficits seen during P1 of our LTP trials.  Although 
the exact mechanism(s) are yet to be established, the relationship between N-cadherin 
and synaptic function is well established and further supported by our present molecular 
and electrophysiological data.   
MMP Inhibition and Cognitive Recovery  
One of the principal concerns following TBI is the presence of persistent 
cognitive impairment.  To study the effect of MMP inhibition on cognitive recovery 
following injury, we used the Morris Water Maze (MWM) task, which is a reliable and 
sensitive measurement of cognitive function following TBI (Hamm, 2001).  In these 
experiments, we did find a significant injury effect on MWM performance during 12-15d 
postinjury trials.  Impaired latency to find the goal platform in the injured-vehicle group 
was consistent with our published studies (Phillips et al., 1994; Phillips and Reeves, 
2001; Falo et al., 2006).  However, using the present GM6001 treatment paradigm we 
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were unable to detect a drug effect on MWM performance.  These results are in 
contrast to a prior TBI+BEC study where the MMP inhibitor FN-439 showed improved 
spatial learning over a five day trial period, utilizing both acute (1-2d) and delayed (6-7d) 
treatment paradigms (Falo et al., 2006).  It is interesting that both studies applied MMP 
inhibitor at 6-7d postinjury, but only FN-439 showed attenuation of cognitive deficits.  
Both GM6001 and FN-439 inhibit MMPs through a common mechanism of binding 
divalent ions critical to engaging the active site of the enzyme. They do, however, 
exhibit specificity for different MMP family members. The FN-439 compound targets 
collagenase, gelatinase and stromelysin, while GM6001 more broadly inhibits a wide 
range of MMPs, inclusive of the MT-MMP family group.  This difference in specificity 
may account for the presence or absence of behavioral effects in the MWM test, which 
would suggest that more specific targeting of MMPs is a better approach than using a 
general profile inhibitor.  Unfortunately, no such inhibitor targeting membrane bound 
MMPs has been developed to test this possibility.   
Despite the challenges of inhibitor specificity, we did find a positive relationship 
between GM6001 treatment and the modest reversal of injury-induced deficits within the 
inductive phase of LTP.  Since LTP may serve as a cellular model for learning and 
memory, and the MWM task tests functional aspects of memory, the emergence of a 
reversal in LTP deficit with MMP inhibition supports the interaction between MMP 
function and behavioral recovery.  The failure to detect attenuation of MWM deficits in 
our experimental paradigm may indicate that a more careful dose/delivery study is 
needed.  For example, shifting to intra ventricular rather than intra peritoneal would 
likely improve delivery and facilitate any drug effect on CNS structures.  It is also 
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important to recognize that while the hippocampus is an essential structure for the 
processing of learning and memory, MWM tested behavior involves the coordination of 
multiple nervous system circuits.   
MMP Inhibition and Synapto-Dendritic Reorganization 
Finally, we examined the effect of MMP inhibition on synaptic ultrastructure in the 
stratum radiatum of the hippocampal CA1 field and the dentate molecular layer at 15d 
postinjury.  Sampling from each area allowed us to compare dendritic and synaptic 
cytoarchitecture in the region subjected to electrophysiological recording, as well as the 
principal deafferented zone undergoing reactive synaptogenesis.  In the injured-vehicle 
animals we found abnormalities in synaptic structure that were consistent with 
maladaptive plasticity as previously described for the TBI+BEC model (Phillips et al., 
1994; Falo et al., 2006).  For example, injured-vehicle animals exhibited damaged 
dendrites, as well as atrophied and disorganized synaptic profiles in both the stratum 
radiatum and outer molecular layer when compared to control tissue.  These 
observations are consistent with our prior TBI+BEC studies showing persistent axo-
dendritic pathology and abnormal synaptic reorganization at 15d postinjury (Phillips et 
al., 1994; Gordon et al., 1996; Phillips and Reeves, 2001; Falo et al., 2006).  By 
contrast, injured-treated animals exhibited robust reorganization of synaptic structure, 
with larger, well organized supportive dendrites.  Post synaptic densities were larger 
and more complex in structure, often abutting axon terminals with well-organized pre-
synaptic vesicles at the membrane surface.  Although we did not use quantitative 
methods for analysis, we did observe that synapses appeared to be more abundant 
following MMP inhibition.  Similar cytoarchitectural changes in synapse structure have 
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been reported following TBI+BEC treatment with the MMP inhibitor FN-439 (Falo et al., 
2006).   
The synapto-dendritic reorganization described here provides a structural 
correlate to the positive effects of MMP inhibition on synaptic function and support 
MMPs as mediators of improved outcome under conditions of maladaptive plasticity.  
Our collective results suggest that such inhibition stabilized synaptic structure which 
contributes to improved induction of LTP and synaptic efficacy after TBI+BEC.  Again, 
these structural improvements can be directly linked to the functional properties of N-
cadherin at the synaptic interface.  N-cadherin mediates specific post-synaptic density 
organization and synaptic stabilization through AMPA receptor placement and actin 
cytoskeleton anchorage, respectively, each of which support the capacity for LTP 
(Nuriya and Huganir, 2006; Togashi et al., 2002; Lilien et al., 1999).  Quantitative EM 
analysis of CA1 dendrites in hippocampal slices transfected with mutated N-cadherin 
constructs also revealed significantly smaller dendritic spines and post-synaptic 
densities and reduced spine stability, further illustrating N-cadherin‟s role in synaptic 
structural organization (Mendez et al., 2010).  Our results support a role for N-cadherin 
in structural synaptic recovery.  They tie together elevated MMP activity, N-cadherin 
lytic fragment production and intracellular signaling to alter synapse structure during 
maladaptive plasticity.  Importantly, MMP inhibition at the onset of this process appears 
to facilitate structural recovery by generating a more adaptive environment for 
synaptogenesis. 
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SUMMARY 
We have shown that MMP inhibition at 6 and 7d postinjury significantly alters the 
expression of hippocampal ADAM-10 and N-cadherin protein at 15d survival in the 
TBI+BEC model of maladaptive plasticity.  This inhibition shifted the expression of 
ADAM-10 and N-cadherin to the pattern seen during adaptive plasticity.  Targeted MMP 
inhibition also reversed deficits in LTP induction and stabilized synapto-dendritic 
integrity.  However, the same treatment paradigm had no effect on cognitive 
performance.  While these results suggest that MMP inhibition during reactive 
synaptogenesis promotes structural and functional recovery, there are important 
limitations to be considered.  Foremost, GM6001 is a broad-spectrum MMP inhibitor, 
affecting multiple soluble and membrane-bound MMPs.  Although we were able to show 
that ADAM-10 expression was altered by GM6001 treatment, we did not provide 
evidence that its enzyme activity was blocked by the compound.  Moreover, the effects 
observed could be due to inhibition of other MMPs as well.  Therefore, for future studies 
it will be important to specifically target ADAM-10 or MMPs activated by MT5-MMP 
(e.g.-MMP2) in order to directly link these enzymes to adaptive synaptic recovery.  
Further investigation is also needed to better define the molecular mechanisms that 
regulate MT-MMP expression and activity, as well as identify the downstream effects of 
their proteolytic products on the process of reactive synaptogenesis.      
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DISCUSSION 
Summary of Results 
Chapters 2 and 3 presented the protein and mRNA profiles of membrane-type 
MMPs, MT5-MMP and ADAM-10, along with a shared substrate N-cadherin, within adult 
rat hippocampus following TBI.  Expression profiles were compared in two models of 
TBI, one exhibiting adaptive synaptic plasticity (UEC) and the other maladaptive 
synaptic plasticity (TBI+BEC).  We also presented the effects of MMP inhibition on 
molecular, electrophysiological, behavioral and structural outcome at 15d following 
TBI+BEC.  MMP inhibition targeted elevated MT5-MMP and ADAM-10 expression 
during the axonal sprouting and synapse formation period of synaptogenesis.  
Collectively, our results provide evidence that membrane-bound MMPs and their 
constitutive substrates (e.g.-N-cadherin, pro-MMP-2) are influence both adaptive and 
maladaptive plasticity in a time and injury-dependent manner.  Inhibition of membrane-
bound MMPs during maladaptive plasticity leads to change in their protein expression 
and improved outcome with respect to synaptic efficacy and structure.  Therefore, 
targeted MMP inhibition has the potential to translate maladaptive plasticity into a more 
adaptive process, facilitating an improved recovery. 
  In Chapter 2, MT5-MMP, ADAM-10 and N-cadherin expression was shown to 
differ between adaptive and maladaptive models of TBI as a function of postinjury 
survival, suggesting that their role(s) in the process are temporally regulated.    
Comparison of model profiles shows that MT5-MMP plays a more acute role during the 
degenerative and regenerative phases (2 and 7d) of injury-induced synaptogenesis, 
potentially through interaction with TIMP-2 and activation of proMMP-2.  Our results 
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suggest that ADAM-10 is the preferred protease targeting N-cadherin during the phase 
of synapse reorganization and stabilization (7 and 15d) postinjury.  Protein analysis at 
15d after TBI+BEC specifically showed a temporal correlation between a persistent 
increase of ADAM-10 and decreased N-cadherin expression, contrasting with the 
opposite pattern of expression in adaptive UEC plasticity.  Changes in hippocampal 
protein expression in both models were consistent with the pattern seen using 
immunohistochemistry, where signal increase was greater over the deafferented 
dentate molecular layer (ML), principally within reactive astrocytes.  These results 
suggest a role for reactive astrocytes in the synthesis and/or processing of MT5-MMP, 
ADAM-10 and N-cadherin following injury.  Synthesis of MT5-MMP by reactive 
astrocytes is further supported by our preliminary 7d in situ hybridization results, 
showing MT5-MMP mRNA signal within reactive astrocytes of both adaptive and 
maladaptive models.  Finally, microarray results suggested the greatest change in 
ADAM-10 transcript post-UEC and TBI+BEC, matching our maximally elevated WB 
ADAM-10 protein expression between 7-15d postinjury.  Preliminary quantitative RT-
PCR (qRT-PCR) analysis on the same 7d ML samples revealed elevated ADAM-10 
mRNA in both models and decreased N-cadherin transcript post-TBI+BEC. These 7d 
changes in ML mRNA track with ADAM-10 and N-cadherin protein expression during 
maladaptive plasticity.  Taken together, MT5-MMP, ADAM-10 and N-cadherin protein 
and mRNA profiles revealed time and recovery-dependent changes which were 
correlated with extent of recovery.  Such results led us to investigate the effect of MMP 
inhibition on not only protein expression, but also synaptic structure and function post-
TBI+BEC.    
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  The results presented in Chapter 3 demonstrated that the significant effect of 
MMP inhibition on ADAM-10 and N-cadherin protein expression likely influenced 
improvements in synaptic structure and function at 15d post-TBI+BEC.  MMP inhibition 
by GM6001 at 6 and 7d after TBI+BEC targeted the period with greatest elevation of 
MT5-MMP and ADAM-10 protein, as well as the onset of axonal sprouting and synaptic 
reorganization.  Our results showed that MMP inhibition had no effect on 15d 
hippocampal MT5-MMP expression, but significantly decreased ADAM-10 and 
increased N-cadherin expression, thereby shifting their profiles to those observed at 15d 
post-UEC.  Changes in ADAM-10 and N-cadherin expression were accompanied by 
improvement in the capacity to induce hippocampal long-term potentiation (LTP), but 
failed to correlate with improved spatial learning and memory performance by injured-
treated animals.  Further, MMP inhibition improved dendritic and synaptic structure 
within the hippocampus and dentate gyrus at 15d post-TBI+BEC.  Given the importance 
of N-cadherin to synapse stabilization, these improvements in synaptic function and 
structure could be influenced by a shift to increased N-cadherin expression following 
MMP inhibition.  Collectively, the novel results presented in Chapters 2 and 3 are 
supported by the current literature and indicate roles for membrane-bound MMPs like 
MT5-MMP and ADAM-10, as well as N-cadherin in synaptic plasticity and recovery 
following TBI.       
Roles of Membrane-Bound MMPs in Synaptogenesis 
 Due to their transmembrane position, membrane-bound MMPs serve a unique 
role in neuroplasticity by interacting with both cellular and extracellular substrates, often 
at very focused sites along the cell surface.  Our results show that membrane-bound 
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MMPs, MT5-MMP and ADAM-10: 1) are expressed at high levels within the 
hippocampus under injury conditions that induce synaptogenesis, 2) are normalized in 
expression by 15d during adaptive synaptogenesis, 3) exhibit a time course of 
expression which is consistent with MMPs secreted during adaptive and maladaptive 
plasticity, 4) are highly localized to reactive astrocytes, not microglia, following injury, 
and 5) may influence postinjury recovery through individual interaction with TIMP-
2/proMMP-2 and N-cadherin, respectively.  The results presented in Chapters 2 and 3 
are further supported by current literature that shows that MT5-MMP and ADAM-10 are 
highly expressed and active during development and disease processes that involve 
plasticity.   
Our study investigated postinjury tissue expression and localization of MT5-MMP 
and ADAM-10 in the hippocampus, a structure known for its ability to exhibit properties 
of neuroplasticity.  We showed a protein and mRNA expression of membrane-bound 
MMPs which is consistent with reported expression during CNS development.  In the 
developing brain, hippocampal MT5-MMP and ADAM-10 are found primarily in neuronal 
axonal growth cones and/or dendritic spines, with some evidence of ADAM-10 glial 
localization.  Based on these patterns, MT5-MMP and ADAM-10 are thought to facilitate 
the outgrowth of neurites and the formation of synapses (Hayashita-Kinoh et. al, 2001; 
Sekine-Aizawa et. al, 2001; Bernstein et al., 2003; Marcinkiewicz and Seidah, 2000).  
Specifically, in vitro developmental studies have shown that MT5-MMP and ADAM-10 
are involved in neurite outgrowth through proteoglycan cleavage and axonal guidance 
through interaction with ephrin, respectively (Hayashita-Kinoh et al., 2001; Hattori et al., 
2000).  ADAM-10 is highly involved in Notch signaling which influences neurogenesis, 
194 
 
axonal and dendritic growth, synaptic plasticity, and neuronal death during both nervous 
system development and disease (Lathia et al., 2008).  Additionally, MT5-MMP has 
been shown to facilitate the re-organization of Aβ fibers within the spinal cord following 
in vivo sciatic nerve injury (Komori et al., 2004).  Together, these studies and our 
current results show that membrane-bound MT5-MMP and ADAM-10 are critical to 
success of the plasticity process in both developing and adult nervous systems.    
Elevation of hippocampal MT5-MMP and ADAM-10 expression during reactive 
synaptogenesis does show some similarity to that of their secreted counterparts 
following TBI.  For example, protein analysis revealed an acute upregulation of MT5-
MMP and ADAM-10 at 2 and 7d post-UEC and TBI+BEC.  MT5-MMP mRNA was 
moderately elevated at 7d for each model.  These results indicate that MT5-MMP and 
ADAM-10 are temporally correlated with the degradation and regeneration of synapses 
during both adaptive and maladaptive plasticity.  However, it is important to note that 
during adaptive recovery, MT5-MMP and ADAM-10 return to control levels by 15d.  This 
shift in expression indicates that as adaptive plasticity proceeds into the synapse 
stabilization phase, high levels of membrane-bound MMPs are not required, perhaps 
due to a reduced need for local ECM and cell-cell modification.  In previous studies we 
have shown similar 2-7d increases of MMP-2, -3, and -9 protein and mRNA for both 
models, however, these secreted MMPs were normalized to control expression by 15d 
(Phillips and Reeves, 2001; Kim et al., 2005; Falo et al., 2006).  We also observed 
persistent elevation of ADAM-10 protein up to 15d post-TBI+BEC.  Prior studies also 
show a persistent elevation of MMPs 2, 3 and 9 after TBI+BEC insult, but for this 
secreted MMP it occurs at 7d, not 15d (Falo et al., 2006).  We have also shown 2 and 
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7d increases in MMP-2 and -9, and elevations in both MMP-2 mRNA and activity 7d 
following TBI+BEC (Phillips and Reeves, 2001).  Other investigators have also shown 
elevation of secreted MMPs during plasticity in models of neurotrauma, including 
controlled cortical impact, lateral fluid percussion injury, olfactory bulb lesion, and 
cerebral ischemia (Wang et al., 2000; Truettner et al., 2005; Costanzo et al., 2006; 
Costanzo and Perrino, 2008; Romanic et al., 1998; Fujimoto et al., 2008).  The fact that 
secreted and membrane-bound MMPs show similar expression patterns suggests that 
they each have important roles in postinjury recovery.  However, the precise role(s) may 
be further dictated by their cellular localization and distribution.   
Our current study showed pronounced upregulation of membrane-bound MT5-
MMP and ADAM-10 in reactive astrocytes, not microglia.  Astrocytic localization of 
secreted MMPs (i.e.-MMP3) has been shown in our previous studies as well (Kim et al., 
2005; Falo et al., 2006).  While soluble MMPs are released from astrocytes over a more 
diffuse area within the ECM, our current results suggest that membrane-bound MT5-
MMP and ADAM-10 are primarily found within the membranes of ML reactive 
astrocytes.  Localization and up regulation of MMP mRNA and protein within astrocytes 
are supported by several published in vitro and in vivo studies.  For example, 
lipopolysaccaride (LPS) stimulated cultured astrocytes produce active MMP-2 and 
proMMP-9 protein (Gottschall and Yu, 1995; Rosenberg et al., 2001). LPS stimulated 
cultured astrocytes also express varying levels of mRNA for MMP-2, -3, -9, -10, -11, -
12, -13 and MT1-MMP (Wells et al., 1996).  Other studies show that, following in vivo 
spinal cord injury peri-lesion reactive astrocytes express MMP-1 (Buss et al., 2007).  
MMP-2, -3 and -9 display a temporal upregulation in reactive astrocytes following 
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middle cerebral artery occlusion (MCAO) in rats (Rosenberg et al., 2001).  Additionally, 
ADAM-10 was found to be constitutively expressed in reactive astrocytes in multiple 
sclerosis patients (Kieseier et al., 2003).  While our immunohistochemical results 
identified reactive astrocytes as sites of MT5-MMP and ADAM-10 localization, they 
failed to show MT5-MMP and ADAM-10 co-localization with microglial markers (CD-11, 
IBa-1), which is consistent with other CNS inflammation and injury studies (Toft-Hansen 
et al., 2007; Kieseier et al., 2003).  Therefore, our results suggest that reactive 
astrocytes likely function as the primary sites for synthesis and recycling of MT5-MMP 
and ADAM-10, thus directly affecting the organization of the ECM during injury-induced 
synaptic plasticity.   
Finally, the present study suggests that, of the two membrane-bound MMPs 
examined, N-cadherin may be preferentially targeted by ADAM-10 during the later 
stages of reactive synaptogenesis.   In vitro studies indicate that N-cadherin can be 
processed by either MT5-MMP or ADAM-10 (Monea et al., 2005; Reiss et al., 2006).  
However, our in vivo results reveal temporal correlates between the levels of ADAM-10 
and N-cadherin which suggest that their specific interaction during the phase of synapse 
stabilization is critical to synaptic recovery after TBI.  Conversely, we found evidence for 
the principal expression of MT5-MMP as a TIMP-2 bound form following injury, opening 
the possibility that it may play a different role in the synaptogenic process.  Specifically,  
TIMP-2 bound MT5-MMP may function to activate proMMP-2 (Sternlicht and Werb, 
2001; Nagase et al., 2006), supporting synapse organization at local sites along the 
dendritic membrane.  The reduction of its expression during the later stages of adaptive 
synaptogenesis points to a lesser role for MT5-MMP in N-cadherin processing during 
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synapse stabilization. Thus, the current study provides evidence that distinct 
enzyme/substrate relationships may exist for membrane-bound MMPs during the 
course of reactive synaptogenesis. 
Understanding Maladaptive Synaptic Plasticity   
 How do our current findings add to what is already known about maladaptive 
plasticity following TBI?  While previous studies have examined secreted MMPs in the 
UEC and TBI+BEC models, this is the first study to show that maladaptive plasticity may 
be influenced by membrane-bound MMP/substrate interaction, specifically during 
periods of synapse stabilization and maturation.  ADAM-10, rather than MT5-MMP, 
emerged as the prominent player in the maladaptive response, persistently elevated up 
to 15d.  Despite different responses at 15d, MT5-MMP and ADAM-10 were both 
similarly elevated at the acute postinjury intervals, much like the secreted MMPs MMP 
2, 3 and 9.  This common elevation of expression suggests that both secreted and 
membrane-bound MMPs contribute to different phases of reactive synaptogenesis.  We 
posit that increased ADAM-10 expression and activity at 15d post-TBI+BEC prevents N-
cadherin-dependent stabilization and organization of nascent synapses, resulting in a 
maladaptive form of synaptic plasticity. This is supported by our EM analysis in Chapter 
3, which shows reversal of synaptic pathology after MMP inhibition.  N-cadherin is also 
directly linked to both post-synaptic density (PSD) organization and synaptic adhesion, 
therefore proteolysis of N-cadherin would disrupt PSD structure, commonly seen in 
synapse pathology (Malenka and Nicoll, 1999; Takeichi and Abe, 2006; Nuriya and 
Huganir, 2006).   The role of ADAM-10/N-cadherin in the generation of maladaptive 
plasticity is also supported by our observation that deficits in LTP induction can be 
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attenuated when MMPs are inhibited, particularly given that attenuation is temporally 
correlated increased in N-cadherin expression.  These improvements in synaptic 
structure and function are consistent with earlier studies which showed that synapse 
reorganization develops concurrently with the re-emergence of LTP following UEC 
lesion (Reeves and Steward, 1986).  Based on these observations, we conclude that 
maladaptive plasticity is generated, in part, by ADAM-10 and N-cadherin synaptic 
interaction, and that MMP inhibition has potential to prevent these impairments. 
Potential benefits of MMP inhibition on Recovery 
        Results presented in Chapter 3 suggest the potential application of MMP inhibition 
as a treatment to improve maladaptive plasticity.  Our results provide evidence that 
broad-spectrum MMP inhibition (GM6001) can alter expression of membrane-bound 
MMPs like ADAM-10, affecting the tissue level of its synapse-related substrate N-
cadherin.  Inhibition of enzyme activity may also reduce expression of MMP genes 
through a feedback mechanism which limits proteolysis of ECM-cell and cell-cell 
contacts, stimulating intracellular signaling pathways which alter downstream 
transcription and protein expression (Conant and Gottschall, 2005).  In the TBI+BEC 
model this would offer the benefit of returning MMP protein levels to those more in line 
with adaptive recovery. We also report that deficits in the early induction phase of LTP 
were attenuated with GM6001 treatment.  Other studies also show that MMP inhibition 
can affect hippocampal LTP following injury.  MMP inhibition by FN-439 at 30 min 
postinjury suppressed the emergence of LTP when compared to controls, suggesting 
that inhibition of MMPs at an inappropriate postinjury period can be detrimental, even 
within an adaptive environment (Phillips and Reeves, 2001).  A similar negative effect of 
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FN-439 on LTP was found using normal hippocampal slices, where both induction and 
maintenance were impaired (Meighan et al., 2007).  Taken together with our data, these 
results suggest that the role of MMPs in synaptic activity is complex, and that the 
application of MMP inhibitors must be considered in the context of both time postinjury 
and tissue condition.  The benefits of MMP inhibition during maladaptive plasticity were 
further strengthened by the observation that GM6001treatment improved dendritic and 
synaptic cytoarchitecture within the hippocampus.  However, we were unable to show 
that MMP inhibition translated into improvements in cognitive performance in the MWM.  
This result emphasizes the importance of optimizing dose and delivery in order to 
confirm whether or not the physiological and structural improvements are translatable 
into behavioral protection.  The inclusion of MMP inhibition in future studies will be 
discussed below.  Our results have shown the beneficial effects of MMP inhibition on 
the expression of and potential interaction between ADAM-10 and N-cadherin, and 
synaptic structure and function.  In addition to altering membrane-bound MMP/substrate 
expression and interaction, TBI and MMP inhibition can modify the downstream 
extracellular and intracellular signaling pathways involved in synaptic plasticity. 
 Signaling Pathways and Plasticity 
 Interaction between MMPs and their substrates is known to influence 
downstream signaling pathways to regulate neuroplasticity.  Our study suggests that 
ADAM-10 and N-cadherin interact at the synaptic membrane, and that TIMP-2 bound 
MT5-MMP may potentially function as an activator of proMMP-2 at the same location.  
In the case of membrane-bound MMPs, interaction with substrates occurs at the cell 
membrane, often involving the cleavage and release of an extracellular molecular 
200 
 
fragment of their substrate.  MMPs which perform this lysis are termed sheddases.  This 
cleavage generates intracellular fragments as well, peptides that can influence 
downstream signaling to affect plasticity following TBI.  These pathways are well 
characterized in vitro. They can involve the shedding of an N-terminal N-cadherin 
fragment (NTF) by ADAM-10, which leads to γ-secretase cleavage and release of the 
intracellular 40  kDa C-terminus fragment (CFT1) (Reiss et al., 2005; Uemura et al., 
2006; Kohutek et al., 2009).  CTF1 can also undergo further calpain proteolysis into a 
35  kDa fragment (CTF2) (Jang et al., 2009).  Each of these fragments has been shown 
to be involved with downstream regulation of neuroplasticity.  For example, ADAM-
10/MMP-mediated cleavage and release of NTF promotes neurite outgrowth in cultured 
cells (Paradies and Grunwald, 1993; Utton et al., 2001).  Based on our results, the 
production of NTF by ADAM-10 sheddase activity may permit modulation at the 
synapse and promote collateral sprouting of spared axons into the damaged region 
during injury-induced synaptogenesis.  In addition to NTF, release of other intracellular 
N-cadherin fragments has been implicated in synaptic function and plasticity. 
Recall that, in Chapter 2, we demonstrated the presence of an N-cadherin 40 
kDa intracellular protein fragment in both adaptive and maladaptive models.  While a 
significant decrease in the 40 kDa fragment was observed only at 2d post-UEC, the 
presence of this fragment indicates that intracellular N-cadherin lysis occurred in both 
adaptive and maladaptive models.  This 40 kDa fragment likely represents CTF1, 
generated through NTF production by ADAM-10.  Increased CTF1 may mediate several 
downstream pathways invoked by injury-induced synaptogenesis.  For example, the 
production of CFT1 influences synaptic structural stability and synaptic Ca2+ 
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conductance (Brusés, 2006; McCusker and Alfandari, 2009).  Synapse structure is 
disrupted when CTF1 is released from the membrane due to the breakdown of N-
cadherin/catenin/cytoskeleton connections, which are necessary to provide structural 
stability to the synapse (Jang et al., 2009).  Our results suggest that persistent ADAM-
10 may be an upstream regulator of the production and release of CTF1.  In this way, 
MMPs may direct the evolution of abnormal synaptic cytoarchitecture which we 
documented in hippocampal stratum radiatum and dentate molecular layer after 
TBI+BEC insult.   
Structural instability can also lead to the failure of synaptic function.  Extracellular 
cleavage of N-cadherin by MMPs and the intracellular release of CTF1 not only alter 
connections to the actin cytoskeleton, but also change the relationship N-cadherin and 
subcellular PSD proteins, including AMPA receptors and p120 catenin.  When binding 
between N-cadherin and these proteins changes, Ca2+ conductance is altered. These 
downstream effects may help to explain the injury-induced deficits we observed in our 
LTP experiment.  N-cadherin has been found to mediate the placement and positioning 
of AMPA receptors into the post-synaptic membrane, which is necessary for synaptic 
transmission and activation of NMDA receptors which results in Ca2+ influx (Silverman 
et al., 2007; Malenka and Bear, 2004).  During the early induction phase of LTP, AMPA 
receptors are inserted into the post-synaptic membrane, strengthening the synaptic 
response.  Here we showed LTP deficits at 15d post-TBI+BEC, a time when high 
ADAM-10 levels were matched with decreased full length N-cadherin.  Following MMP 
inhibition, full length N-cadherin was increased, along with a reduction in LTP deficit.  
Restoration of intact N-cadherin may have facilitated AMPA receptor membrane 
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placement, therefore increasing Ca2+ conductance and improved synaptic efficacy.  
Neuronal Ca2+ conductance may also be altered when p120 catenin dissociates from 
RhoA and binds the juxtamembrane domain (JMD) of CTF1.  In this series of events, 
intracellular cleavage of N-cadherin produces a form of the molecule which recruits and 
binds to p120 catenin, releasing RhoA.   Free RhoA is activated upon release from p120 
catenin and can then modulate voltage activated Ca2+ channels (VACC) in both pre- 
and post-synaptic sites.  Through interaction with myosin-actin cytoskeleton, soluble, 
active RhoA ultimately decreases synaptic Ca2+ influx (Marrs et al., 2009).  Although the 
mechanism is different from N-cadherin/AMPA receptor interaction, CTF1/p120 catenin 
interaction has similar downstream effects on Ca2+ conductance which would also 
support a decrease in synaptic efficacy after TBI+BEC and our observed effects on 
LTP.   
While we were unable to visualize hippocampal N-cadherin fragments smaller 
than 40 kDa following injury, it is important to consider the role that such fragments may 
play in neuroplasticity after TBI.  Current literature shows that CTF1 can be further 
processed into a 35  kDa fragment (CTF2), which also may affect synaptogenesis 
through interaction with CREB and β-catenin (Reiss et al., 2005; Marambaud et al., 
2003; McCusker and Alfandari, 2009).  CTF2 binds CREB binding protein (CBP), 
targeting it for degradation, therefore interfering with downstream transcription of CREB-
dependent genes.  Many of these genes are critical for CNS plasticity, such as c-fos, 
synapsin I, K+ channels and the alpha subunit of Ca2+/calmodulin-dependent kinase II 
(Marambaud et al., 2003; Lonze and Ginty, 2002; Deisseroth et al., 1996).     
Additionally, CTF2 associates with the Wnt signaling molecule, β-catenin, promoting 
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transcription of genes important for cell proliferation and survival, as well as synaptic 
plasticity:  cyclin D1, c-myc, c-jun, and N-cadherin (Reiss et al., 2005; McCusker and 
Alfandari, 2009).  CFT2-dependent action on transcription of any of these plasticity-
associated genes could play a role in synaptic reorganization following TBI.  Clearly, 
both extracellular and intracellular N-cadherin fragments generated by ADAM-10 are 
capable of altering trauma-induced synaptic plasticity through different signaling 
pathways.  While the role of MT5-MMP appears to be less clear, some reasonable 
predictions as to its effect on reactive synaptogenesis can be made based on our 
current results.  
Our Western blot (WB) results showed that MT5-MMP was not detectable in its 
active 58 kDa form, but rather, predominantly seen as an 80 kDa band, likely bound to 
its endogenous inhibitor TIMP-2.  As previously mentioned, MT5-MMP is capable of 
binding toTIMP-2 in a complex with proMMP-2.  The formation of this complex occurs at 
the cell membrane, where the binding of TIMP-2 inhibits any catalytic activity of MT5-
MMP, the enzyme functioning as a docking station.  TIMP-2 possesses a C-terminal 
domain with a high affinity for the HLD domain of proMMP2. The proMMP-2 “substrate” 
docks to the C-terminus of TIMP-2 and forms the ternary complex (Strongin et. al, 1995; 
Maskos and Bode, 2003). The binding of these three proteins is insufficient to activate 
proMMP-2, thus an adjacent TIMP-free MT5-MMP is needed to initiate the first pro-
MMP-2 cleavage.  Following the initial cleavage, an additional MMP-2 molecule 
removes the remaining propeptide domain from the intermediate MMP-2 to yield a 
mature and fully-active MMP-2 molecule (Deryugina et. al, 2001).  This series of 
downstream events is initiated by the placement of MT5-MMP into the cell membrane.  
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Based on results from our lab and others, all components of the MT5-MMP/TIMP-
2/proMMP-2 complex are found to be expressed in astrocytes (Conant and Gottschall, 
2005).  This molecular localization and proximity further supports their interaction and 
possible influence on plasticity within the deafferented molecular layer.  Our lab has 
previously demonstrated increases in MMP-2 gene expression and activity in the injured 
hippocampus, as well as increased localization of MMP-2 in the deafferented molecular 
layer 2 and 7d following both UEC and TBI+BEC (Phillips and Reeves, 2001).  This data 
is consistent with our the hypothesis that a significant increase in hippocampal MT5-
MMP expression at 2 and 7d postinjury may result in formation of the MT5-
MMP/TIMP2/MMP-2 complex and local MMP-2 activation.   
 The results presented in this dissertation add to our understanding of how 
membrane-bound MMPs and N-cadherin might influence the efficacy of synaptic 
plasticity following TBI.  Interpretation of these results in the context of TBI 
neuropathology and recovery did reveal possibilities for targeting MMP inhibition in 
developing new therapies to improve postinjury recovery.  While many of our initial 
questions were answered, new ones arose during our investigation.  The following 
section describes some of these questions and the future studies which could address 
them.  
Future Directions 
In our lab group the overall research goal is to gain greater understanding of TBI 
pathophysiology and design treatment paradigms translatable to the clinic for improved 
patient recovery and rehabilitation.  This study expands our current understanding of 
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synaptic recovery and reveals that membrane-bound MMP/substrate interaction can 
positively or negatively influence this process following TBI.  Our results provide 
evidence that spatio-temporal changes in MT5-MMP, ADAM-10 and N-cadherin 
expression correlate with functional and structural recovery, and differ in effect 
depending on the plasticity conditions.  However, additional investigation is needed to 
confirm two missing aspects of MMP involvement:  1) to fully characterize MT5-MMP, 
ADAM-10, and N-cadherin mRNA expression, and 2) to confirm injury-dependent 
differences in proteolytic activity for these membrane-bound MMPs.  To further examine 
the specific cellular localization of ADAM-10, MT5-MMP and N-cadherin we plan to use 
EM immunohistochemical techniques.  We also plan to take a closer look at MMP-
related molecular mechanisms guiding neuroplasticity and identify additional 
manipulations to more specifically inhibit MT5-MMP and ADAM-10.  These future 
studies are needed to confirm the findings in the current study.   
Although we have profiled hippocampal MT5-MMP, ADAM-10, and N-cadherin 
protein expression over the time course of reactive synaptogenesis, we have yet to fully 
document the transcript profiles of these genes.  Our preliminary 7d qRT-PCR results 
provide useful information about mRNA expression in enriched ML samples, pointing to 
larger model shifts in ADAM-10 and N-cadherin transcription at the tissue site of 
synaptogenesis.  Nevertheless, it will be important to examine mRNA expression at 
later postinjury intervals in order to further dissect the persistent ADAM-10 expression in 
the maladaptive model of TBI.  Also, our results failed to show pronounced model 
differences in MT5-MMP mRNA expression, suggesting that we need to investigate 
MT5-MMP transcription at more acute postinjury periods.  
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Measurement of MT5-MMP and ADAM-10 proteolytic activity is also needed to 
fully understand the relationship between enzyme expression and function during 
postinjury recovery.  Unfortunately, no commercial assays specific for either MT5-MMP 
or ADAM-10 are currently available.  While we were able to assess the active 70 kDa 
ADAM-10 with Western blots, this only confirms the expression of active enzyme, not its 
endogenous activity.  Nevertheless, we have worked with a commercial supplier of 
enzyme assays in an attempt to measure ADAM-10 specific lysis using hippocampal 
tissue samples from our models.  The assay tested was designed for cultured cells and 
did not show the same specificity in extracts from fresh brain.  A feasible indirect option 
for exploring MT5-MMP activity would be to first measure MMP-2 lysis in our samples.  
Changes in MMP-2 activity would further support the postulated role of MT5-MMP as a 
facilitator of proMMP-2 activation.  While less quantitative in nature, gel zymography 
methods have been used to assay membrane-bound MMP activity (Wang, 2004), which 
is another option.  In future studies, we will continue to investigate the different options 
for accurate measurement of MT5-MMP and ADAM-10 proteolytic activity. 
In addition to above directions, we will focus on molecular mechanisms involving 
membrane-bound MMPs which might influence the postinjury plasticity process.  For 
example, we are currently investigating the role of β-catenin in postinjury gene 
transcription.  N-cadherin lysis by ADAM-10 results in intracellular processing of N-
cadherin fragments and the release of binding partner β-catenin, leading to its nuclear 
translocation and altered gene transcription of plasticity pathways (McCusker and 
Alfandari, 2009; Reiss et al., 2005; Lyuksyutova, AI et al., 2003; Yu and Malenka, 2003; 
Gogolla et al., 2009).  Our preliminary studies with hippocampal β-catenin protein show 
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a significant decrease of full-length (94 kDa) β-catenin and an increase in detection of 
fragments (90 and 75 kDa) across all post-TBI+BEC times (See Appendix Fig E-1).  
Interestingly, in molecular layer enriched samples, this pattern of fragment generation 
was detected only at the acute 2d postinjury interval (See Appendix Fig E-2).  These 
results show that hippocampal β-catenin protein lysis occur throughout the time course 
of reactive synaptogenesis, with pronounced increases in a 75 kDa form.  Overall, 
maladaptive recovery produces greater change in β-catenin at 2 and 7d postinjury, 
generating more of the 75 kDa fragment.  Notably, these shifts are spatio-temporally 
correlated with elevation of ADAM-10 and reduction of N-cadherin.  For future studies 
we posit that ADAM-10 proteolysis of N-cadherin alters β-catenin binding within the 
post-synaptic site, resulting in the generation of fragments which are translocated to the 
cell nucleus as transcription factors, targeting genes associated with synaptic plasticity.  
In the context of this β-catenin hypothesis, we will investigate changes in transcript and 
protein expression of plasticity associated genes.  Manipulation of these molecules or 
the mechanism by which they act will also support our current findings.        
In Chapter 3 we showed that broad-spectrum MMP inhibition improved synaptic 
structure and function in the maladaptive TBI+BEC model.  While these effects were 
modest, we believe that inhibition of membrane-bound MMPs remains an important 
area of study with clinical relevance, not only for TBI, but also for additional pathologies 
that involve MMPs.  We have traditionally used broad-spectrum MMP inhibitors, 
including FN-439 and GM6001, when characterizing MMP activity and role during injury-
induced plasticity.  A chief issue with these drugs is the lack of specificity for individual 
MMPs.  Specific MT5-MMP and ADAM-10 inhibitors were not commercially available for 
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use in the present experiments.  In the interim, new inhibitors have been developed that 
preferentially target ADAM-10.  In several studies, the compound GI254023X has been 
shown to block in vitro ADAM-10 induced shedding of N-cadherin, L1, Fas-ligand, 
Pcdhγ, VE-cadherin, and CX3CL1 (Ludwig et al, 2005; Hoettecke et al., 2010; 
Hundhausen et al, 2003; as reviewed in Pruessmeyer and Ludwig, 2009).  Specific 
pharmacological inhibitors of MT5-MMP have yet to be developed, therefore future 
MT5-MMP studies in TBI may involve knock down experiments employing siRNA or 
transgenic approaches. In a preliminary study, we have applied MT5-MMP siRNA in 
vivo 24h prior to UEC and successfully reduced injury-induced elevations in MT5-MMP 
protein at the 2d postinjury (Phillips, unpublished data).  Additionally, both ADAM-10 
and MT5-MMP knockout mice are commercially available for use in neuropathology 
research and will be a useful tool for TBI as well (Komori et al, 2003; Folgueras et al., 
2009; Postina et al., 2004).  
In addition to broad-spectrum MMP inhibition, we have used established 
neuroprotective treatments to determine their effect on MMP expression and activity.  
Drugs such as MK-801(NMDA antagonist) show tandem neuroprotection and altered 
expression of secreted MMPs (Phillips and Reeves, 2001; Falo et al., 2006).  We will 
use such agents in future studies to determine how membrane-bound MMPs and their 
synaptic substrates respond to protective therapies.  In the case of MT5-MMP activation 
of proMMP-2, we have already shown that MK-801 treatment results in reduction of 
MMP-2 activity at 7d post-TBI+BEC.  Based on this data, we would predict that 
postinjury treatment with MK-801 may also result in significant effects on ADAM-10 and 
N-cadherin expression and/or function.  Such experiments will further identify specific 
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role(s) of membrane-bound MMPs MT5-MMP and ADAM-10 and their substrates during 
injury-induced plasticity.  Lastly, regardless of the method or target of manipulation, it is 
imperative to develop the appropriate dosing and delivery paradigm.  Therefore, future 
manipulations will first require more complete pharmacological studies to characterize 
treatment response along the synaptogenic time course.  This approach is particularly 
important with respect to our MWM experiments, where, using a single dosing paradigm 
for GM6001, we failed to detect significant effects on cognitive performance.  
Final Remarks 
Collectively, the series of experiments presented in this dissertation give greater 
insight into the role of membrane-bound MMPs and their substrates during synaptic 
plasticity induced by TBI.  Through characterization and manipulation of these 
molecules, we also broadened our understanding of the process of maladaptive 
synaptic plasticity, and developed additional questions for future studies.  Our lab 
continues to test the importance of matrix molecules such as MMPs in the process of 
synaptic recovery.  We strive to develop treatment options that prevent the persistent 
impairments that ensue following TBI and promote successful recovery.   
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Figure A-1 Unilateral Entorhinal Cortex Lesion Stereotaxic Sites.  Coronal section 
of rat brain with stereotaxic lesion sites indicated by black circles at 3, 4, and 5mm 
lateral to midline. 
 
 
 
 
 
263 
 
 
 
Figure A-2 Craniectomy Sites and Fluid Percussion Injury Device. (A) Craniectomy 
site (black) for central fluid percussion injury hub placement (located midway between 
bregma and lambda); Right and left craniectomy sites (red) for bilateral entorhinal cortex 
lesions (superior to entorhinal cortex).  
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Figure B-1 Co-migration of MT5-MMP and TIMP-2 in Protein Analysis.  
Representative gel blots illustrating co-migration of TIMP-2 with MT5-MMP within gel 
system, indicating potential MT5-MMP/TIMP-2 binding in hippocampal tissue.  
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Figure B-2 Hippocampal Protein Expression of Additional MT5-MMP Forms 
following UEC.  Values expressed as percent of contralateral hippocampus over 2, 7, 
and 15d postinjury time intervals.  As indicated in Chapter 2, UEC insult produced 
significant increases in 80 kDa MT5-MMP (MT5) at 2 and 7d, however, an additional 
minor 85 kDa form was observed to decrease across all postinjury time intervals.  2d: 
n=7; 7d: n=4; 15d n=6. *p<0.05, **p<0.01, ***p<.001. 
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Figure B-3 Hippocampal Protein Expression of Additional ADAM-10 Forms 
following UEC.  Values expressed as percent of contralateral hippocampus over 2, 7, 
and 15d postinjury time intervals.  As indicated in Chapter 2, UEC insult induced a 
significant increase in 70 kDa ADAM-10 protein expression at 2 and 7d with a reduction 
to levels not different from controls at 15d.  By contrast, 100 kDa and 80 kDa forms 
showed significant reductions across all postinjury time intervals.  2d: n=4; 7d: n=5; 15d 
n=4. *p<0.05, **p<0.01. 
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Figure B-4 Hippocampal Protein Expression of Additional N-cadherin Forms 
following UEC.  Values expressed as percent of contralateral hippocampus over 2 and 
15d postinjury time intervals.  As indicated in Chapter 2, UEC insult produced a 
significant reduction at 2d for both 130 kDa and 40 kDa forms, and 15d elevation for the 
130kDa form. The 40 kDa form was not measurable at 7d, therefore this time interval 
was not represented.  2d: n=7; 15d n=6. *p<0.05, **p<0.01. 
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Figure B-5 Hippocampal Protein Expression of Additional MT5-MMP Forms 
following TBI+BEC.  Values expressed as percent of sham controls over 2, 7, and 15d 
postinjury time intervals.  As indicated in Chapter 2, TBI+BEC induced a significant 
increase in 80 kDa MT5-MMP (MT5) protein expression at 2 and 7d, with reduction to 
levels not different from controls at 15d.  By contrast, the additional 85 kDa form 
showed significant reduction across all postinjury time intervals. Injured=I, Sham=S; 2d: 
I=10, S=8; 7d: I=16, S=10; 15d I=8, S=7; *p<0.05, **p<0.01, ***p<0.001. 
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Figure B-6 Hippocampal Protein Expression of Additional ADAM-10 Forms 
following TBI+BEC.  Values expressed as percent of sham controls over 2, 7, and 15d 
postinjury time intervals.  As indicated in Chapter 2, TBI+BEC produced a significant 
increase in 70 kDa ADAM-10 over all postinjury time intervals.  By contrast, 100 kDa 
and 80kDa showed a significant reduction at 2d only, and levels not different from 
controls at 7 and15d.  Injured=I; Sham=S; 2d: I=6, S=8; 7d: I=7, S=9; 15d I=7, S=8; 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure B-7 Hippocampal Protein Expression of Additional N-cadherin Forms 
following TBI+BEC.  Values expressed as percent of sham controls over 2, 7, and 15d 
postinjury time intervals.  As indicated in Chapter 2, TBI+BEC produced a significant 
reduction at 2 and 7d in the 130 kDa form and levels not different from control in the 40 
kDa form across all postinjury time intervals. Injured=I; Sham=S; 2d: I=9, S=8; 7d: I=15-
16, S=10; 15d I=7, S=3-8; *p<0.05. 
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Figure B-8 Representative β-actin load control for Western blot Analysis.  β-actin 
(42kDa) was selected as a load control for TBI+BEC Western blot analysis in Chapters 
2 and 3.  Representative samples from 2, 7, and 15d TBI+BEC blots show a typical 
pattern indicative of even loading in injured (I) and sham control (S) lanes across all 
postinjury time intervals. 
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Figure B-9 Downstream Intracellular Signaling as a Result of N-cadherin 
Processing by ADAM-10.  Schematic representation of ADAM-10 induced N-cadherin 
ectodomain shedding at the synaptic interface.  N-cadherin processing and 
fragmentation may have downstream influence on ion conductance, structural integrity 
of the synapse, and β-catenin and CREB driven gene transcription.  These events may 
potentially affect the plasticity process and recovery following TBI. 
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Figure C-1 Molecular Layer Localization of ADAM-10 with GFAP at 2 and 15d 
following UEC.  Confocal overlay images showing ADAM-10 (green) and GFAP (red) 
co-localization (yellow) in ipsilateral (injured) and contralateral (control) dentate 
molecular layers at 2 and 15d postinjury.  In ipsilateral images note increased ADAM-10 
signal filling reactive astrocytes throughout molecular layer at 2d.  By 15d, signal is 
concentrated in the outer molecular layer. Contralateral side shows ADAM-10 
localization within non-reactive astrocytes, but with a much reduced level of signal. 40X 
magnification. 
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Figure C-2 Molecular Layer Localization of ADAM-10 with GFAP at 2 and 15d 
following TBI+BEC.  Confocal overlay images showing ADAM-10 (green) and GFAP 
(red) co-localization (yellow) in combined-injured and sham dentate molecular layers at 
2 and 15d survival.  Note increased ADAM-10 signal filling reactive astrocytes 
throughout molecular layer at 2d postinjury.  As in the UEC, ADAM-10 signal is 
concentrated in the outer molecular layer at 15d post-TBI+BEC.  Sham shows reduced 
ADAM-10 signal within non-reactive astrocytes throughout molecular layer. 40X 
magnification. 
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Figure C-3 Molecular Layer Localization of MT5-MMP with GFAP at 2 and 15d 
following UEC.  Confocal overlay images showing MT5-MMP (green) and GFAP (red) 
co-localization (yellow) in ipsilateral (injured) and contralateral (control) dentate 
molecular layers.  In the ipsilateral side, note increased outer molecular layer signal at 
2d and 15d.  MT5-MMP is clustered within reactive astrocyte cell bodies and extends 
into the glial processes. Neuronal labeling is seen as punctate signal in granule cell 
bodies and throughout molecular layer neuropil. At 15d ipsilateral and contralateral 
overlays show similar signal intensity and profile for MT5-MMP, despite differences in 
astrocytic response.  MT5-MMP granule cell signal will need further confirmation with 
neuronal antibody markers. 40X magnification. 
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Figure C-4 Molecular Layer Localization of MT5-MMP with GFAP at 2 and 15d 
following TBI+BEC.  Confocal overlay images showing MT5-MMP (green) and GFAP 
(red) co-localization (yellow) in injured and sham dentate molecular layers.  In injured 
images, note increased in cluster-like MT5-MMPsignal within reactive astrocyte cell 
bodies and out into selective processes, as well as punctate signal throughout 
molecular layer and over granule cell bodies at 2d.  At 15d injured and sham overlays 
show similar signal intensity and profile for MT5-MMP, despite the difference in 
astrocytic response.  MT5-MMP granule cell signal will need further confirmation with 
neuronal antibody markers. 40X magnification. 
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Figure C-5 Molecular Layer Localization of N-cadherin with GFAP at 2 and 15d 
following UEC.  UEC confocal overlay images showing N-cadherin (green) and GFAP 
(red) co-localization (yellow) at 2 and 15d in ipsilateral (injured) and contralateral 
(control) dentate molecular layers.  In ipsilateral images note increased N-cadherin 
signal filling reactive astrocytes throughout molecular layer at 2d and concentrated in 
the outer molecular layer at 15d.  UEC contralateral side shows N-cadherin localization 
within non-reactive astrocytes, but with much reduced signal. 40X magnification. 
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Figure C-6 Molecular Layer Localization of N-cadherin with GFAP at 2 and 15d 
following TBI+BEC.  Confocal overlay images showing N-cadherin (green) and GFAP 
(red) co-localization (yellow) at 2 and 15d injured and sham dentate molecular layers.  
In 2d injured images, note increased N-cadherin signal primarily within reactive 
astrocyte cell bodies, as well as punctuate signal throughout molecular layer. At 2d, 
sham shows a much reduced N-cadherin signal and less reactive astrocytic labeling, 
although neuropil punctuate profile is similar.  At 15d injured and sham overlays show 
similar signal intensity and profile for N-cadherin, despite the moderate difference in 
astrocytic response.  Punctate N-cadherin signal is also visible throughout the molecular 
layer at 15d in both injured and sham.  40X magnification. 
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Figure C-7: Representative Minus Primary Controls for ADAM-10, MT5-MMP and 
N-cadherin immunostaining with GFAP.  7d UEC injured examples of tissue 
processed without the primary antibody show an absence of signal. Overlay images are 
representative of tissue for all immunohistochemical experiments in the study.  From top 
to bottom: MT5-MMP/GFAP; ADAM-10/GFAP; and N-cadherin/GFAP confocal overlay 
images. 40X magnification.   
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Figure C-8 Representative Molecular Layer Localization of MT5-MMP, ADAM-10, 
and N-cadherin with microglial markers CD-11/Iba-1.  Co-localization of MT5-MMP 
with CD-11, and ADAM-10 and N-cadherin with Iba-1 in TBI+BEC injured tissue.  Note 
no MT5-MMP, ADAM-10 and N-cadherin signal within molecular layer microglia 
following injury.  MT5-MMP/ADAM-10/N-cadherin (green), CD-11/Iba-1 (red); 40X 
magnification. 
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Fig. D-1 Molecular layer Co-localization of MT5-MMP RNA transcript with GFAP 7d 
post-UEC.  Confocal images showing single channel MT5-MMP anti-sense ribroprobe 
(red) and reactive astrocytic marker GFAP (green) and overlay (yellow).  Note increased 
co-labeling in outer molecular layer, primarily within astrocytic processes. 40X 
magnification. 
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Figure E-1 Hippocampal Protein Expression of β-catenin following TBI+BEC.  
Values expressed as percent of sham controls. Significant increase of 90 kDa and 75kD 
β-catenin forms was seen at all time points, with significant decrease in 94 kDa at 2 and 
7d. Greatest change in expression was found in the 75 kDa form, peaking at 7d. 
Representative blots shown below.  I=Injured; S=Sham. 2d: Injured n=5, Sham n=3; 7d: 
Injured n=9, Sham n=4; 15d: Injured n=4, Sham n=3. *p<0.05. 
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Figure E-2 Molecular Layer Protein Expression of β-catenin following TBI+BEC.  
Values expressed as percent of sham controls. Significant increase in 75 kDa form and 
decrease in 94 kDa form was seen only at 2d.  No significant changes in β-catenin 
expression were found at 7 and 15d.  A measurable 90 kDa form was not detectable in 
ML samples. Representative blots shown below.  I=Injured; S=Sham; n-values: 2d I=4, 
S=6; 7d I=4, S=4; 15d I=3, S=3; *p<0.05.A 
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